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 General introduction and outline of the thesis: 
new opportunities in the fi ght against obesity and diabetes
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Introduction
The increasing incidence of obesity is an obvious consequence of changes in human life 
style. Obesity is a result of physiological, environmental, and behavioral factors. In the 
last decades enormous changes occurred in the latter two factors. The environment has 
changed quickly due to an increase of new technologies requiring less physical activity. 
Additionally, we developed a more sedentary lifestyle with drastically changes in food 
consumption that includes an increasing amount of sugars and calories. This results in a 
disbalance in energy intake and expenditure leading to overweight and obesity. 
Obesity
The body mass index (BMI) was initially developed to relate body weight to body length 
in a standardized matter. Further studies showed that an increased BMI was related to 
increased morbidity and mortality. Although not accurate in all situations, for example 
in people with large amounts of muscle tissue, it is a widely used parameter. A BMI 
between 18 and 25 kg/m2 is considered healthy, as a BMI between 25 and 30 kg/m2 
indicates overweight. When BMI surpasses 30 kg/m2, one is considered obese (class 
I: BMI 30.0-34.9 kg/m2; class II: BMI 35.0-39.9 kg/m2; class III: BMI ≥40.0 kg/m2). 
The World Health Organization (WHO) reported that in 2016 worldwide over 1.9 billion 
adults (39%) were overweight, of which 650 million were obese (13% of the worldwide 
adult population). The incidence of obesity nearly tripled since 1975. Moreover, in 2016 
a total of 41 million children under the age of 5 were overweight or obese, which shows 
that it is not only a problem at adult age1. An analysis of 200 countries between 1975 and 
2014 showed an increase in obesity in men from 3.2% to 10.8%, and from 6.4% to 14.9% 
in women, respectively2.
Obesity, insulin resistance and type 2 diabetes mellitus
Adipose tissue can result in a decreased insulin sensitivity by releasing an increased 
amount of non-esterified fatty acids, glycerol, hormones, and pro-inflammatory cytokines. 
Moreover, abnormalities in β-cell function can lead to an impaired glucose tolerance 
(IGT) and type 2 diabetes mellitus (T2DM)3. Therefore, an unhealthy life style leading 
to an increased body weight, can be the primary cause of T2DM. A large meta-analysis 
showed an association between an increased risk of cardiovascular diseases and pre-
diabetes, which is defined as IGT, impaired fasting glucose, or raised HbA1c4. The WHO 
estimated that in 2014 all types of diabetes combined, affected 8.5% of the worldwide 
adult population, and caused 1.6 million deaths in 20155. The increased morbidity and 
mortality caused by obesity and diabetes results in decreased quality adjusted life years 
(QALY) and high worldwide direct and indirect costs in high-income countries, as well 
as low- and middle–income countries6. 
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1Obesity and other related diseases
Apart from the relationship with T2DM, obesity leads to many other physiological 
changes, resulting in an increased cardiovascular risk. An increased lipid production can 
result in non-alcoholic fatty liver disease (NAFLD) and coronary artery disease. Adiposity 
induced activity of the sympathetic nervous system combined with renal compression 
can lead to hypertension. All these pathologic changes combined result in an increased 
long term risk of congestive heart failure, stroke and chronic kidney disease. This is 
separate from other mechanism resulting in obstructive sleep apnea, osteoarthritis, and 
gastroesophageal refl ux disease7. Additionally, obesity is related to an increased risk for 
several types of malignancies. The relation between obesity and an increasing prevalence 
of cardiovascular and metabolic risk factors already starts in children and young adults8. 
However, the causal relationship between obesity and increased cardiovascular risk is 
unknown to many patients, resulting in an underestimation of the potential hazard of their 
obesity.
Strategies and therapies
To diminish the increased morbidity and mortality caused by obesity and its related 
diseases, numerous strategies, drugs and therapies have been developed to improve 
cardiovascular health. These strategies differ widely, ranging from consumption of a 
healthier diet to invasive bariatric surgery. Despite this large spread of possibilities, a 
defi nite cure is often hard to accomplish. Although it is best to study defi nite outcome 
parameters in intervention studies, such as cardiovascular events or death, these are 
unpractical parameters in most studies for reasons of study length and costs. Therefore, 
the majority of studies use intermediate outcome parameters to determine the effect of the 
treatment on obesity and T2DM, such as changes in body weight, fasting plasma glucose 
(FPG), HbA1c, lipids and blood pressure. 
Lifestyle and diet
The cornerstone of cardiovascular health is a healthy life style. This consists of suffi cient 
physical activity and a varied and healthy diet. An extensive literature review of Eijsvogels 
et al. illustrated that only 15 minutes of daily moderate physical exercise can lead to an 
improved cardiovascular health9. A trial in obese patients with T2DM that compared an 
intensive lifestyle intervention by promoting a decrease in caloric intake and increase 
in physical activity, compared with diabetes support and education, showed greater 
improvements for weight, diabetes and several cardiovascular parameters. However, the 
rate of cardiovascular evens between both groups was comparable10. Therefore prevention 
of obesity and T2DM is of utmost importance. 
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The second aspect of a healthy lifestyle is a varied and healthy diet. A large Cochrane 
review suggested that a reduction of saturated fat intake could result in a decreased 
cardiovascular risk11. However, food and nutrition guidelines differ widely, resulting in 
confusion in health professionals, policy makers, and patients12. In a modern society with 
an excess of unhealthy food, sticking to a healthy diet proves difficult for many patients. 
Moreover, healthy food like vegetables and fruit are in many countries more expensive 
than fast-food. This causes more unhealthy food consumption in people with a lower 
socioeconomic status13. Furthermore, fast-food is available everywhere, and most often 
more easier accessible than healthy food.
Dieting
The first strategy to attack excess weight is to start dieting, with or without the support of 
a dietician. There are many different type of diets. The most important factors to success 
are that the diet has less energy than patients requirements for daily maintenance and the 
patient is able to adhere to the diet14. However, daily practice shows that most patients 
experience the yo-yo effect, also known as weight cycling; after an initial reduction in 
weight after start of dieting, stopping of the diet leads to weight regain. Moreover, this 
often causes additional weight compared to the situation before the start of the diet. 
Medication
When life style changes and dieting are insufficient to obtain a healthy body weight or 
normal plasma glucose levels, medication can be started. Drugs to treat diabetes are 
commonly accepted and is considered standard care. 
Obesity
Anti-obesity drugs are used in a minority of patients. The biggest disadvantages are their 
lifelong use and accompanied high costs. The number of drugs for treatment of obesity 
that are approved by the Food and Drug Administration (FDA) is limited due to frequent 
adverse events (AEs), ranging in seriousness. A large meta-analysis reported of at least 
5% weight loss from baseline between five drug treatments for obesity after 1 year of 
use15. Phentermine-topiramate, liraglutide, naltrexone-bupropion, lorcaserin, and orlistat 
resulted in at least 5% weight loss in 75%, 63%, 55%, 49%, and 44% of the patients 
after 1 year, respectively. A Cochrane literature review of the latter one, orlistat, showed 
weight loss of 2.3 kg after 1 year of use compared to placebo16. Although it resulted 
in a significant weight loss, it is unknown if, and how much relapse occurred after the 
therapy stops. Additionally, although orlistat is evaluated as a drug with a positive safety 
profile, treatment is still accompanied with several gastrointestinal events, such as fatty 
stool or fecal urgency, occurring in 15 to 30% of patients. Formerly approved drugs are 
withdrawn of the market due to their AEs. For example, 2,4-dinitrophenol (DNP) can lead 
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to death by hyperthermia by uncoupling of the oxidative phosphorylation17. Although 
prohibited, this drug is still available on the internet.
Type 2 diabetes
Oral antidiabetic drugs are widely used according to predefi ned schemes. When insulin 
resistance advances and glucose regulation deteriorates and is insuffi cient in control with 
help of oral diabetic drugs, insulin therapy might be needed. Although initial therapy 
with insulin often leads to better controlled plasma glucose and HbA1c, insulin therapy 
often needs to be adjusted with increasing dosages due to a gradual increase in insulin 
resistance. Since insulin therapy leads to an increase in body weight and thereby results 
in more insulin resistance and larger amounts of insulin needed, a vicious circle arises of 
a deteriorating T2DM with an increasing weight. 
One of the recently introduced drugs for T2DM, liraglutide, has proven to induce weight 
loss in patients without diabetes or with prediabetes. A large randomized clinical trial 
showed that liraglutide in high dosing induces a placebo subtracted weight loss of 5.6 
kg when combined with counseling on lifestyle modifi cation. A third of the patients lost 
more than 10% of their body weight18. Although new opportunities are created by these 
new drugs, it seems fairly impossible at this point to cure T2DM with only the help of 
lifestyle changes and medication. Anti-diabetic drugs often only lead to stabilization of 
disease, rather than improvement. Therefore, to break this vicious circle, more invasive 
therapies are often needed.
Bariatric surgery
When conservative treatments fail to improve obesity, as a last resort, bariatric surgery was 
the fi nal treatment in line since the 1950s which resulted in excellent weight loss19,20. With 
increasing experience, it became clear that diseases related to obesity improved or even 
cured. Next to improvements in arthrosis, caused by the reduced weight, improvements 
were seen of hypertension, dyslipidemia, and diabetes21. Therefore bariatric surgery is 
also referred to as metabolic surgery.
Bariatric surgery is reserved for a selection of patients that fulfi ll the IFSO (International 
Federation for the Surgery of Obesity and Metabolic Disorders) criteria. Although all 
patients need to be evaluated individually to see if they are eligible for bariatric surgery, 
they need to fulfi ll the following criteria22:
• BMI ≥40 kg/m2, independently of accompanying co-morbidities
• BMI 35-40 kg/m2 with co-morbidities that are expected to improve after bariatric 
surgery, such as:
 ◦ metabolic disorders,
 ◦ cardio-respiratory disease,
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• Reasonable attempts at other weight loss techniques
• Age 18-65
• No active psychiatric or drug dependency problems
• A capacity to understand the risks and commitment associated with the surgery
• Pregnancy not anticipated in the first 2 years following surgery
 
When patient fulfill above criteria and are personally willing and motivated to undergo 
bariatric surgery, several types of surgery are available. Depending on patients’ personal 
situation and preference, within the framework of individual care, several types of 
bariatric surgery can be selected.
Outcome parameters
Success of bariatric surgery in terms of weight loss can be expressed in different outcome 
parameters. First, differences can be reported as absolute changes in weight in kilograms 
or as absolute changes in BMI in kg/m2. Secondly, since absolute changes in weight are 
relative to the amount of excess weight, other measurements were developed. Excess 
weight is defined as the weight above the median weight for height at 25 kg/m2 in the 
Metropolitan Life Insurance tables. With help of a formula the percent excess weight 
loss (EWL) can be calculated, which expresses the weight lost compared to the ideal 
body weight; a body weight with a BMI of 25 kg/m2. Recently it was suggested that 
this measurement gives an overestimation in patients with lower baseline weights23. 
Therefore, weight loss should be expressed in percentage total body weight loss (TBWL); 
the proportion of weight loss compared to the total baseline body weight.
Complete or partial remission of diabetes is defined by the American Diabetes Association 
as normal glycemic measures or hyperglycemia below diagnostic thresholds for diabetes, 
respectively24. These criteria need to have a duration of at least 1 year, with no active 
pharmacologic therapy or ongoing procedures. 
Other cardiovascular parameters such as blood pressure or serum lipid spectrum are most 
often described by their absolute change. Additionally, these parameters can be described 
as the proportion of patients returning to normal levels.
Roux-en-Y gastric bypass and sleeve gastrectomy
Currently, the two most performed bariatric procedures in the Netherlands are the 
laparoscopic Roux-en-Y Gastric Bypass (RYGB) and the Laparoscopic Sleeve 
Gastrectomy (LSG). Both procedures result in an average TBWL of 25-30% at 12 
months25 and 21-25% 3 years after surgery26. Several studies showed that bariatric surgery 
is superior compared to diet as well in the short, as the long term26-28.
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Biliopancreatic diversion and biliopancreatic diversion with duodenal switch
Other types of surgeries for more extreme forms of morbid obesity (BMI greater than 60 
kg/m2) are the biliopancreatic diversion and the biliopancreatic diversion with duodenal 
switch. A greater part of the small intestine is bypassed compared to the RYGB. These 
procedures therefore result in greater weight loss, but are also accompanied with more 
AEs, such as frequent daily diarrhea, malnutrition, and gastroesophageal refl ux29.
Adjustable gastric banding
The fi rst widely applied form of bariatric surgery in Europe was laparoscopic adjustable 
gastric banding (LAGB). With this procedure an adjustable infl atable gastric band is placed 
surrounding the proximal part of the stomach. By fi lling the subcutaneous access port, the 
diameter of the gastric band can be adjusted to increase or decrease food restriction to the 
stomach. Although this type of surgery is still performed often in the United States and 
other parts of the world, it is becoming less popular. In the Netherlands the number of 
procedures reduced sharply in the last years and is nowadays hardly performed anywhere. 
Studies showed frequent weight regain after several years of band placement and the 
majority of patients experienced AEs in follow-up, leading to band removal30,31.
Safety
Bariatric surgery was initially, when performed as open procedure, accompanied with 
high morbidity and mortality. Introduction of the laparoscopic technique in bariatric 
surgery in 1994 led to a sharp decrease in morbidity and mortality, with nowadays a 
within, and after 30 days mortality rate of 0.08% and 0.31%, respectively. Additionally, 
it is associated with a complication rate of 17%32. Next to the short term AEs related to 
surgery, long term AEs include vitamin and nutritional defi ciencies, marginal ulcera, and 
re-surgery due to AEs such as internal herniation33,34. Additionally, our center experiences 
in some patients weight regain, anorexia, and inexplicable chronic complaints leading to 
an undo; an operation to reverse the previous performed bariatric surgery.
Adjustments
Bariatric techniques are continuously adjusted, trying to achieve better weight loss, 
glucose control, and safety profi le. Studies are currently performed in which new types 
of bands are placed surrounding the pouch of the RYGB or the LSG, preventing weight 
regain. To increase benefi cial effects, other studies focus on adjusting the pouch size and 
changing the lengths of the Roux-limb, biliopancreatic limb, and common channel (data 
not yet published). Additionally, new types of surgery are performed, such as the mini 
gastric bypass in which only a single anastomosis is used35. However, the demand for 
new, better, and less invasive techniques that do not involve surgery, remains unchanged. 
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Minimal invasive bariatric techniques
Bariatric surgery is currently seen as the most effective treatment for (morbid) obesity 
and T2DM. However, the vast majority of patients with an increased cardiovascular 
risk, patients with overweight or obesity class I, do not fulfill the criteria required 
for bariatric surgery. Moreover, the level of invasiveness is large compared to other 
therapeutic options; lifestyle changes and medication. It results in a permanent change 
in gastrointestinal anatomy and is accompanied with possible severe short and long term 
AEs. Therefore new endoscopic techniques are explored which are less invasive and are 
preferably reversible. These techniques consider a wide range of gastric and small bowel 
interventions36.
The intragastric balloon
The intragastric balloon (IGB) was first approved by the FDA in 198537. It is the oldest 
minimal invasive technique for obesity and the only one for a prolonged period of time. 
The IGB is swallowed by the patient and filled with liquid or gas when it reaches the 
stomach. The IGB is thought to cause weight loss by a premature sensation of satiety 
and a suggested impeded gastric emptying38. Intragastric duration varies from several 
weeks to several months, depending on the type of balloon. Over the years, several types 
of IGBs were disapproved by the FDA because of their safety profile. Currently, only a 
few types are approved and available. Although the IGB keeps being improved, AEs are 
reported frequently, ranging from abdominal complaints to death39. Another disadvantage 
of treatment with the IGB is the sustainability of the reached effects after IGB removal.
Endoscopic bariatric techniques and devices
Since several years other minimal invasive endoscopic techniques to treat obesity and 
T2DM arose. Most of these treatments decrease the volume of the stomach or bypass the 
stomach and/ or a part of the small intestine. 
There are comparable upcoming techniques in which the volume of the stomach is 
endoscopically reduced by placing full-thickness sutures in the gastric wall. One of these 
techniques creates a sleeve gastroplasty, another technique is the primary obesity surgery 
endoluminal (POSE) procedure40,41. Although it does not involve surgery, this technique 
remains rather invasive because of the full-thickness sutures. The AspireAssist Aspiration 
Therapy System is a device that does not change the structure of the stomach or small 
intestine. This is a modified percutaneous endoscopic gastrostomy which allows the 
patient to release food from the stomach after a meal. This prevents further digestion and 
uptake and thereby induces weight loss42,43.
Other bariatric techniques focus on the small intestine instead of the stomach. Duodenal 
mucosal resurfacing is an endoscopic intervention in which complete circumferential 
ablation of the duodenal mucosa is performed with subsequent mucosal healing, thereby 
improving hyperglycaemia in patients with T2DM44.
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The last category of devices focus on bypassing a part of the gastrointestinal tract, 
comparable with the RYGB. The gastro-duodenal-jejunal bypass sleeve (ValenTx) is a 
sleeve of 120cm that bypasses the stomach, the duodenum, and the proximal part of 
the jejunum. In the fi rst part of the procedure the sleeve is endoscopically deployed 
down through the pylorus into the proximal jejunum. In contrast, the second part of the 
procedure considers proximal cuff attachment by a laparoscopic procedure in which the 
device is attached at the gastro-esophageal junction with help of nitinol suture anchors45. 
The disadvantage of this technique is that it requires a laparoscopic procedure, making it 
more invasive as the previously described devices.
A technique that also bypasses a part of the small intestine and is completely placed 
endoscopically is the duodenal-jejunal bypass liner (DJBL).
The duodenal-jejunal bypass liner
The DJBL (EndoBarrier®, GI Dynamics, Boston, Massachusetts, USA) is minimal 
invasive endoscopic device to treat obesity and T2DM. It consists of two parts and is 
placed completely endoscopically. The distal part is a 61cm fl uoropolymer liner and 
is enrolled from the duodenum into the proximal part of the jejunum. The liner covers 
the wall of the proximal small bowel, including the papilla of Vater. However, bile and 
pancreatic fl uids are able to pass and mix with bowel content further downstream. Food is 
transported from the stomach into the liner and thereby bypasses the fi rst part of the small 
bowel. The liner is attached to the proximal part of the device: a self-expanding nitinol 
anchor that fi xates itself in the duodenal wall with help of 10 barbs that are located in two 
directions. This helps to keep the DJBL in place. The DJBL is endoscopically positioned 
in the duodenum bulb by upper endoscopy and fl uoroscopic guidance. During delivery, 
liner and anchor are positioned in a protective capsule which is passed to the duodenum, 
just distal to the pylorus. 
During development of the DJBL multiple adjustments have been made to prevent the 
DJBL from migrating distally. The length of the barbs of the anchor were increased and 
the initial hollow barbs were replaced by solid barbs. Additionally, the implantation 
device was adjusted to facilitate more convenient implantation. After several animal 
studies46-48, the human implantation period was at fi rst 12 weeks49,50. When DJBL 
implantation appeared feasible, the implantation period was gradually increased to 52 
weeks. However, removal of the device can be achieved at any time point.
Through bypassing the proximal part of the small intestine, the DJBL is thought to cause 
changes in gastrointestinal peptides resulting in increased satiety levels, weight loss, and 
improved glucose control in patients with T2DM. Three randomized controlled trials 
showed encouraging results on weight loss and glucose control51-53. Supported by these 
results and the increased commercial availability, the number of DJBL placements rose 
sharply. Yet, multiple aspects of this device still have to be enlightened to determine the 
true effi cacy-safety ratio.
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Aim and outline of thesis
The overall aim of this thesis is to determine the efficacy as well as the safety profile of the 
DJBL in the real world setting. We hypothesize that the DJBL results in significant weight 
loss and improvement of diabetes parameters during implantation and that these effect 
sustain for at least one year after removal of the DJBL. Additionally, we hypothesize that 
the DJBL has a beneficial safety profile with a low rate of severe AEs that can be managed 
appropriately.
In accordance with the aim, this thesis is divided in two parts. Part A considers the 
effects of the DJBL on body weight and glycemic control in patients with T2DM during 
a varied length of implantation periods, as well as the effects after removal of the DJBL. 
Part B illustrates the safety profile of the DJBL with an extensive description of a wide 
variety of AEs related to the use of the DJBL. Table 1.1 shows an overview of the research 
questions, study design and measures per chapter of this thesis.
Part A, on the efficacy of the DJBL, consist of 4 chapters. Chapter 2 describes the effects 
of the DJBL on type 2 diabetes, obesity and other cardiovascular parameters during an 
intended 12 month implantation time in a large observational prospective cohort study. In 
addition, we address the number and causes of early explantations and accompanying AEs 
related to the treatment. Finally, we defined predictive factors for success of treatment. 
Chapter 3 presents a multi-center cross-over study in which patients first received a 
dietician supported diet during 6 months which was followed by DJBL treatment for 6-12 
months. This study design made it possible to have patients treated with the DJBL to be 
their own controls, comparing their outcomes with the dietary period. After removal of 
the device, patients were followed for an additional 6 month period. Chapter 4 addresses 
an important aspect of a technique that is temporarily of nature: the durability of the 
gained effects after removal of the DJBL. This chapter describes changes in body weight, 
glucose control and other cardiovascular parameters until 1 year after explantation. In 
Chapter 5, the last part of the efficacy of the DJBL, results are shown of patients who 
underwent an extended implantation time of up to 24 months. Besides efficacy, early 
removals and AEs are elaborated.
Part B, safety aspects of the DJBL, is introduced by Chapter 6, a systematic review 
presenting all AEs in literature. This systematic review classified the AEs systematically 
and determined in all articles quality of reporting of the AEs. Chapter 7a provides a 
short introduction and rationale to the following chapters. Chapter 7b considers the 
safety profile of the DJBL and shows a wide variety of AEs and provides basic advices 
how to recognize and manage these AEs. A frequently and potentially severe AE, acute 
pancreatitis, is elaborated in Chapter 7c. This case series describes 5 cases of acute 
pancreatitis in patients treated with the DJBL and the assumed etiology. Chapter 7d, the 
last of part B, contains an illustrative atlas of the normal situation after placement and 
AEs that are related to the treatment of the DJBL.
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Finally, this thesis is completed with a summarizing discussion with future perspectives 
in Chapter 8. The general discussion gives an overview of the previous chapters and 
values the effi cacy-safety margin of treatment with the DJBL and places this within our 
current medical ethical context.
Table 1.1: Research question, study design, and measures of this thesis
Part A. Effi cacy of the duodenal-jejunal bypass liner
# Research question Study design Measures
2
• What are the effects of DJBL on obesity, 
T2DM, and other cardiovascular 
parameters during 12 months 
implantation?
• What is the safety profi le of DJBL?
• What are predictive factors for success?
Prospective, 
observational 
cohort
• Prior to and during DJBL 
implantation:
 ◦ registration of body weight, 
medication, and AEs
 ◦ taking blood samples 
• Poisson regression analysis
3
• What are the effects of DJBL on obesity 
and T2DM during 6 and 12 months 
implantation preceded with 6 months 
diet?
• What ere the effects on obesity and 
T2DM 6 months after explantation of 
DJBL?
• What is the safety profi le of DJBL?
Multicenter, 
prospective, 
crossover 
cohort
• Prior to and during DJBL implantation 
and after DJBL explantation:
 ◦ registration of body weight, 
medication, and AEs
 ◦ taking blood samples 
• 4-hour meal tolerance test
4
• What are the effects on obesity and 
T2DM 12 months after explantation
Prospective, 
observational 
cohort
• After explantation:
 ◦ registration of body weight, 
medication, and AEs
 ◦ taking blood samples
5
• What are the effects of DJBL on 
obesity and T2DM during 24 months of 
implantation?
• What are the effects on obesity and 
T2DM 24 months after explantation?
• What is the safety profi le of DJBL?
Prospective, 
observational 
cohort
• Prior to and during DJBL implantation 
and after DJBL explantation:
 ◦ registration of body weight, 
medication, and AEs
 ◦ taking blood samples 
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Table 1.1: Research question, study design, and measures of this thesis (continued)
Part B. Safety of the duodenal-jejunal bypass liner
# Research question Study design Measures
6
• What is the safety profile of DJBL?
• What are factors associated with 
unfavorable outcome?
Systematic 
review of 
literature
• Systematic literature search (PRISMA)
• Classification AEs according to ASGE 
guidelines
• Qualitative assessment of reporting 
AEs (McHarm)
• Assessment of risk of bias (Newcastle-
Ottawa scale)
7a – – –
7b
• What are AEs related to DJBL?
• What are underlying causes of AEs?
• What strategies can be used to manage 
AEs?
Prospective, 
observational 
cohort
• Registration of AEs during DJBL use
• Extensive analysis of types of AEs
7c
• What is the causal relation between 
DJBL and acute pancreatitis?
• How to recognize and manage acute 
pancreatitis in patients with DJBL?
Retrospective 
case series • Individual analysis of 5 cases
7d
• What endoscopic and radiological 
appearances are expected with AEs of 
DJBL?
Retrospective 
case reports • Individual analysis of cases
AEs: adverse events; ASGE: American society of gastrointestinal endoscopy; DJBL: 
duodenal-jejunal bypass liner; PRISMA: preferred reporting items for systematic reviews 
and meta-analyses; T2DM: type 2 diabetes mellitus
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Abstract
BACKGROUND: The duodenal-jejunal bypass liner (DJBL) is an endoscopic treatment 
for patients with type 2 diabetes mellitus (T2DM) and (morbid) obesity. The aim of the 
current study was to determine its efficacy and safety profile.
METHODS: Inclusion criteria for treatment with a DJBL were: age 18–70 years, BMI 
28–45 kg/m2, and T2DM with a HbA1c >48 mmol/mol. Primary outcomes were changes 
in HbA1c and body weight. Secondary outcomes included changes in blood pressure, 
lipids, and anti-diabetic medication. Predictive factors for success of treatment with the 
DJBL were determined.
RESULTS: Between 2011 and 2014, 185 out of 198 patients successfully underwent a 
DJBL implantation procedure, with an intended implantation time of 12 months. In these 
185 patients, body weight decreased by 12.8 ± 8.0 kg (total body weight loss of 11.9 ± 6.9 
%, p <0.001), HbA1c decreased from 67 to 61 mmol/mol (p <0.001) despite a reduction 
in anti-diabetic medication, and blood pressure and serum lipid levels all decreased. In 
total, 57 (31 %) DJBLs were explanted early after a median duration of 33 weeks. Adverse 
events occurred in 17 % of patients. C-peptide ≥1.0 nmol/L and body weight ≥107 kg at 
screening were independent predictive factors for success.
CONCLUSTIONS: Treatment with the DJBL in T2DM patients with (morbid) obesity 
results in improvement in glucose control, a reduction in anti-diabetic medication, and 
significant weight loss. The largest changes are observed within the first 3–6 months. 
Initial C-peptide levels and body weight may help to select patients with the greatest 
chance of success.
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Introduction
The prevalence of obesity and related diseases, such as type 2 diabetes mellitus (T2DM), 
has reached epidemic proportions1. Many patients struggle with conservative treatment 
for morbid obesity and T2DM and are not eligible or motivated for bariatric surgery. 
Additionally, patients with obesity class I (BMI 30–35 kg/m2) are often denied surgery, 
although there might be an indication2. As a result, several new endoscopic techniques 
have been introduced to fi ll the gap between conservative treatment and bariatric surgery. 
One of these treatments is the duodenal-jejunal bypass liner (DJBL), which has been used 
as a treatment for T2DM and (morbid) obesity for several years now. This endoscopic 
device has an intended implantation time of 12 months. Several short-term studies have 
shown positive effects on insulin resistance and weight loss. However, these results are 
based on 4 small randomized controlled trials (RCTs) including a total of 108 patients in 
the DJBL treatment arm3-6, one comparative study7 and several observational studies8-14, 
only including patients without T2DM or with a limited number of patients with T2DM. 
Additionally, the majority of these studies reported the results of a 6-month implantation. 
The aim of the present study was to determine the effects on T2DM and obesity and the 
safety profi le in patients treated by the DJBL with an intended implantation time of 12 
months.
Methods
Patient selection and outcome
In this prospective, observational cohort study, patients were eligible for treatment with a 
DJBL if they met the following criteria: age 18–70 years, BMI 28–45 kg/m2, T2DM with 
glycosylated hemoglobin A1C (HbA1c) levels >48 mmol/mol, and tested negative for H. 
pylori. If patients tested positive for H. pylori, eradication was performed with PantoPac. 
Patients using nonsteroidal anti-infl ammatory drugs or anticoagulant medication were 
excluded because of an increased risk of bleeding. All patient implanted with the DJBL 
received a proton pump inhibitor twice daily. Eight of the patients who were implanted 
with the DJBL were part of a RCT which was approved by the National Medical Ethics 
Review Committee6. The other patients were implanted with commercially available 
DJBLs (EndoBarrier, GI Dynamics, Lexington, Massachusetts, USA). The study was 
approved by the local institutional review board (Registration Number 746\100111). 
Implantation was planned for a duration of 12 months. Early explantation, defi ned as 
removal before 12 months, was performed in case of intolerance or adverse events 
(AEs) likely to be related to the DJBL. Intolerance was defi ned as persisting abdominal 
discomfort reducing quality of life, not responding to lifestyle interventions and/or 
medication. 
All patients visited the outpatient clinic 1 week, and 1, 3, 6, 9, and 12 months after 
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implantation. During each visit, body weight and blood pressure (BP) were measured 
and symptoms were recorded. In addition, fasting morning blood samples were taken for 
a complete blood count, and measurement of fasting plasma glucose (FPG), HbA1c, and 
lipid levels. At each visit, the importance of life style changes was stressed.
Dietary advice
Each patient received individual, professional dietary advice prior to, and 3 months after 
implantation. They were instructed to consume only fluids during the first 2 days after 
implantation, followed by pureed food during the remaining first 2 weeks to allow the 
liner to settle. Thereafter, the diet could be expanded, with some restrictions of specific 
foods to avoid discomfort and AEs. 
Adjustment of anti-diabetic medication
During the first 3 months, all patients were monitored by a single-center team of 
specialized diabetes nurses under supervision of an endocrinologist. Medication was 
adjusted according to predefined schedules that were derived from regimens used in 
patients undergoing gastric bypass surgery15. After 3 months, patients returned to their 
referring physicians. During the first 3 months, the primary aim of treatment was to allow 
weight loss to occur. Since hyperinsulinism is a major cause of weight gain, the primary 
aim was to reduce insulin levels. However, glucose levels were not allowed >10 mmol/L 
during this 3-month period. Metformin was continued in the maximally tolerated dose, 
sulfonylureas were decreased by 50 %, and GLP-1 agonists were changed on individual 
basis. Longacting insulin administered at bedtime was replaced by glimepiride 2 mg at 
8PM and thereafter titrated upwards to a maximum of 8 mg if necessary to maintain 
fasting glucose levels <8.0 mmol/L15.
Definitions
Changes in body weight were analyzed as the difference in absolute body weight, change 
in BMI, excess weight loss (EWL), and total body weight loss (TBWL). Changes in 
T2DM were analyzed as the absolute change in HbA1c, FPG and changes in anti-diabetic 
medication. Differences in cholesterol and BP were analyzed as absolute differences. 
Since the DJBL is a metabolic therapy according to the ASGE/ASMBS task force, success 
of the DJBL treatment can be considered in two areas: weight loss and T2DM. Success for 
weight loss was defined as a TBWL >5 % at time of explantation16. Success for remission 
of T2DM was more difficult to define because the official consensus definition of the 
American Diabetes Association relates to changes established after 1-year of treatment17. 
As explantation occurred earlier in a significant number of patients, we considered success 
in T2DM treatment as: (1) HbA1c <48 mmol/mol at time of explantation, with or without 
anti-diabetics; (2) stabilization or a decrease in HbA1c combined with a reduction in 
diabetes medication; (3) stabilization or a decrease in HbA1c with discontinuation of 
insulin. The latter criterion was used because many patients had a strong wish to stop their 
insulin treatment since this greatly affected their quality of life. Treatment with the DJBL 
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was considered successful if the criterion for weight loss as well as at least one criterion 
for T2DM was met.
Statistical analysis
Analyses were conducted with IBM SPSS Statistics for Windows, version 23.0 (Armonk, 
NY, IBM Corp.). Data are reported as mean ± standard deviation (SD) unless specifi ed 
otherwise. A p value of <0.05 was considered statistically signifi cant. Analyses between 
different groups were performed with an independent samples t-test for continuous 
variables and with the Pearson χ2 or Fisher’s exact test for dichotomous variables. 
Analyses between different time points were conducted with a paired sample t-test or 
Wilcoxon signed-rank test. All patients were included in the analysis according to the 
intention-to-treat principle when the implantation was successful, independent of the total 
implantation time. To identify independent factors for success, Poisson regression with 
robust standard errors was performed to produce relative risk ratios. Figures were created 
using GraphPad Prism version 5.1 (GraphPad Software, Inc.).
Results
Patient selection
Between March 2011 and November 2014, 198 patients underwent a DJBL implantation 
procedure, which was successful in 185 patients. Implantation failed in 13 (7 %) patients, 
Figure 2.1:  Total number of implantation procedures of the DJBL 
* One DJBL was explanted preliminary due to uterus carcinoma; two DJBLs were removed 
early because of start of anticoagulants due to an ocular stroke and a transient ischemic 
attack. DJBL: duodenal-jejunal bypass liner
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mainly because of abnormalities in local anatomy of the small intestine, such as polyps or 
sharp angulations in the small intestine that blocked the advance of the DJBL implantation 
system (Fig. 2.1). The 8 patients who were part of a RCT6 had an extension of their initial 
implantation time from 6 to 12 months. A total of 128 (69.2 %) patients completed the 
full implantation time after a mean implantation duration of 54 (±3.4) weeks. In 57 (30.8 
%) patients, the DJBL had been removed early after a median duration of 33 (range 1–51) 
weeks because of intolerance or AEs.
Table 2.1: Baseline demographics for the total group of patients in which the DJBL was 
successfully implanted, patients who completed the full implantation time, and patients 
who were explanted early
Total group
Full 
implantation 
time
Early 
explantation
p value
n = 185 n = 128 n = 57
Age (years) 52 ± 8 53 ± 8 52 ± 8 0.593*
Female 90 (48.6 %) 59 (46.1 %) 31 (54.4 %) 0.297†
Body weight (kg) 107 ± 18 109 ± 18.0 104 ± 16.8 0.097*
BMI (kg/m2) 35.1 ± 4.3 35.3 ± 4.4 34.5 ± 3.9 0.230*
Systolic BP (mmHg) 137 ± 15 139 ± 16 132 ± 13 0.014*
Diastolic BP (mmHg) 85 ± 10 85 ± 10 84 ± 10 0.541*
Duration T2DM (years) 8 (1–36) 8 (1–36) 8 (1–24) 0.672*
Blood values
Total cholesterol (mmol/L) 4.62 ± 1.08 4.60 ± 1.00 4.65 ± 1.25 0.775*
HDL (mmol/L) 1.08 ± 0.30 1.08 ± 0.32 1.07 ± 0.26 0.808*
Triglyceride (mmol/L) 2.50 ± 1.83 2.49 ± 1.76 2.53 ± 2.00 0.912*
LDL (mmol/L) 2.46 ± 0.89 2.50 ± 0.87 2.39 ± 0.93 0.495*
Fasting glucose (mmol/L) 10.9 ± 3.4 10.6 ± 3.2 11.6 ± 3.6 0.081*
HbA1c (mmol/mol) 67 ± 16 66 ± 15 69 ± 19 0.181*
Insulin (mU/L) 36 ± 51 34 ± 40 40 ± 69 0.469*
C-peptide (nmol/L) 1.18 ± 0.56 1.21 ± 0.59 1.13 ± 0.50 0.423*
Vitamin D (nmol/L) 43 ± 21 44 ± 22 42 ± 17 0.544*
Vitamin B12 (pmol/L) 312 ± 145 312 ± 146 312 ± 146 0.993*
Ferritin (lg/L) 178 ± 154 185 ± 158 164 ± 146 0.484*
Helicobacter pylori? 36 (19 %) 23 (19 %) 13 (23 %) 0.522†
Values are means with standard deviation, median with range in parentheses, or n with percents in 
parentheses. DJBL: duodenal-jejunal bypass liner, BMI: body mass index, BP: blood pressure, HbA1c: 
glycosylated hemoglobin AIc, HDL: high-density lipoprotein, LDL: low-density lipoprotein, T2DM: 
type 2 diabetes mellitus. * Independent samples t test,  † Pearson χ2
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Baseline characteristics
At time of screening, the total group had a mean age of 52 (±8) years, and a mean body 
weight of 107 kg (±18) with a mean BMI of 35.1 kg/m2 (±4.3). Males and females were 
equally distributed. Analysis was limited to the group of 185 patients who had been 
implanted with the DJBL. Thus, patients in which the DJBL could not be implanted (n 
= 13) were excluded from further analysis. When patients were divided into two groups: 
those completing the 12-month period and those with early removal, both groups were 
comparable for all baseline characteristics, except for systolic BP (p = 0.014) (Table 2.1). 
Therefore, all further analyses were performed considering the total group of 185 patients. 
Change in weight
Explantation was performed after a mean implantation time of 46 (±15) weeks for the 
total group. Weight decreased from 107.1 kg (±17.7) at baseline to 94.3 kg (±16.7) 
at explantation (p <0.001) (Fig. 2.2A). This decrease in weight of 12.8 kg (±8.0) was 
associated with a decrease in BMI from 35.1 kg/m2 (±4.3) to 30.9 kg/m2 (±4.3) (p <0.001) 
Figure 2.2: Changes in absolute body weight (A), body mass index (B), percentage excess 
weight loss (EWL) (C), and percentage total body weight loss (TBWL) (D) at baseline, 
during implantation with the DJBL, and at time of explantation (mean with 95 % CI)
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Figure 2.4: Changes in fasting plasma glucose (FPG) (A) and HbA1c (B) at baseline, 
during implantation with the DJBL, and at time of explantation (mean with 95 % CI)
Figure 2.3: Course of percentage total body weight loss (TBWL) classified by TBWL at 
time of explantation (mean with 95 % CI)
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Figure 2.5: Changes in percentage of patients on various types of anti-diabetic medication 
(A) and changes in medication dose (mean with 95% CI) (B) at baseline, during implantation 
with the DJBL, and at time of explantation
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(Fig. 2.2B). Percentage EWL increased from 14.3 % (±10.6) at 1 week after implantation 
to 40.9 % (±27.3) at 6 months, and to 46.3 % (±31.1) at time of explantation (p <0.001) 
(Fig. 2.2C). This is comparable with a %TBWL of 3.8 % (±2.7) at 1 week, 10.6% (±5.8) 
at 6 months, and 11.9 % (±6.9) at time of explantation (p <0.001) (Fig. 2.2D). 
Figure 2.3 shows the course of the %TBWL when the patients are classified by their final 
result in %TBWL (≤5 %; 5.0–9.9 %; ≥10 %). Good responders (%TBWL ≥10) show as 
of 1 week after implantation a significant greater %TBWL (p = 0.001) compared to bad 
responders (%TBWL ≤ 5).
Type 2 diabetes mellitus
The median time since diagnosis of T2DM was 8 (range 1–36) years at time of screening. 
The patients had a mean HbA1c of 67 mmol/mol (±16), a FPG of 10.9 mmol/L (±3.4), 
and a fasting C-peptide level of 1.18 nmol/L (±0.56). HbA1c and FPG decreased 
significantly by 6 to 61 mmol/mol (p <0.001) and by 1.2 to 9.7 mmol/L (±3.2) (p = 0.001) 
at explantation (Fig. 2.4). 
The four most used anti-diabetic drugs consisted of metformin, glimepiride, liraglutide, 
and insulin. Figure 2.5A, B shows the changes in percentages of use and dosage during 
the course of implantation, respectively. At baseline, 156 patients (84 %) were on 
metformin with a mean dose of 1962 mg (±712). Metformin was used in combination 
with another oral anti-diabetic (sulfonylurea derivate or DPP4- inhibitor) in 70 (38 %) 
patients, together with insulin in 88 (48 %) patients, and combined with liraglutide in 
20 (11 %) patients. The dosage and percentage of users of metformin remained stable. 
The number of patients using glimepiride increased at time of implantation compared to 
screening from 64 (35 %) to 115 (62 %) because patients were switched from long-acting 
insulin to glimepiride. As a result, the number of insulin users decreased from 90 (49 %) 
at screening to 70 (38 %) at implantation, and the mean daily dose of long-acting insulin 
decreased from 51 ± 30 to 24 ±13 IU (p = 0.001). Additionally, Fig. 2.5A shows that the 
number of patients using short-acting insulin decreased over time from 69 (37 %) to 40 
(22 %) patients at explantation. Both the number of patients using liraglutide and the 
dosage of liraglutide increased during follow-up from 20 to 24 patients and from 1.89 to 
2.15 mg, respectively.
Cardiovascular parameters
Systolic and diastolic BP decreased significantly by a mean of 4.9 ± 19.2 and 6.4 ± 
13.4 mmHg, respectively (Table 2.2). All serum lipid levels had decreased at time of 
explantation compared to baseline. Total cholesterol, HDL cholesterol, and triglycerides 
showed a statistically significant decrease of 0.37 ± 1.02, 0.06 ± 0.19, and 0.41 ± 1.27, 
respectively. The decline in LDL cholesterol from 2.51 ± 0.91 to 2.39 ± 0.85 mmol/L did 
not reach statistical significance (Table 2.2). In the majority of patients, cardiovascular 
medication was not adjusted during implantation time.
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Table 2.2: Changes in blood pressure and cholesterol values at baseline, during implantation 
with the DJBL, and at time of explantation
Parameter Baseline Month 1 Month 3 Month 6 Month 9 Explantation
Systolic BP 
(mmHg) 137 ± 15 130 ± 15 131 ± 16 130 ± 13 130 ± 14 132 ± 18*
Diastolic BP 
(mmHg) 85 ± 10 84 ± 9 81 ± 11 82 ± 9 83 ± 9 79 ± 12*
Total 
cholesterol 
(mmol/L)
4.63 ± 1.07 4.07 ± 1.07 4.05 ± 0.87 4.15 ± 1.09 4.22 ± 0.80 4.25 ± 0.99*
HDL 
(mmol/L) 1.09 ± 0.31 0.98 ± 0.24 0.98 ± 0.26 1.01 ± 0.28 1.05 ± 0.29 1.03 ± 0.30*
Triglyceride 
(mmol/L) 2.44 ± 1.64 2.07 ± 1.03 2.05 ± 1.05 2.01 ± 1.14 1.92 ± 1.04 2.02 ± 0.93*
LDL 
(mmol/L) 2.51 ± 0.91 2.15 ± 0.87 2.20 ± 0.79 2.18 ± 0.79 2.35 ± 0.73 2.39 ± 0.85NS
Values are means with standard deviation in parentheses. Statistical comparison was only performed 
between baseline and explantation. DJBL: duodenal-jejunal bypass liner, BP: blood pressure, HDL: 
high-density lipoprotein, LDL: low-density lipoprotein, NS: not statistically signifi cant. Independent 
samples t test; * p <0.01
Intolerability and adverse events
Minor AEs, such as abdominal discomfort and nausea, were frequently reported, in 
particular in the fi rst 2 weeks after implantation. In total, 34 (18 %) patients became 
intolerant and required early removal (Fig. 2.1). More serious adverse events leading 
to hospitalization or prolonged hospital stay are listed in Table 2.3. These AEs are 
classifi ed in four categories: procedure related, defi nitely related, probably related, or 
a low suspicion to be related to the DJBL. In total, 39 AEs were reported in 32 (17 %) 
patients, which led to early removal in 20 patients. Two DJBLs were removed surgically 
because of an arterial bleeding and an affi xed anchor in the duodenal bulb. One patient 
experienced an esophageal lesion during implantation and one an esophageal perforation 
during explanation. One patient developed severe acute pancreatitis and was hospitalized 
for 18 weeks. Four patients developed hepatic abscesses, all possibly related to the 
DJBL. No mortality was reported, while the DJBL was in place or during follow-up after 
explantation.
Predicting variables for success and failure of the DJBL
Success of the DJBL treatment was univariately related to the continuous variables age, 
weight, BMI, and C-peptide at time of screening and the dichotomous variable sex. 
Subsequently, all continuous variables were converted to dichotomous measures to allow 
Poisson regression analyses. After backward selection, the fi nal model produced two 
independent predictive variables. Fasting C-peptide at time of screening ≥1.0 nmol/L
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Table 2.3: Adverse events during the complete implantation time of the DJBL and just after 
explantation resulting in hospitalization or prolonged hospital stay
Adverse event N Weeks to event Mean
Procedure related
Esophageal perforation during explantation procedure 1 49
Esophageal lesion during implantation procedure 1 –
Subtotal 2
Definitely device related
Anchor related
Perforation of the anchor next to pylorus into the stomach 4 51; 52; 54; 55 53
Anchor affixed in the duodenal bulb due to tissue 
overgrowtha
1 53
Ulceration and stenosis of the duodenal bulb by a distally 
migrated anchor
1 43
Bleeding, arteriala,b 3 6; 6; 50 21
Bleeding, venous 8 1; 2; 2; 3; 3; 4; 37; 44 12
Bleeding, venous, after start of anticoagulants because of 
myocardial infarction
1 50
Bleeding, venous, after explantation 2 0.5; 0.5c 0.5c
Sleeve related
Obstruction sleeve 1 17
Obstruction sleeve and intussusception of the small intestine 1 37
Subtotal 22
Suspected device related
Acute pancreatitis, mild 5 2; 30; 33; 35; 49 30
Acute pancreatitis, severe 1 21
Liver abscess 4 20; 32; 44; 53 37
Duodenitis 1 1
Subtotal 11
Low suspected device related
Hypokalemia and hypomagnesemia due to persistent 
diarrhea (4 months) during implantation time
1 49
Reversible acute kidney injury due to persisting diarrhea 1 2
Severe constipation during implantation time poorly 
responding to treatment
1 25
Thrombosis of the mesenteric vein till the portal vein 1 2
Subtotal 4
Total 39
a Two surgical removals needed to be performed: one to explant the affixed anchor in the duodenal bulb, and 
other to treat the arterial bleed. b One arterial bleed was first managed by embolisation of the gastroduodenal 
artery, after which one day later the DJBL was explanted endoscopically. c Number of weeks after explantation 
of the DJBL
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and body weight at time of screening ≥107 kg (comparable with a mean BMI 35 kg/ m2) 
had a relative risk ratio of 1.63 (95 % CI 1.135–2.340) and 1.37 (95 % CI 1.004–1.857), 
respectively. 
Discussion
Our cohort study with the largest group of T2DM patients treated with the DJBL up till 
now shows a mean TWBL of 11.9 % and a mean decrease in HbA1c of 6 mmol/mol 
combined with a substantial reduction in anti-diabetic drugs at explantation, after a mean 
implantation time of 46 weeks. Additionally, BP and all cholesterol levels decreased 
during implantation. However, DJBL treatment was associated with one or more AEs in 
17 % of the patients and an early removal rate of 31 %. 
The changes in weight, glycemic control, BP and lipid levels vary widely in previous 
reports. This is partly explained by different durations of implantation time and 
variability in drug regimens. Implantation durations ranged from 12 to 52 weeks, since 
the maximum permitted implantation duration increased over time. Our cohort showed 
a decrease in weight of 12.8 kg (TBWL 11.9 %; EWL 46.3 %). Other studies with a 
52-week implantation time reported an absolute weight loss of 5.9 and 6.5 kg13,18, and 
an EWL ranging from 39 to 47 %11,12,14. These same studies, in which the largest study 
included 22 T2DM patients, showed reductions in HbA1c up to 23 mmol/mol and FPG 
reductions up to 2.7 mmol/L. It is unclear whether these patients are comparable to our 
patient group, since no baseline HbA1c and FPG are presented. Although our results 
on weight loss are superior or comparable to other studies, the results on HbA1c and 
FPG improvement are inferior. The difference in response might be attributed to a major 
difference in medication adjustment. The comparator studies tried to remain the anti-
diabetic medication constant, as we performed a major reduction in insulin use to amplify 
DJBL-induced weight loss. As a result, 51 % had stopped insulin at explantation. In the 
patients who were still using insulin, predominantly short-acting insulin, the daily dose 
had signifi cantly decreased by 40 IU per day. This large reduction might explain the 
relatively minor improvements in FPG and HbA1c. Additionally, our patient group had 
a median duration of T2DM of 8 years. A longer duration of T2DM is associated with a 
decline in β cell function and larger dependence on anti-diabetic drugs. 
Decreases in BP and lipid levels, including HDL, have been observed in previous studies, 
and are comparable to our data11-13. Other benefi cial systemic effects of the DJBL on 
plasma parameters of nonalcoholic fatty liver disease were recently demonstrated19. 
Our data show that the largest metabolic effects are observed during the fi rst 3–6 months 
after implantation, with changes in weight occurring as of 1 week. After the fi rst 6 
months, most parameters stabilized or improved only slightly. Moreover, in patients with 
early DJBL removal at a median of 33 weeks, the changes in study parameters were 
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comparable to those completing the full implantation time. This suggests that the main 
effect is reached before 52 weeks. 
The rapid response after placement might be explained by the strict diet changes during 
the first 2 weeks. Lips et al. showed that early improvement of glycemic control is caused 
by restriction in calories20. Additionally, as of placement of the DJBL, patients report 
an increased satiety, resulting in a continuing decreased caloric intake. This might be 
related to intestinal hormone changes, such as lowering of plasma ghrelin levels, as has 
been shown after RYGB. Recently, it has been observed that GLP-1 levels increase, and 
GIP levels and glucagon response decrease within 1 week after DJBL implantation21. 
We hypothesize that early changes in weight and insulin sensitivity result from reduced 
intake combined with changes in incretin hormones. Persisting changes in incretin levels 
with an improved satiety and therefore sustained reduced intake result in stabilization 
during the second part of the implantation period. 
Treatment with the DJBL is accompanied by intolerance and AEs, of which some are 
serious. In our cohort, the DJBL was explanted early in 31 %, which is slightly higher 
than the 24 % previously reported22. However, this review included studies with a 
shorter implantation time. Studies considering an implantation time of 1 year reported 
early explantations rates from 20 to 38 %11-14, except for one that reported no early 
explantations18. The review presents 6 (4 %) gastrointestinal bleeds out of 162 patients22, 
and an additional three case reports considered three AEs related to the DJBL23-25. A part 
of our AEs are extensively discussed in two separate articles concerning the safety of the 
DJBL treatment, with in particular the relation to acute pancreatitis26,27. It is important that 
patients and physicians are informed concerning these serious AEs. The barbs that hold 
the DJBL in place can cause perforation of the esophageal mucosa during implantation 
and explanation. Additionally, during the complete implantation time, there is a bleeding 
risk. The barbs of the anchor can lead to a venous bleed by mucosal damage, but also can 
cause a perforation of an artery located at the duodenum. Compared to other literature, 
our number of AEs is considerably higher. This is possibly explained by a shorter 
implantation time and small patient numbers in other studies. 
To determine which patients benefit most from DJBL treatment, fasting C-peptide at time 
of screening ≥1.0 nmol/L and body weight at time of screening ≥107 kg were detected 
as independent predictive factors for success of DJBL treatment. The C-peptide cutoff 
of 1.0 nmol/L was selected because a previous report showed that these patients have a 
higher chance of complete T2DM remission after RYGB28. Body weight of 107 kg was 
comparable with BMI 35 kg/m2, which reflects the limit of bariatric surgery for patients 
with T2DM. 
Our data illustrates that patients that were classified as good responders (%TBWL ≥10) 
show a significant better early response in weight loss than others (%TBWL <10.0) as of 
1 week after implantation. Therefore, patients who need additional counseling to change 
their lifestyle can be identified in the first week to month after implantation. 
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Patients suffering from (morbid) obesity with T2DM have several therapeutic options: 
fi rstly, lifestyle modifi cation, although safe, long-term results are disappointing; secondly, 
medication such as orlistat, which leads to a placebo-subtracted weight loss of 2.3 kg 
(95 % CI 1.6–3.0) in patients with diabetes when treated for 1 year. However, this is 
associated with gastrointestinal side effects in 15–30 % of patients29. Treatment of T2DM 
with oral anti-diabetics or insulin is considered standard care. However, start of insulin 
is commonly associated with weight gain. The exceptions are metformin monotherapy 
(possibly a slight decrease in weight), DPP4 (weight neutral), and GLP-1 agonist (TBWL 
of 8 %30). More invasive treatment starts with the intragastric balloon. When combined 
with conventional treatment, it results in weight loss of 14.7 kg (TBWL 12.2 %) with 
a majority of mild complications and an early removal rate of 4.2 %31. However, the 
durability of the weight loss and effects on diabetes is unclear. The currently gold standard 
for treatment of morbid obesity is bariatric surgery (EWL >50 %)32 and glucose control 
in 42 % one year postoperative33. Thirty-day mortality is 0.3 %, and 4.3 % of the patients 
had at least one major adverse outcome34. Therefore, treatment with the DJBL could fi ll a 
niche. It combines adequate weight loss with improved glucose control and is reversible 
with no defi nite changes to normal anatomy. We suggest that the combined use of DJBL 
and GLP-1 might serve to potentiate the effects of both approaches. 
Our study has several limitations. The patients received a combination of lifestyle changes 
and DJBL treatment. Since there was no control group that received lifestyle changes only, 
the true effect of the DJBL alone cannot be established accurately. Results of large RCTs 
are needed to determine this effect. Recently, such RCT was conducted (ClinicalTrials.
gov NCT01728116), but had to be terminated early. Therefore, the demand for such RCTs 
continues to exist. A second limitation of our study considers that the mean implantation 
time was <1 year due to early explantations. This might have led to an underestimation of 
the effects of the DJBL. However, implantation for 1 year is not feasible in 31 %. At last, 
the reduction in anti-diabetics may have been too drastic in some patients, resulting in an 
underestimation of the effect of the DJBL on T2DM. 
Future research should consider re-implantation of the DJBL when patients experience 
relapse after explantation. This might be considered in patients who achieved good results 
during their initial implantation. Also, patients who responded well and experience no 
discomfort or AEs might become eligible for an extended implantation time to stabilize 
the benefi cial effects over a prolonged period of time. This could improve the cost-benefi t 
ratio. 
The results of our cohort study shows that treatment with the DJBL has signifi cant 
benefi cial effects on weight, glycemic control, lipid levels, and BP in patients with 
uncontrolled T2DM and (morbid) obesity. The largest benefi cial effects are seen 
during the fi rst 3–6 months after implantation. However, interindividual effi cacy varies 
considerably and since 1 out of 6 patients experiences an AE, of which some are serious, 
patients should be carefully selected. Although fasting C-peptide and body weight may 
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help to select patients with the greatest expected benefit, future studies will be needed to 
further specify patient characteristics, the optimal way of support during implantation 
and the sets of anti-diabetic medication that are associated with the largest benefits. When 
optimized, the DJBL might fill a useful niche in the treatment of patients with T2DM and 
(morbid) obesity.
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Abstract
OBJECTIVE: The aim of this research was to study the duodenal-jejunal bypass liner 
(DJBL) treatment for obesity and type 2 diabetes mellitus (T2DM) in patients after 
dietary treatment in a crossover design. 
BACKGROUND: DJBL treatment has been proven effective for treatment of obesity and 
T2DM. However, data on safety and efficacy of a 12-month DJBL treatment is limited.
METHODS: In 2014, our research group reported on a multicenter randomized clinical 
trial. Patients were randomized to DJBL or dietary treatment (control group). Twenty-
eight patients crossed over after their dietary treatment and received up to 12 months 
of DJBL treatment. Patient visits were conducted at baseline, during DJBL treatment (1 
week, 1–6, 9, 12 months) and 6 months after removal of the liner. Patients underwent a 
standard physical examination, blood sampling, assessment of adverse events, nutritional 
and diabetes counseling, and a standardized meal tolerance test. 
RESULTS: Of the 28 patients included in this study, 24 patients completed 6 months of 
treatment. Eighteen patients were extended to 12 months of DJBL treatment; 13 patients 
completed this treatment period. After 6 months of DJBL treatment, a significant increase 
in excess weight loss (EWL) and decrease in weight, BMI, HbA1c, fasting glucose, 
cholesterol, HDL and LDL improved significantly. After 12 months of DJBL treatment, 
these parameters stabilized. 
CONCLUSIONS: The DJBL is an effective, minimally invasive treatment option. 
Even after successful treatment with dietary restrictions, the DJBL is still capable of 
significantly reducing weight and improving cardiovascular and type 2 diabetes mellitus 
parameters in obese patients.
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Introduction
Worldwide over 600 million people suffer from obesity (BMI ≥30 kg/m2)1,2. The 
population of the USA accounts for 13% of this obese population, which is approximately 
one third of the country’s population3. Indicating the magnitude of this disease, also in 
Europe 15–30% of the adult population is affected4. 
The obese population is at high risk to develop chronic diseases, such as metabolic 
disorders (diabetes mellitus, fatty liver disease), cardiovascular diseases, cancer, and 
wear and tear of the musculoskeletal organ5-8. Furthermore, obesity is associated with 
increased mortality9. Surgery has been proven most successful in the treatment of obesity 
and its comorbidities10-12. However, current surgical techniques are still accompanied 
by perioperative and postoperative complications. Not all patients can benefi t from 
these surgical approaches since only patients with a BMI ≥35 with comorbidities or a 
BMI of ≥40 without comorbidities are, according to the current guidelines, considered 
for surgical treatment12-14. Several endoluminal techniques have been developed with 
the intent to reduce perioperative and postoperative complications while maintaining 
treatment success. These techniques also provide an alternative treatment option for the 
growing overweight and obese population (BMI between 25 to 35 kg/m2). 
The duodenal-jejunal bypass liner (DJBL) is a promising endoluminal device mimicking 
the Roux-en-Y gastric bypass. The liner consists of an impermeable sleeve that is open at 
both ends to allow food passage. The liner is temporarily fi xed in the duodenal bulb and 
extends into the jejunum. This way the pancreatic secretions and bile will only mix with 
the food distal to the liner, hereby creating a functional bypass of the duodenum and the 
proximal jejunum. Several studies investigating the DJBL have shown the procedure to 
be safe and effective with good results regarding weight reduction, improvement of type 
2 diabetes parameters, and a decrease in cardiovascular parameters15-19. 
However, most studies investigated a treatment duration of 3–6 months and data on safety 
and effi cacy of 12 months duration of treatment with the DJBL is limited. 
The aim of this study was to evaluate the safety and effi cacy of 12 months treatment with 
the DJBL in a randomized crossover study design, making the patients their own controls. 
We hypothesize that treatment for 12 months with DJBL is safe and will accomplish a 
decrease in body weight accompanied by an improvement in blood glucose levels and 
cardiovascular parameters. 
Methods 
In 2014, our research group reported on a large cohort study of 77 patients that were 
included in a multicenter randomized clinical trial conducted in the Netherlands at the 
Maastricht University Medical Center, the Zuyderland Medical Center (formerly known 
as the Atrium Medical Center) Heerlen, and the Rijnstate hospital Arnhem. During this 
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clinical trial, patients were randomized either to the DJBL treatment group or to the diet 
control group. 
In short, inclusion criteria consisted of a BMI ranging from 30 to 50 kg/m2, type 2 diabetes 
for less than 10 years, and a glycated hemoglobin A1c (HbA1c) level between 7.5%–10%. 
In addition, patients were only allowed to take metformin, sulfonylurea (SU) derivatives, 
and/or insulin with a maximum dose of 150 IU. Most important exclusion criteria 
consisted of: prior weight loss of more than 4.5 kg, use of weight loss medication, innate 
insulin production failure as indicated by low C-peptide levels, GI tract abnormalities 
or prior surgery of the GI tract that could affect device placement, bleeding disorders, 
connective tissue disorders, and severe liver or kidney disease16. 
At baseline, patients were assessed extensively. Before the procedure, patient 
demographics and medical history were evaluated, and a physical examination (including 
weight, BMI, and blood pressure) was performed. Further patient evaluation consisted 
of blood parameter outcomes (diabetes parameters and cardiovascular parameters) and 
a standardized 4-h meal tolerance test using a liquid meal. Throughout the study, a diet 
with a maximum of 1200 kcal for women and 1500 kcal for men was prescribed of which 
the first week consisted of a liquids only regimen. Additionally, a diabetes nurse under 
supervision of an endocrinologist carried out the management of medical treatment of 
T2DM. 
A total of 38 patients were randomized to the DJBL treatment group and 39 patients to 
the diet control group. Treatment protocol consisted of 6 months of DJBL treatment or 
control treatment with subsequently 6 months of follow-up. After 12 months, patients that 
were randomized to the diet group were offered the DJBL treatment for 6 months with an 
optional extension to 12 months treatment. We here describe this cross-over group. 
Patient visits were conducted at baseline and during DJBL treatment at 1 week, monthly 
during the first 6 months, and for the extended treatment also at 9 and 12 months. In 
addition, patients were followed until 6 months after removal of the device. 
During these visits, patients underwent a standard physical examination (including 
weight, BMI, and blood pressure), blood sampling, assessment of adverse events, and 
nutritional and diabetes counseling. Furthermore, a standardized meal tolerance test using 
a liquid meal (Ensure Plus vanilla flavor, Abbott Laboratories, Abbott Park, IL; 333 mL, 
500 kcal, 20.8 g of protein, 67.3 g of carbohydrates, and 16.4 g of fat) was conducted at 
baseline, 3, 6, and 12 months during the DJBL treatment. 
The study was conducted according to the principles of the Standard ISO 14155: 2003 on 
clinical investigations with medical devices and the recommendations guiding physicians 
in biomedical research involving human patients adopted by the 18th World Medical 
Assembly, Helsinki, Finland, 1964 and later revisions and also in accordance with the 
guideline Medical Research Involving Human Subjects Act (WMO). The study was 
approved by the medical ethical committee of all three participating medical centers. The 
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general principles of informed consent, ethics review, and data management were in line 
with good clinical practice (GCP). 
DJBL procedure 
The DJBL was developed to mimic the duodenal bypass component of the Roux-en-Y 
gastric bypass. The device consists of a 61-cm long impermeable fl uoropolymer liner 
and a nitinol anchor, which is used to fi xate the liner in the duodenal bulb. The procedure 
was performed endoscopically. After positioning of the endoscope in the stomach, the 
fl uoropolymer liner was advanced into the duodenum and unfolded into the proximal 
jejunum. Removal of the DJBL was performed as previously described15-16. 
Statistical analysis 
All data are presented as median and interquartile ranges (IQR) since data were not 
normally distributed. Comparisons were performed using the Wilcoxon signed rank test. 
The repeated measures Friedman analysis of variance was used to assess change over 
time. Post hoc testing was performed using the Wilcoxon signed rank test with Bonferroni 
correction. p <0.05 was regarded as signifi cant. Missing data were not imputed. All 
statistical analyses were performed using commercially available computer software 
(IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, 
NY: IBM Corp.). 
Results 
Patient characteristics 
Twenty-eight patients were implanted with the DJBL. Patient characteristics were 
compared between baseline and preimplantation as described in Table 3.1 (17 males, 
Figure 3.1: Flow-chart
Boek.indb   53 21-03-2019   10:23
54
Chapter 3
3
median age 52 (48–56), 11 females, median age 48 (44–55)). Of these 28 patients, 18 
were extended to 12 months of DJBL treatment. Reasons for early removal consisted 
of device related adverse events (Fig. 3.1). During the dietary treatment period, prior to 
12 months implantation with the DJBL, patient characteristics already had significantly 
changed compared to baseline. This resulted in a significant difference prior to the DJBL 
intervention period for the following parameters: patients that were initially in the control 
group had a significant lower weight, BMI, systolic and diastolic blood pressure before 
implantation of the DJBL (Table 3.1). 
Effect of DJBL treatment on weight, cardiovascular, and type 2 diabetes parameters 
At 6 months of DJBL treatment, median weight was decreased from 109.7 (92.2–122.5) 
kg to 100.2 (86.7–114.8) kg (p <0.001). Correspondingly, a median drop in BMI from 
34.8 (31.4–39.0) kg/m2 to 32.8 (29.9–37.7) kg/m2 (p <0.001) and an excess weight loss 
of 32.8 (22.3–40.0) % (p <0.001) was seen (Fig. 3.2). As shown in Fig. 3.3, HbA1c 
decreased from 8.2 (7.1–9.0) % to 7.6 (6.7–8.3) % (p <0.01). In addition, fasting glucose 
levels dropped from 9.7 (8.8–13.3) mmol/L to 8.1 (7.1–9.8) mmol/L (p <0.01). During 
6 months of treatment, also a significant decrease in total cholesterol was seen from 4.5 
(4.1–5.0)mmol/L to 3.9 (3.2–4.4) mmol/L (p <0.01). Simultaneously, HDL decreased 
from 1.2 (1.0–1.5) mmol/L to 1.1 (0.78–1.25) mmol/L (p <0.001) and LDL from 2.3 
(1.93–3.0) mmol/L to 2.1 (1.5–2.4) mmol/L (p <0.01). After 6 months of DJBL treatment, 
parameters remained stable during the extended treatment period up to 12 months. 
Table 3.1: Comparison of weight, glucose metabolism and cardiovascular parameters 
between baseline and preimplantation time point (n = 28). 1 n = 25 patients included for analysis
Baseline
6 months dietary treatment 
plus 6 months FU
p value
Sex (male/female) 17/11 - -
Age (years) 50 (46-56) - -
Weight (kg) 113.4 (99.4-128.7) 110.4 (93.4-122.5) 0.001
BMI (kg/m2) 37.0 (33.0-42.9) 35.2 (31.7-40.0) 0.001
Duration of T2DM (years) 5.0 (3.3-7.8 - -
HbA1C (%) 8.1 (7.7-8.8) 8.2 (7.0-8.8) NS
Fasting glucose (mmol/L) 11.0 (9.1-8.8) 8.2 (7.0-8.8) NS
Fasting insulin (pmol/L) 128.6 (83.4-284.5) 114.0 (57.7-165.8) NS
Systolic blood pressure (mmHg) 152 (131-159) 137 (121-147) 0.001
Diastolic blood pressure (mmHg) 90 (80-95) 82 (77-90) 0.002
Total cholesterol (mmol/L) 4.3 (3.5-5.3) 4.4 (3.9-5.0) NS
HDL (mmol/L) 1.2 (0.9-1.3) 1.2 (1.9-2.9) NS
LDL (mmol/L)1 2.2 (1.7-2.8) 2.3 (1.9-2.9) NS
Triglycerides (mmol/L) 1.8 (1.4-3.1) 1.7 (1.3-2.3) NS
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Overall effect after 6 months diet plus 6 months follow-up and DJBL treatment 
Weight parameters signifi cantly decreased after diet followed by DJBL treatment 
compared to baseline. An overall change in weight of 10.3 (7.1–16.4) kg (p <0.001) with 
an EWL of 32.7 (22.3–40.0) % (p <0.001) and a drop in BMI by 3.7 points (2.5–5.0) kg/
m2 (p <0.001) was seen. Type 2 diabetes parameters also signifi cantly changed with a 
decrease in HbA1c of 0.8 (−0.1–1.7) % (p <0.05), fasting glucose of 3.4 (1.2–4.8) mmol/L 
(p <0.001), and fasting insulin of 69.2 (27.8–190.4) pmol/L (p <0.001). Cardiovascular 
parameters were also signifi cantly reduced after dietary plus DJBL treatment. Total 
cholesterol decreased by 0.7 (0.2–1.5) mmol/ L (p <0.01). Additionally, triglycerides and 
HDL reduced by 0.4 (−0.4–1.0) mmol/L (p <0.05) and 0.1 (0.0–0.29) mmol/L (p <0.01), 
respectively. An overview of the results is listed in Table 3.2. 
Figure 3.2: Effect of DJBL treatment on change in weight parameters over time. A Change 
in weight (kg); B Change in BMI (kg/m2); C Change in EWL (%). * p < 0.01
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Six months after explantation of the DJBL 
After 12 months of DJBL treatment, ten patients were eligible for 6 months of follow-up 
after explantation of the DJBL. Six months after removal of the DJBL weight and BMI 
increased from 99.5 (86.1–114.2) kg to 102.8 (90.2–116.0) kg and from 31.4 (30.4–26.4) 
kg/m2 to 32.5 (31.2–37.2) kg/m2 (both p = 0.02), respectively. Also, fasting insulin levels 
rose from 92.2 (58.2–137.5) pmol/L to 203.5 (99.9–415.5) pmol/L (p = 0.03). Regarding 
the other parameters, no significant increase was seen 6 months after DJBL explantation. 
Table 3.2: Change in weight, glucose metabolism parameters, and cardiovascular 
parameters after 6 months of dietary treatment, 6 months of DJBL treatment, and dietary 
plus DJBL treatment
6 months dietary 
treatment (n=24)
6 months of DJBL 
treatment (n=24)
Overall change 
after dietary and 
DJBL treatment 
(n=24)
Weight change (kg) 4.5 (1.1-8.6) 5.8 (2.6-11.2) 10.3 (7.1-16.4)
BMI change (kg/m2) 1.5 (3.1-3.3) 2.0 (1.0-3.5) 3.7 (2.5-5.0)
Excess weight loss (%) 13.3 (2.1-28.4) 20.9 (10.0-28.8) 32.7 (22.3-40.0)
HbA1C (%) 0.6 (0.3-1.3) 0.5 (0.1-1.3) 0.8 (-0.1-1.7)
Fasting glucose (mmol/L) 1.7 (1.5-4.0) 1.6 (0.3-3.2) 3.4 (1.2-4.8)
Fasting insulin (pmol/L)3 23.3 (32.4-118.8) 27.1 (6.9-104.9) 69.2 (27.8-190.4)
Systolic blood pressure (mmHg)1 4 (3-26) 6 (4-12) 19 (5.5-28)
Diastolic blood pressure 
(mmHg)1
8 (4-11) 0 (2-5) 7 (-3-13)
Total cholesterol (mmol/L) 0.2 (0.2-0.4) 0.6 (0.1-1.1) 0.7 (0.2-1.5)
HDL (mmol/L)1 0.1 (0.0-0.2) 0.2 (0.1-0.3) 0.1 (0.0-0.29)
LDL (mmol/L)2 0.0 (0.2-0.3) 0.3 (0.0-0.8) 0.2 (-0.1-1.0)
Triglycerides (mmol/L) 0.1 (0.3-0.8) 0.2 (0.1-0.3) 0.4 (-0.4-1.0)
1 n = 23 patients included for analysis 
2 n = 22 patients included for analysis 
3 n = 18 patients included for analysis
Glucose-lowering medication 
During the study period, usage of glucose-lowering medication was assessed. Medication 
usage was classified as “increased” if the dose of one or more agents was increased or an 
additional glucose-lowering agent was added. Medication was classified as “decreased” if 
the dose of one or more agents was lowered, or if one or more agents were discontinued. 
All patients used glucose-lowering medication prior to implantation with the DJBL. 
Twenty-seven (96 %) patients were taking metformin, 19 (68 %) patients SU derivatives, 
and 13 (46 %) patients were on insulin treatment. Alteration in glucose-lowering 
medication was evaluated in each of the 28 patients just prior to explantation of the DJBL. 
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Glucose-lowering medication was decreased in 15 (54 %) patients, increased in 8 (28 %) 
patients and remained unchanged in 5 (18 %) patients. Additional information on the use 
of metformin, SU derivatives, and insulin is described in Table 3.3. 
Safety 
During DJBL treatment, adverse events consisted mainly of minor gastrointestinal 
complaints (78.6 %). Abdominal pain and discomfort was present in 39.3 % of patients 
and nausea and vomiting were present in 31.1 and 14.3 % of the patients, respectively. 
Figure 3.3: Effect of DJBL treatment on glucose metabolism parameters; A Glucose 
concentrations during the meal tolerance test; B The AUC calculations for glucose; 
C Insulin concentrations during the meal tolerance test; D The AUC concentrations for 
insulin; E Change in HbA1c (%). * p <0.01
A B
C D
E
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Table 3.3: Change in glucose-lowering medication. Values are given in percentages
Change in glucose lowering medication post-explantation (%) 
Metformin
Decreased, discontinued 14.8
Increased 18.5
SU derivatives
Decreased, discontinued 44.4
Increased 22.2
Insulin
Decreased, discontinued 40.0
Increased 40.0
In addition, hypoglycemia occurred in 17.9 % of patients. Complaints occurred primarily 
during the first 2 weeks of DJBL treatment after which most resolved. 
During DJBL treatment, six adverse events required hospitalization. Four of these adverse 
events were device related, making early removal necessary. One patient was admitted 
because of complaints of upper abdominal pain due to an eversion of the liner after 1 month 
of treatment causing obstruction of the DJBL. A second patient was admitted because of 
abdominal pain and nausea caused by a food bolus blocking the liner after 9 months of 
treatment. Another patient developed postprocedure vomiting due to pylorospasm and in 
one patient a migration of the liner occurred after 9 months. After removal, all complaints 
resolved without sequelae. Additionally, during the study period, five patients withdrew 
because of ongoing abdominal pain, nausea, and vomiting. In summary, four patients 
(14%) had an early removal of the device. These patients were explanted before the 
3-month treatment time point. In addition, five patients did not complete their extended 
period of DJBL treatment and were explanted between 9 and 11 months. No procedure 
related serious adverse events occurred.
Discussion
In this study, we evaluated the impact of 6 and 12 months of DJBL treatment in a crossover 
cohort from a multicenter randomized clinical trial. This is the first study assessing the 
effect of DJBL treatment in a cohort of patients who first underwent dietary treatment 
prior to implantation of the DJBL. 
In this patient group, 6 months of treatment with the DJBL showed a significant decrease 
in weight, and improvement of cardiovascular parameters and type 2 diabetes mellitus 
parameters. An extension to 12 months of treatment with the DJBL showed a stabilization 
of these parameters. In addition, in patients who underwent 12 months of DJBL treatment, 
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6 months after removal of the device only a signifi cant increase for weight parameters 
was seen. 
Overall results after dietary and DJBL treatment showed an even more pronounced 
decrease for weight, type 2 diabetes mellitus and cardiovascular parameters than 
expected. Our results indicate that 6 and 12 months of DJLB treatment can even lead to 
a further reduction in weight, cardiovascular, and diabetes parameters after a controlled 
diet period. 
As mentioned earlier, the effect of the DJBL is attributable to its barrier function. 
Pancreatic and bile secretions will only mix with food distal to the liner, creating a 
functional bypass of the duodenum and the proximal jejunum. As a result, local absorption 
of micronutrients is decreased. Furthermore, it was recently shown that weight loss and 
improvement of obesity related comorbidities is accompanied by changes in satiety 
hormones. Postprandial GLP-1 and peptide YY increased during 6 months of DJBL 
treatment. At the same time, CCK and leptin concentrations decreased20,21. It is known 
that these hormones play an important role in satiety experienced by both healthy and 
obese individuals22,23. The changes in these incretins and leptin caused by implantation of 
the DJBL might explain the positive effects of this treatment. 
Six months of treatment with the DJBL resulted in a signifi cant excess weight loss and 
a decrease in weight, BMI, HbA1c, fasting glucose levels, total cholesterol, HDL, and 
LDL. This is in line with several other studies evaluating the effect of the DJBL that 
have also shown a decrease in weight, cardiovascular, and type 2 diabetes mellitus 
parameters15-19,24-27. The previously published randomized clinical trial showed that 
DJBL treatment was superior in the reduction of these parameters compared to dietary 
treatment16. In this crossover study, as shown in Table 3.1, prior to DJBL implantation 
patients already had a signifi cant decrease in weight, BMI, systolic and diastolic blood 
pressure. Our results show that the patients in the diet group performed exceptionally 
well. This might be explained by the intrinsic motivation of the patients to perform well 
during the diet period, since this was followed by implantation of the DJBL. This study 
demonstrates that after this controlled dietary treatment period, the DJLB is still capable 
of signifi cantly reducing weight and improving cardiovascular and type 2 diabetes 
mellitus parameters. 
After 12 months of DJBL treatment, patients seemed to reach a plateau phase. No 
difference was seen between 6 and 12 months of treatment with the DJBL. This is in 
accordance with recent literature, reporting that ongoing weight loss is diminished after 
approximately 6 months of DJBL treatment28. 
In this study, six serious adverse events were reported. Fourteen percent (4/28) required 
hospital admission because of device related adverse events. Additionally, almost all 
patients experienced minor adverse events. A recent study on safety experience with the 
DJBL showed a serious adverse event rate of 10 %. In this study, adverse events consisted 
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of gastrointestinal bleeding, hepatic abscess, pancreatitis, and perforation of the anchor. 
Therefore, patients need to be well instructed and have close contact with a specialized 
DJBL treatment center because early and quick removal might be necessary in case of 
device and procedure related serious adverse events29. In the current patient population 
none of these serious complications occurred. 
Some limitations to this study should be addressed. The design of the study is non-
randomized. In addition, the number of patients is limited; it consists of 28 patients of 
which only 13 extended and completed their 12 months of treatment with the DJBL. The 
strength consists of patients functioning as their own control in this crossover designed 
study. This is the first study describing the effect of DJBL treatment after a controlled diet 
period. 
In conclusion, the DJBL is an effective minimally invasive treatment option with the 
capability to reduce weight and improve cardiovascular and type 2 diabetes mellitus 
parameters in obese patients. Even after a significant reduction with dietary restrictions 
the DJBL is still capable of reducing these parameters even further.
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Abstract
BACKGROUND AND AIMS: The duodenal-jejunal bypass liner (DJBL) is an endoscopic 
device that induces weight loss and improves glycemic control in patients with type 2 
diabetes mellitus (T2DM). The aim of the current study was to assess the effects of DJBL 
explantation on glycemic control and body weight.
METHODS: This prospective, observational study included only patients with T2DM who 
had the DJBL implanted for at least 6 months and had a follow-up of at least 12 months 
after explantation. The primary endpoints were changes in glycosylated hemoglobin A1c 
(HbA1c) and body weight during the 12 months after explantation. Secondary endpoints 
were changes in fasting plasma glucose, blood pressure, and plasma lipid levels.
RESULTS: In total 59 patients completed the 12-month follow-up after explantation. 
During this period body weight increased by 5.6 (standard deviation, 6.4) kg (p <0.001) 
and HbA1c rose from 65 (SD 17) to 70 (SD 20) mmol/mol (p <0.001). However, body 
weight remained 8.0 (SD 8.6) kg (p <0.001) lower than before implantation, that is, 
corresponding to a net total body weight loss of 7.4 % (SD 7.6) (p <0.001). Although 
HbA1c was significantly higher 12 months after explantation compared with baseline and 
the mean daily dose of insulin used was comparable, the number of patients on insulin 
remained significantly lower than before implantation.
CONCLUSIONS: Explantation of the DJBL is associated with weight gain and worsening 
of glycemic control, although some beneficial effects remained detectable 12 months 
after explantation. A change in strategy is needed to preserve the beneficial effects of 
DJBL treatment. (Clinical trial registration number: 746\100111.)
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Introduction
The effi cacy of the duodenal-jejunal bypass liner (DJBL) as a treatment to induce weight 
loss and improve glycemic control in obese patients with type 2 diabetes mellitus (T2DM) 
has now been studied for more than 5 years. Rapid total body weight loss (TBWL) of over 
10% and early improvement of glucose control in the fi rst months after implantation has 
been demonstrated in several randomized controlled trials1-4 and cohort studies5-10. In the 
hope to enhance the benefi cial effects of the DJBL, the maximum implantation period has 
been gradually increased from 12 to 52 weeks. 
It is generally advised to combine the implantation of the DJBL with efforts to induce 
lifestyle changes, such as a healthy diet and optimal physical exercise. This combination 
is considered to be essential to gain a maximal benefi cial effect of DJBL treatment and 
to prepare patients for a life after explantation with preservation of the benefi ts achieved 
during implantation. There is currently no consensus regarding the optimal approach for 
the medical treatment of T2DM during implantation and after explantation. 
Although a substantial number of studies have published the results of the DJBL 
treatment, little is known about the consequences of explantation of the DJBL. The aim 
of the current study is to assess the impact of DJBL explantation on T2DM parameters 
and body weight. 
Methods
Patient selection and outcome 
This is a prospective, observational, single-center study performed in the Rijnstate 
Hospital, Arnhem, the Netherlands. The study included all patients with T2DM who 
had received the DJBL for a period of at least 6 months and had a follow-up of at least 
12 months after explantation. The primary endpoints were changes in glycosylated 
hemoglobin A1c (HbA1c) and body weight 12 months after explantation compared with 
the start of DJBL treatment. Secondary endpoints were changes in fasting plasma glucose 
(FPG), blood pressure (BP), and plasma lipid levels. 
As of the start of this study, the DJBL was commercially available in the Netherlands 
(Endobarrier; GI Dynamics, Lexington, Mass, USA). Patients received standard care, as 
described below. This study was approved by the local institutional review board. 
Patients visited the outpatient clinic 1 week and 1, 3, 6, and 9 months after implantation. 
Explantation was performed after 12 months. However, in cases of intolerance or adverse 
events, explantation was performed at an earlier stage. During the fi rst 3 months of 
implantation, T2DM treatment was centralized and carried out by a single center team 
of specialized diabetes nurses under supervision of an endocrinologist. Medication was 
adjusted according to predefi ned schedules. Thereafter, T2DM treatment was performed 
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by the referring physicians. Additionally, each patient received individual dietary advice 
before and 3 months after implantation of a dietician specialized in bariatric patients. 
After explantation, outpatient clinic visits were scheduled at 1 week and 6 and 12 months. 
During each visit body weight and BP were measured and blood samples were taken to 
evaluate T2DM treatment and to determine serum lipid levels. To increase compliance 
and reduce the number of missing values, patients received a repeat appointment and 
were phoned after missing an outpatient visit. 
Statistical analysis 
Changes in body weight were analyzed as the difference in absolute total body weight, 
change in body mass index, excess weight loss, and TBWL. Changes in T2DM were 
analyzed as the absolute change in HbA1c, FPG, and changes in T2DM medication. 
Differences in lipid levels and BP were analyzed as absolute differences. 
Analyses were conducted with IBM SPSS Statistics for Windows, version 20.0 (IBM 
Corp, Armonk, NY). Data are reported as mean values with standard deviation within 
parentheses, unless specified otherwise. A p <0.05 was considered to be statistically 
significant. Analyses between different time points in the same group were conducted 
with a paired-sample t-test or a Wilcoxon signed rank test when not normally distributed. 
Analyses between different groups were performed with an independent-samples t test 
for continuous variables and with the Pearson χ2 or the Fisher exact test for dichotomous 
variables. A complete case analysis was performed, despite the missing data, because 
intention-to-treat analysis with the last observation carried forward would overestimate 
the true effects of the DJBL. Significance was only calculated at 12 months after 
explantation to reduce multiple testing. Figures were created with GraphPad Prism 
version 5.1 (GraphPad Software, Inc, La Jolla, Calif, USA). 
Results 
Patient selection 
In total, 96 patients had undergone explantation of the DJBL at time of analysis. 
Follow-up of all explanted patients, including the number of patients who missed their 
outpatient visits and those who received bariatric surgery after explantation of the DJBL, 
is illustrated in Figure 4.1. Thirty patients (31 %) were lost to follow-up at 12 months 
after explantation. An additional 7 patients (7 %) were excluded because they had chosen 
to undergo bariatric surgery during the 1-year postexplantation period. The 30 patients 
who were lost to follow-up were comparable with the 59 patient who completed the 
12-month follow-up in all baseline characteristics and main outcome parameters at time 
of explantation (Table 4.1). 
Table 4.1 shows that the total group of 59 patients who completed the outpatient visit 12 
months after explantation had a mean age of 52 (standard deviation, 8) years and 46% 
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were women. All patients were diagnosed with T2DM, with a mean duration of 8 (SD 5) 
years at time of implantation of the DJBL. The mean implantation time was 48 (SD 7) 
weeks. Eighteen patients (31%) were explanted early between 6 and 12 months. 
Table 4.1: Baseline demographics and changes between baseline and explantation for 
patients who completed and who were lost to follow-up at the outpatient visit 12 months 
after explantation of the DJBL
12-Month follow-up 
completers (n= 59)
12-Month lost to 
follow-up (n= 30)
p value*
Baseline characteristics
Age (years) 52 (8) 50 (7) 0.311
Female 27 (46%) 12 (40%) 0.604†
Body weight (kg) 106.4 (15.6) 108.9 (19.7) 0.510
BMI (kg/m2) 34.4 (3.5) 35.8 (5.6) 0.238
Systolic BP (mm Hg) 139 (16) 138 (20) 0.942
Diastolic BP (mm Hg) 87 (10) 855 (10) 0.508
T2DM duration (years) 8 (5) 9 (5) 0.669
Blood values
  Total cholesterol (mmol/L) 4.56 (1.29) 4.86 (0.98) 0.279
  HDL (mmol/L) 1.10 (0.27) 1.10 (0.30) 0.886
  Triglyceride (mmol/L) 2.38 (2.08) 2.72 (1.54) 0.430
  LDL (mmol/L) 2.41 (0.94) 2.59 (0.79) 0.425
  FPG (mmol/L) 10.8 (2.9) 11.2 (4.1) 0.595
  HbA1c (mmol/ mol) 65 (15) 68 (20) 0.570
  Insulin (mU/L) 33 (50) 31 (40) 0.895
  C-peptide (nmol/L) 1.15 (0.49) 1.20 (0.70) 0.765
Explantation characteristics
Implantation time (weeks) 48 (7) 50 (9) 0.293
∆ Absolute weight (kg) -13.6 (9.4) -11.6 (6.5) 0.316
EWL, % 49 (30) 42 (26) 0.330
TBWL, % 12.6 (7.7) 10.6 (5.6) 0.216
∆ HbA1c (mmol/mol) -4.1 (14.7) -8.1 (13.3) 0.218
∆ FPG (mmol/L) -0.9 (3.0) -0.7 (3.7) 0.777
Values are means with standard deviations in parentheses or number of cases with percents in 
parentheses. DJBL: Duodenal-jejunal bypass liner; BP: blood pressure; TBWL: total body weight loss; 
HbA1c: glycosylated hemoglobin A1c; T2DM: type 2 diabetes mellitus; FPG: fasting plasma glucose; 
BMI: body mass index; HDL: high-density lipoprotein; LDL: lowdensity lipoprotein; EWL: excess 
weight loss; ∆: difference between baseline and explantation. * Independent-samples t test. † Pearson 
χ2 test
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Figure 4.2: Changes in (A) absolute body weight and (B) HbA1c at baseline, during 
implantation with the DJBL, and until 12 months after explantation (mean with 95% 
confidence interval). HbA1c: Glycosylated hemoglobin A1c; DJBL: duodenal-jejunal 
bypass liner
Figure 4.1: Total number of explantation procedures of the DJBL and follow-up until 
12 months after explantation. DJBL: duodenal-jejunal bypass liner; RYGB: Roux-en-Y 
gastric bypass; LSG: laparoscopic sleeve gastrectomy
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Table 4.2: Characteristics at baseline, at time of explanation, 6 - 12 months after explantation
Implantation
(n = 59)
Explantation*
(n = 59)
6 months PE*
(n = 54)
12 months PE*
(n = 59)
Weight, kg 106.4 (15.6) 92.8 (14.5) 97.2 (16.0) 98.4 (15.3)
  ∆ baseline   -13.6 (9.4) (p<0.001)   -9.1 (9.9)  -8.0 (8.6) (p<0.001)
  ∆ explantation   +4.9 (4.8)  +5.6 (6.4) (p<0.001)
BMI, kg/m2 34.4 (3.5) 30.1 (3.5)   31.4 (3.6) 31.8 (3.4)
  ∆ baseline  -4.4 (3.2) (p<0.001)   -3.0 (3.4)  -2.6 (3.0) (p<0.001)
  ∆ explantation   +1.5 (1.4)  +1.7 (2.0) (p<0.001)
EWL, % N/A 48.8 (30.0) 32.0 (32.1) 27.7 (28.9)
  ∆ baseline +48.8 (30.0) (p<0.001)   +32.0 (32.1) +27.7 (28.9) (p<0.001)
  ∆ explantation   -18.3 (17.4) -21.0 (24.0) (p<0.001)
TBWL, % N/A 12.6 (7.7) 8.4 (8.6) 7.4 (7.6)
  ∆ baseline +12.6 (7.7) (p<0.001)   +8.4 (8.6)   +7.4 (7.6) (p<0.001)
  ∆ explantation   -4.6 (4.3)   -5.2 (5.8) (p<0.001)
HbA1c, mmol/mol 65 (15) 61 (17) 65 (17) 70 (20)
  ∆ baseline -4.1 (14.7) (p=0.039)   -0.6 (13.9)   +4.8 (16.0) (p=0.025)
  ∆ explantation   +4.3 (11.2)   +8.8 (15.4) (p<0.001)
FPG, mmol/L 10.8 (2.9) 9.9 (3.0) 10.7 (3.6) 11.7 (3.7)
  ∆ baseline  -0.9 (3.0) (p=0.028)   -0.13 (3.73)   +1.0 (3.5) (p=0.033)
  ∆ explantation   +0.88 (2.69)   +1.6 (3.5) (p=0.001)
BP, systolic, mmHg 139 (16) 136 (21) 132 (13) 140 (15)
  ∆ baseline -2.9 (21.6) (p=0.358)   -7.3 (20.0)   +0.4 (21.9) (p=0.913)
  ∆ explantation   -0.2 (21.1)   +4.0 (25.3) (p=0.284)
BP, diastolic, mmHg 87 (10) 83 (12) 85 (8) 87 (10)
  ∆ baseline   -4.0 (14.0) (p=0.054)   -1.5 (9.9)   -0.4 (11.6) (p=0.836)
  ∆ explantation   +2.7 (11.2)   +3.6 (14.8) (p=0.101)
Total chol., mmol/L 4.48 (1.17) 4.31 (0.94) 5.08 (1.08) 4.88 (1.06)
  ∆ baseline  -0.17 (0.96) (p=0.185)   +0.43 (1.16)   +0.35 (1.16) (p=0.031)
  ∆ explantation   +0.64 (0.91)   +0.52 (1.01) (p<0.001)
HDL, mmol/L 1.11 (0.27) 1.08 (0.35) 1.16 (0.35) 1.10 (0.32)
  ∆ baseline -0.02 (0.21) (p=0.376)   +0.04 (0.21)   -0.01 (0.20) (p=0.755)
  ∆ explantation   +0.05 (0.20)   +0.01 (0.19) (p=0.623)
Triglycerides, mmol/L 2.16 (1.25) 2.04 (0.97) 2.76 (2.13) 3.11 (3.03)
  ∆ baseline  -0.11 (0.93) (p=0.351)   +0.31 (1.83)   +0.77 (2.68) (p=0.039)
  ∆ explantation   +0.55 (1.59)   +0.89 (2.32) (p=0.006)
LDL, mmol/L 2.44 (0.93) 2.42 ± 0.81 2.85 (0.91) 2.58 (0.91)
  ∆ baseline -0.02 ± 0.78 (p=0.844)   +0.33 (1.01)   +0.12 (0.82) (p=0.322)
  ∆ explantation   +0.35 (0.69)   +0.11 (0.75) (p=0.333)
Values are means with standard deviations in parentheses (continues on next page).
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∆ Baseline, comparison with values observed at the time of screening; ∆ Explantation, comparison 
with data registered at the day of explantation; BMI: body mass index; EWL: excess weight loss; 
N/A: not applicable; HDL: high-density lipoprotein; LDL: low-density lipoprotein; TBWL: total body 
weight loss; BP: blood pressure; HbA1c: glycosylated hemoglobin A1c; FPG: fasting plasma glucose. 
* Paired-samples t test.
Body weight 
During the implantation period, body weight decreased by 11.6 (SD 7.8) kg at 6 months 
and by 13.6 (SD 9.4) kg at 12 months (p <0.001) (Table 4.2 and Fig. 4.2A). The latter 
is comparable with a TBWL of 12.6 % (SD 7.7) (p <0.001). Twelve months after 
explantation, body weight had increased by 5.6 (SD 6.4) kg but remained 8.0 (SD 8.6) kg 
lower (p <0.001) compared with baseline. This is equivalent to a net reduction in TBWL 
of 7.4 % (SD 7.6). In total, 18 patients (31 %) still had a net TBWL greater than 10 % 12 
months after explantation. 
Type 2 diabetes 
During implantation, HbA1c and FPG decreased from 65 (SD 15) to 61 (SD 17) mmol/
mol (P = 0.039) and from 10.8 (SD 2.9) to 9.9 (SD 3.0) mmol/L (P = 0.028), respectively. 
However, at 6 months after explantation, both parameters had increased to the same level 
as observed at baseline. Twelve months after explantation, HbA1c and FPG had increased 
to 70 (SD 20) mmol/mol (P = 0.025) and to 11.7 (SD 3.7) mmol/L (P = .033), respectively, 
both significantly higher than before implantation (Table 4.2 and Fig. 4.2B). 
Metformin, glimepiride, glucagon-like peptide-1 (GLP-1) agonists, and insulin were 
the main antidiabetics used in the study population. The trends within these medication 
groups are summarized in Table 4.3. The median dose of metformin and number of 
users remained unchanged after implantation as well as explantation. Implantation 
was associated with a significant increase in the number of patients using glimepiride, 
although the mean daily dose remained stable, ranging from 4.2 (SD 2.2) to 5.2 (SD 
2.0) mg. The number of patients on GLP-1 agonist significantly rose from 8% at the 
time of screening to 25 % 12 months after explantation; the median dose did not change 
significantly. Implantation was associated with a decrease in the number of patients on 
insulin and a decrease in mean daily dose. However, after explantation the number of 
patients on insulin and their mean doses increased again. One year after explantation, an 
overall net beneficial effect of the DJBL intervention was observed only for the number 
of patients treated with insulin at baseline. At 12 months after explantation, the number of 
patients on insulin had decreased significantly from 47 % to 24 %. The insulin dose at 12 
months after explantation was comparable with baseline: 88 (SD 62) versus 99 (SD 68) 
IU. In contrast, the number of patients on glimepiride and GLP-1 agonists had increased 
significantly, although the mean doses remained comparable. 
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Table 4.3: Dosage and number of users of the four most-used diabetic medications at time 
of screening, explantation, and 12 months after DJBL explantation
At time of DJBL 
screening
At time of DJBL 
explantation
12 months after DJBL 
explantation
Dosage n (%) Dosage* n (%) Dosage* n (%)
Metformin (mg) 2000 (700) 49 (83%) 1900 (800) 52 (88%) 1900 (800) 51 (86%)
Glimepiride (mg) 5.2 (2.0) 22 (37%) 4.2 (2.2) 38 (64%)† 4.5 (2.3) 34 (58%)†
GLP agonist (mg) 1.9 (0.7) 5 (8%) 2.0 (0.7) 11 (19%)† 2.1 (0.5) 15 (25%)†
Insulin (IU)
  Long acting 53 (27) 23 (39%) 30 (9) 4 (7%)† 42 (27) 12 (20%)†
  Short acting 65 (43) 24 (41%) 36 (23)† 10 (17%)† 61 (38) 12 (20%)†
  Total 99 (68) 28 (47%) 44 (28) † 11 (19%)† 88 (62) 14 (24%)†
Changes in diabetic medication; 12 months after explantation of the DJBL compared with the time of DJBL 
implantation. DJBL: Duodenal-jejunal bypass liner; GLP: glucagon-like peptide. * Values are means with 
standard deviations in parentheses. † p <0.05 compared with time of DJBL screening, analyzed with Wilcoxon 
signed rank test
Cardiovascular parameters 
Slight variations in BP were observed during and after implantation of the DJBL (Table 
4.2). Both systolic and diastolic BP decreased nonsignifi cantly during implantation and 
rose to baseline levels again 12 months after explantation. During the DJBL implantation 
period, no signifi cant changes were observed in lipid levels. Explantation was associated 
with a rise in all lipid levels. However, 12 months after explantation only total cholesterol 
and triglycerides were signifi cantly higher than observed just before implantation, with 
increments of 0.35 (SD 1.16) mmol/L and 0.77 (SD 2.68) mmol/L, respectively. 
Discussion
This is the fi rst study to present long-term follow-up after explantation of the DJBL. 
It shows that after the loss of weight and improvement of diabetes parameters during 
implantation, there is a partial loss of benefi t within 12 months after explantation. 
Explantation was associated with weight regain and deterioration of glycemic control. 
Nevertheless, at 12 months after explantation, body weight was still signifi cantly lower 
than before implantation. In contrast, HbA1c and FPG were signifi cantly higher at 12 
months after explantation compared with before implantation. Although a greater number 
of patients were on glimepiride and GLP-1 agonists, the number of insulin users was 
still decreased by 50 % as compared with baseline. Most of all other cardiovascular 
parameters measured were comparable with start of treatment, except for total cholesterol 
and triglycerides, which had increased signifi cantly 1 year after explantation. 
So far, only a limited number of studies have reported changes after DJBL explantation. 
The numbers of patients included in these studies have been small (ranging from 8 to 
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31 patients), and follow-up after explantation was relatively short, ranging from 1 week 
up to 6 months4,7,9-11. Moreover, implantation time varied among these studies. In 2 of 5 
studies the DJBL was implanted for 6 months, and only 3 studies considered a 12-month 
implantation time, which is currently the standard treatment. de Jonge et al.9 studied 16 
patients 6 months after implantation and found a sustained decrease in glucose response 
after a meal test 1 week after explantation. No changes in homeostatic model assessment of 
insulin resistance (HOMA-IR) or insulin response were observed9. Two studies evaluated 
the effects on T2DM 26 weeks after explantation in 16 and 11 patients treated by the 
DJBL for 1 year10,11. Explantation was associated with an increase in HbA1c of 3 and 6 
mmol/mol, respectively, but compared with baseline, HbA1c levels remained 10 and 19 
mmol/mol lower than before implantation. Unfortunately, changes in diabetic medication 
were not reported. This hampers the opportunity to separate the impact of adjustments 
in antidiabetic medication and that of the DJBL. The largest randomized controlled trial 
published so far included 31 patients treated with the DJBL for 26 weeks with a follow-
up of another 26 weeks after explantation4. HbA1c increased by 4 mmol/mol and FPG 
by .5 mmol/L after explantation in the patients treated with the DJBL. A similar trend 
was observed in our study, although the increments in our patients were larger with an 
increase in HbA1c of 8.8 mmol/mol and FGP of 1.6 mmol/L after explantation. Although a 
reduction in antidiabetic medication was also described in the randomized controlled trial 
referred to above, the 50% reduction in insulin users that was realized in our study might 
explain the differences in glycemic control during implantation and after explantation. 
Additionally, because HbA1c increased after explantation in most of our patients, it can 
be concluded that dose adjustments in antidiabetic medication have been insufficient. 
Weight change in patients with T2DM after explantation of the DJBL has been reported 
in 2 studies. After a reduction in body weight of 10.6 kg induced by a 26-week DJBL 
implantation, body weight increased by 3.8 kg in the 6 months after explantation4. 
However, compared with prior to implantation a net effect of 6.8 kg remained, which was 
comparable with a net TBWL of 5.8 % (excess weight loss of 19.8 %) at 26 weeks after 
explantation. In the study reporting 26-week explantation follow-up after an implantation 
time of 12 months, body weight increased by 4.4 kg after explantation, but the overall 
effect was a net loss in body weight of 17.7 kg compared with baseline7. In our study the 
weight gain observed 6 months after explantation was 4.9 kg, which was comparable 
with the findings in these previous studies. After 6 months, weight gain appeared to level 
off. The net effect at 12 months after explantation was a TBWL of 7.4 % (excess weight 
loss 27.7 %). Although statistically significant, this is below the limit of 10 % weight 
reduction now commonly used to evaluate the efficacy of anti-obesity interventions. In 
the present study, 31 % of patients had a TBWL >10% 1 year after explantation. 
The beneficial metabolic effects of the DJBL have been attributed to favorable hormonal 
changes of intestinal hormones such as GLP-1, ghrelin, peptide YY, and cholecystokinin9-12. 
It was hoped that the new hormonal settings induced by the DJBL might remain after 
explantation. However, emerging evidence suggests that the effects of the DJBL are 
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transient and disappear after removal. Recently, it has been reported that the delayed 
gastric emptying observed during implantation reverses to normal after explantation13. 
Both mechanisms might explain why most patients report to have a reduced satiety level 
again after explantation and why glycemic control deteriorates after explantation. Specifi c 
measures to prevent these changes in satiety and glucose control are needed to maintain 
the benefi cial effects of DJBL implantation. We hypothesize that the use of high-dose 
GLP-1 agonists may prove to be useful in this setting14. It has been shown that high-dose 
liraglutide slows gastric emptying, increases satiety, and improves glycemic control. It 
appears to be a promising agent to combine with the DJBL. A potentiating effect during 
implantation is not unlikely, and continuation of the GLP-1 agonist after explantation 
may help to reduce the risk of relapse. 
Relapse after a variable period of time seems to be an upcoming issue in all bariatric 
techniques. It is observed after minimal invasive techniques, such as the intragastric 
balloon, but also after varies types of bariatric surgery such as adjustable gastric banding 
or Roux-en-Y gastric bypass15,16. Until now the literature describing this relapse has 
been limited. However, the widespread occurrence seen in clinical practice may serve to 
underline the importance of intensifi ed research focusing on relapse prevention. 
To improve the results of DJBL implantation and to prevent or reduce the degree of 
relapse, several issues will need to be given attention. Optimization of patient selection 
and improved counseling to establish benefi cial lifestyle changes during the implantation 
period may improve the effects of DJBL and minimize relapse. We also believe that a 
strict protocol for diabetes management during implantation, as well as after explantation, 
is key to improve the results. It is well known that the use of insulin in T2DM leads 
to major weight gain by stimulating lipogenesis and inhibiting lipolysis and that these 
physiologic effects also create a great barrier for any therapy directed at achievement of 
weight loss. Thus, if possible, insulin therapy should be avoided during DJBL treatment. 
Based on their pharmacologic characteristics, metformin and GLP-1 agonist are the 
preferred candidate agents to be combined with the DJBL, at least in theory. Prevention 
or delay of relapse might be established by prolongation of the implantation time. The 
feasibility of reimplantation has already demonstrated on a limited scale17. 
Our study has several limitations. First, it concerns a cohort study in which confounding 
factors cannot be controlled for, such as diet and physical activity. Because all patients 
received dietary advice and were stimulated to expand their physical activity to improve 
their lifestyle, this may have had some additional effect on glycemic control and weight. 
This obscures the net effect of the DJBL to some extent. Another more subjective 
confounding factor and one diffi cult to measure is motivation. Patients who choose a 
temporarily treatment such as the DJBL might be less motivated than patients who choose 
for a defi nitive treatment such as surgery and therefore might be more prone to relapse. 
Another limitation of our study is the high lost-to-follow-up rate. This might be related to 
a decline in interest and limited personal benefi t to complete the follow-up after removal 
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of the DJBL. Because DJBL treatment was offered at only 1 site in the Netherlands, this 
aspect may have played a role in particular in patients who lived remotely. However, it is 
also possible that patients who had a greater relapse after explantation were less motivated 
to attend the follow-up visits. This might have led to an underestimation of weight gain 
and loss of glycemic control after explantation. Finally, adjustments of T2DM treatment 
were only centralized during the first 3 months of implantation, with subsequent T2DM 
treatment by the referring physicians. Because of this variance in therapy adjustments, 
it is not completely clear to what extent the increase in HbA1c and FPG is caused by 
explantation of the DJBL or by inadequate adjustment of diabetic medication. 
In conclusion, explantation of the DJBL is associated with weight regain and worsening of 
glycemic control, although some beneficial effects remained 12 months after explantation. 
New strategies are required to preserve the beneficial effects of DJBL treatment. 
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 Clinical follow-up on weight loss, glycemic control, and 
safety aspects of 24 months of duodenal-jejunal bypass 
liner implantation
Bark Betzel, Mellody I. Cooiman, Edo O. Aarts, Ignace M.C. Janssen, Peter J. Wahab, 
Marcel J.M. Groenen, Joost P.H. Drenth, Frits J. Berends
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Abstract
BACKGROUND: The duodenal-jejunal bypass liner (DJBL) is an endoscopic device 
designed to induce weight loss and improve glycemic control. The liner is licensed for a 
maximum implant duration of 12 months. It might be hypothesized that extension of the 
dwelling time results in added value. The goals of our study were to determine weight 
change, change in glycemic control, and safety in patients with an intended 24 months of 
DJBL dwelling time.
METHODS: Patients were initially selected for a 12-month implantation period. When no 
physical complaints or adverse events (AEs) occurred, motivated patients who responded 
well were selected for extension of dwelling time to 24 months. Patients underwent a 
control endoscopy 12 months after implantation and visited the out-patient clinic every 3 
months up to explantation. Patients agreed to remove the DJBL when complaints or AEs 
occurred that could not be treated conservatively.
RESULTS: Implantation was extended in 44 patients, and 24 (55 %) patients completed 
the full 24 months. Twenty patients required early removal due to AEs. During dwelling 
time, body weight decreased significantly (15.9kg; TBWL 14.6 %). HbA1c decreased 
non-significantly (4.9 mmol/mol). The number of insulin users and daily dose of insulin 
both decreased significantly. At 24 months after removal, glycemic control had worsened, 
while body weight was still significantly lower compared to baseline. In total, 68 %  of the 
patients experienced at least one AE. Two patients developed a hepatic abscess.
CONCLUSION: DJBL treatment results in significant weight loss and improves 
glycemic control during implantation. The largest beneficial effects occur during the 
first 9-12 months after implantation. Extension of dwelling time to 24 months results 
only in stabilization of body weight and glycemic control. After explantation, weight 
improvements are maintained, but glycemic control worsens. As the cumulative risk of 
AEs increases with time, a maximal dwelling time of 12 months is advisable.
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Introduction
The increasing prevalence of obesity calls for the development of weight control 
measures. The current mainstay of treatment for morbid obesity is bariatric surgery. 
Roux-en-Y gastric bypass is one of the most performed bariatric procedures and has 
proven to be effective in inducing weight loss and controlling comorbidities such as 
type 2 diabetes mellitus (T2DM) and hypertension1,2. As surgery carries the risk of 
intra- and postoperative adverse events (AEs), there is great interest for less defi nitive 
solutions. The duodenal-jejunal bypass liner (DJBL) is an endoscopic device that has 
been developed to mimic the effect of a gastric bypass3. The endoscopically placed 
DJBL prevents direct contact of nutrients with the duodenum and proximal jejunum. 
This results in metabolic changes that induce weight loss and improve glycemic control. 
Since not all patients are eligible for bariatric surgery or willing to undergo surgery, the 
DJBL might be a therapeutic option for these patients. The advantage of the DJBL is that 
it can be removed at any time point without leaving any change in original anatomy. Early 
studies employed an implantation period of 3 months and gradually stretched dwelling 
time to 12 months. It was hypothesized that extension of the implantation period would 
result in additional weight loss and further improvement of diabetic and cardiovascular 
parameters. Furthermore, it might be possible that an increased implantation period results 
in long lasting positive effects that extend beyond removal. Safety and effi cacy data that 
report on longer implantation periods could assist in clinical decision making since longer 
implantation of a medical device in the small intestine potentially holds the risk of an 
increased AE rate. Because of its current safety profi le, the DJBL is not approved by the 
Food and Drug Administration (FDA) and is therefore not allowed for use in the United 
States. As the primary implantation site in Europe, we assembled a cohort to examine the 
effect of long term (>12 months) implantation. The primary goals of our study were to 
determine effi cacy, measured as weight change and change in glycemic control, as well 
as safety in patients with an intended 24 months of DJBL implantation. As secondary 
endpoint, we studied changes in weight and glycemic parameters after removal of the 
DJBL.
Methods
Patient selection
All patients were initially selected for a 12-month implantation period with DJBL4. 
The major inclusion criteria consisted of age 18-70 years, BMI 28-45 kg/m2, and type 2 
diabetes mellitus (T2DM) with glycosylated hemoglobin A1c (HbA1c) levels >48 mmol/ 
mol. The major exclusion criteria were use of non-steroidal anti-infl ammatory drugs or 
anticoagulant medication. After nine months of implantation, patients were selected for 
this prospective cohort study with an extended implantation time to 24 months when they 
met and agreed to the following criteria (Figure 5.1): no physical complaints or AEs that 
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are, or might be, related to the DJBL present during the first 12 months of implantation; 
consent to undergo an endoscopy 12 months after implantation to evaluate the anatomical 
position of the DJBL and in case abnormalities are present, consent to removal of DJBL; 
out-patient clinic visits every 3 months with laboratory tests up to explantation; agree to 
report physical complaints immediately to the treating physician and allow early removal 
of the DJBL when the complaints cannot be treated conservatively; and received informed 
consent on the potential increased risks of prolonged implantation such as migration, 
ulceration, and hemorrhage. Finally, motivated patients were selected who showed a 
decrease in weight and diabetes parameters during the first 9 months of treatment. After 
explantation, follow-up continued for at least 12 additional months.
The extension of the implantation period was approved by the local institutional review 
board and the research ethics committee of Nijmegen, the Netherlands (registration 
number 2013/510).
Definitions
We analyzed changes in weight as change in absolute weight, BMI, and total body weight 
loss (TBWL). HbA1c is expressed as mmol/ mol. The following formula can be used to 
change the unit mmol/ mol to percentage: (0.0915 * HbA1c in mmol/ mol) + 2.15 %. We 
used analysis of change in HbA1c and changes in anti-diabetic drugs to determine T2DM 
regulation. Changes in anti-diabetic drugs were analyzed as percentage of use over time 
and changes in dosages were compared with initial use.
AEs were classified as mild, moderate, or severe according to the severity grading system 
defined by the American Society of Gastrointestinal Endoscopy (ASGE)5.
Statistical analysis
IBM SPSS Statistics for Windows, version 23.0 (Armonk, NY, IBM Corp.) was used for 
statistical analyses. Continuous variables are reported as mean ± standard deviation (SD) 
unless specified otherwise. Since Bonferroni correction was used for multiple testing, a 
p value of < 0.017 was considered statistically significant. Since data were not normally 
distributed, analyses between different time points were conducted with a Wilcoxon 
signed-rank test or McNemar’s test.
Figure 5.1: Flow chart of study protocol
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To deal with missing data because of early explantations, data were analyzed using last 
observation carried forward until the time point of 24 months after implantation was 
reached. Figures were created using GraphPad Prism version 5.03 (GraphPad Software, 
Inc.).
Results
Patient selection and baseline characteristics
In total, 44 patients had their implantation period extended with an intended period of 
24 months between June 2013 and January 2018. The mean dwelling time was 22.0 ± 
4.3 months. At time of screening, the 44 included patients had a mean age of 58 (± 7.2) 
years of which 52 % was female (Table 5.1). At time of screening, mean body weight was 
108.3 kg (± 17.3), compatible with a BMI of 35.1 kg/ m2 (± 4.4). All patients suffered 
from T2DM with a mean duration of 10 years and a mean HbA1c of 67 mmol/ mol (± 
16.5). The majority of the patients were treated at time of screening with metformin (84 
%) and 59% used insulin with a mean dose of 95 IU (± 62) each day. Twenty-four (55 
%) patients completed the full implantation period and twenty (45 %) patients required 
premature explantation.
Table 5.1: Baseline characteristics at time of screening for patients with extension of the 
intended dwelling time to 24 months
N= 44
Age (years) 58 ± 7.2
Female 23 (52.3%)
Body weight (kg) 108.3 ± 17.3
BMI (kg/m2) 35.1 ± 4.4
Duration T2DM (years) 10.1 ± 6.4
Blood values
HbA1c (mmol/ mol) 67 ± 16.5
Fasting glucose (mmol/ L) 10.7 ± 3.5
Anti-diabetic drugs (% users and dosage)
Metformin (mg) 84% (1975 ± 690)
Glimepiride (mg) 34% (4.7 ± 2.2)
GLP-1 agonist (mg) 11% (2.2 ± 0.8)
Insulin (IU) 59% (95 ± 62)
Body weight
Figure 5.2 shows mean changes in weight, BMI, and TBWL during DJBL dwelling 
time and after explantation. There was a mean weight loss of 15.9 kg (± 9.3) (p <0.001) 
between start of implantation and explantation, that is comparable to a TBWL of 14.6 %
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(± 7.8) (p <0.001). Twelve months after explantation there was weight regain of 6.5 kg 
(± 5.6) or a TBWL increase of 6.9 % (± 5.3) (p <0.001). However, 24 months after 
explantation weight had decreased again with 13.2kg (± 9.0) or 12.0 % (± 7.7) TBWL, 
and was still significantly lower compared to baseline (n = 15).
Type 2 diabetes mellitus
After implantation of the DJBL, HbA1c decreased sharply during the first 3 months 
and bottomed off during the dwelling time, with a mean decrease after 24 months of 
Figure 5.2: Mean changes with 95% confidence interval in weight, BMI, and TBWL 
during DJBL dwelling time and after explantation
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4.9 mmol/ mol (± 16.7) (p = 0.087). Compared with explantation, HbA1c rose with 6.9 
mmol/ mol (± 18.5) (p = 0.085) 12 months after explantation, and with 15.3 mmol/ mol 
(± 29.1) to 74.8 mmol/ mol (± 23.9) (p = 0.059) 24 months after explantation (Figure 5.3).
We observed several changes in composition and dose of anti-diabetic drugs 
(Supplementary table 5.1). The majority of medication number and dosage analysis 24 
months after explantation were not possible because of the low numbers per group due 
to lost to follow-up and scheduled visits in the future. During the DJBL dwelling time, 
11 patients could stop their insulin while its use in the remaining 14 patients decreased 
with 62 IE ± 72 per day (p = 0.007). However, at 12 months after explantation, the daily 
dosage of insulin had increased again by 20 IE ± 25 (p = 0.028) per day compared to 
explantation. By contrast, the number of glimepiride users and its dosage rose, albeit not 
signifi cantly, during DJBL dwelling time; 15 vs 20 users, and an increase of 3.5 mg ± 1.7 
per day (p = 0.319). The number of metformin users and their dosage remained similar 
during DJBL dwelling time. 
One of the 44 patients reached complete resolution of T2DM. This was reached as of 3 
months after implantation till explantation (37 months after implantation). At the time of 
screening, patient had a starting HbA1c of 49 mmol/ mol, a BMI of 32.8 kg/ m2, and used 
2 types of oral anti-diabetic drugs. At the time of explantation her BMI had decreased to 
27.2 kg/ m2 (TBWL 17.1 %), her HbA1c to 41 mmol/ mol, and she had stopped all of her 
anti-diabetic drugs.
Safety
In total, 20 (45 %) patients required early removal due to AEs, starting as early as 1 
month after extension of the dwelling time (Figure 5.4). Thirty (68 %) patients reported 
at least one AE. These 30 patients reported 49 AEs in total, ranging from mild to severe 
(Table 5.2). No patients died. Two patients (4.1 %) developed a hepatic abscess 14 and 
17 months after implantation and were classifi ed as severe AEs. In three (6.5 %) patients 
mechanical failure of the device was observed, in which the sleeve of the DJBL was 
Figure 5.3: Mean change with 95% confi dence interval of HbA1c during DJBL dwelling 
time and after explantation
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disconnected from the anchor. In one patient, the DJBL was removed 37 months after 
implantation since she refused to explant the DJBL in spite of signed informed consent. 
Ultimately, the DJBL was removed because of abdominal complaints.
Table 5.2: Adverse events during dwelling time and after explantation
Mild AEs N
- Mucosal laceration esophagus* 1
- Reflux esophagitis Los Angeles grade A 1
- Sleeve disconnected from anchor 3
Moderate AEs
- Mucosal laceration esophagus 1
- Gastrointestinal events (e.g., abdominal pain, nausea, vomiting) 13
- GI hemorrhage 1
- GI hemorrhage after explantation 1
- Anemia‡ 1
- Migration (>5 cm) of DJBL 8
- Partial migration (<5 cm) of DJBL 11
- DJBL anchor tissue overgrowth 1
- DJBL anchor perforation** 1
- Dilatation pylorus required to pass pylorus 1
- Obstruction liner with food 1
- Two explantation procedures required† 2
Severe AEs
- Hepatic abscess 2
Total 49
* No admission required. ‡ Four days prior to anemia patient underwent abdominal wall reconstruction 
with active bleeding out of two drains. ** Presentation 36 months after DJBL implantation. † Unable 
to pass the esophagus due to a stenosis in the esophagus and inability to pass the lower esophageal 
sphincter
Figure 5.4: Follow-up of DJBL dwelling time
Boek.indb   88 21-03-2019   10:23
89
Clinical follow-up of 24 months DJBL implantation
5
Bariatric surgery
Prior to implantation, 17 (39 %) patients met the eligibility criteria for BMI and diabetes 
to undergo bariatric surgery. The remaining 27 patients had a BMI <35 kg/m2. At the time 
of explantation only 7 patients (16 %) met the eligibility criteria. Twelve months after 
explantation, the number of patients eligible for bariatric surgery had increased to 11 
patients (37 % - no data available of 14 patients). In total, four patients underwent Roux-
en-Y gastric bypass surgery after explantation of the DJBL and one additional patient was 
still waiting for surgery.
Discussion
DJBL implantation results in weight loss and improvement of glycemic control as of 
implantation. The reached decrease in body weight and glycemic control after 12 months 
of implantation could be maintained during the increased dwelling time. The largest 
improvements are observed during the fi rst 9 to 12 months after implantation. At the time 
of explantation, average weight loss per patients was almost 16kg (TBWL 14.6 %). In this 
period, HbA1c showed a non-signifi cant decreasing trend of 4.9 mmol/ mol. The number 
of patients requiring insulin and the daily dose of patients still on insulin both decreased 
signifi cantly during dwelling time. During the extension of the dwelling time, over two 
thirds of the patients experienced at least one AE, and 45 % of the patients required early 
removal of the DJBL due to AEs. Twelve months after removal of the DJBL, clinical 
relapse occurred with weight regain (6.5kg), which had improved again 48 months after 
explantation. A sharp increase of HbA1c and daily dose of insulin was seen compared 
with time of explantation.
Our data demonstrate that the biological effects of the DJBL are reached within 9 to 
12 months after implantation. The desired biological effects stabilize after the fi rst 12 
months after implantation and DJBL removal results in weight regain and loss of glycemic 
control. This accords with data from a study with DJBL dwelling times up to 3 years6. 
A possible reason for the observed stabilization during dwelling time might be that the 
DJBL is tolerated better over time, patients have less abdominal complaints, early satiety 
diminishes, and therefore intake is increased. The weight change after removal, which 
shows an initial substantial increase in the fi rst 12 months after explantation, followed 
by improvements in the second 12 months, is more diffi cult to understand. This might be 
explained by a new weight plateau that has been reached by the DJBL. However, this could 
also be explained by potentially confounding factors, such as selection bias. The results 
on glycemic control depend on the presence of the DJBL in the gastrointestinal tract, as 
removal results in complete reversal of the benefi cial effects. It can be hypothesized that 
initial changes in incretins after implantation revert to levels seen prior to implantation 
when the DJBL is removed. Additionally, the possible achieved restricted food intake 
disappears after removal. The substantial relapse of all parameters that occurs is also 
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seen in other studies7,8. This indicates, at least for glycemic control, that only temporary 
suppression during implantation is possible as opposed to cure of disease. 
Although relapse occurs after explantation, weight is still improved 48 months after 
explantation and patients have experienced a temporarily improvement in glycemic 
control. Without implantation of the DJBL, the expected natural course would be further 
weight gain and deterioration of their T2DM. Therefore, when our study population 
would have been compared with a control group without any intervention, the changes 
in weight and glycemic control might have been larger when just comparing the results 
within patients between explantation and baseline. A possibility to preserve achieved 
improvement in body weight and glycemic control and to diminish risks of long-term 
implantation, is explantation of the DJBL after 12 months, followed by reimplantation 
of the DJBL after a short time of removal. However, feasibility was tested only in a 
small case series9. Additionally, costs will increase due to the need of an extra device and 
implantation and explantation procedure.
Patients were selected for 24 months implantation when they tolerated the DJBL well 
during the first 12 months. In this cohort, 31 % of the patients required early explantation 
during the first year of implantation, mainly caused by intolerability and AEs4. Moreover, 
the risk of AEs continuously increased during the second year. In this selection of well 
responders, still 45 % of the patients required early removal after extension of the 
implantation period due to persisting abdominal complaints or AEs. In total, over two 
thirds of the patients experienced an AE. Additionally, two patients developed a SAE 
and required prolonged hospitalization and intensive treatment as a result of a deep 
hepatic abscess. The cohort study of Quezada et al. describes an early removal rate of 
86 % before 36 months. In total, 29 % of the early removals were due to AEs and 55 
DJBL-related SAEs were observed in 80 patients of which 3 were hepatic abscess6. This 
suggests that all patients are at risk to develop (S)AEs during the complete dwelling time. 
Moreover, the occurrence of such hepatic abscess in patients with a DJBL resulted in 
early termination of a large clinical trial in the United States.
An alternative endoscopic bariatric therapy is the intragastric balloon (IGB). When 
combined with conventional treatment, IGB results in a mean weight loss of 14.7kg 
(TBWL 12.2 %) after 6 months of therapy in a large meta-analysis. Early balloon removal 
occurred in 4.2 % of the patients10. Another meta-analysis saw a mean decrease of HbA1c 
of 9% compared to baseline and a SAE rate of 1.3 % that included 5 cases of gastric 
perforation with 2 patients who died (mortality rate 0.04 %)11. This same meta-analysis 
showed a mean weight loss of 13.5kg (p <0.001) 6 months after IGB removal, comparable 
with 4.8 kg/m2 BMI loss. A retrospective analysis of 114 patients implanted with an IGB 
for 6 to 12 months, found a BMI reduction of 4.1 kg/ m2 one year after IGB removal12. 
Both devices, DJBL and IGB, have a similar efficacy profile during and after use. Early 
removal and the SAE rate of the IGB are certainly lower compared to the DJBL, although 
recent literature shows multiple case reports of SAEs due to IGB use, such as gastric 
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perforation and severe bleeding13,14. In contrast to the IGB, that has been implicated in 33 
deaths, no mortality has been reported so far with DJBL15,16.
This study has several strengths and limitations. With this study, we present one of the 
fi rst clinical real world data of DJBL implantation over 12 months. Additionally, we show 
clinical outcomes after explantation of the DJBL. Moreover, we provided safety data of 
long-term implantations that are much needed for clinical decision making. This study 
also had several limitations. First of all this study is an observation cohort study. As 
with any observational study, a placebo control group was not included; therefore, this 
study cannot account for the natural course of obesity and diabetes over time. Secondly, 
responder rates should be interpreted with caution because patients who did not respond 
to or did not tolerate DJBL withdrew from the trial, resulting in infl ated response 
rates. Additionally, since motivated patients were selected during the fi rst 9 months of 
treatment, the presented results might be an overestimation of the true effect in a non-
selected population. Finally, there was a large number of lost to follow-up 24 months after 
explantation, leading to bias and an overestimation of the results.
In conclusion, implantation of the DJBL results in signifi cant weight loss and improved 
glycemic control. The largest benefi cial effects are seen during the fi rst 9 to 12 months 
after implantation. Further extension of implantation results only in stabilization of the 
parameters as long as the DJBL is in situ. However, after explantation relapse is seen in 
glycemic control. Although body weight shows also initial relapse after explantation, it 
is still signifi cant improved 48 months after removal. The cumulative risk of developing 
AEs increases with extended dwelling time with potentially high severity. Therefore, we 
advise on basis of our results not to extent the dwelling time over 12 months until a better 
effi cacy-safety margin is achieved.
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Supplementary table 5.1: Characteristics and mean changes at explantation and 12 and 24 
months after explantation
Explantation* 12 months post explantation*
24 months post 
explantation*†
Body weight and T2DM
Weight (kg)
∆ Screening
∆ Explantation
92.2 ± 16.6 (n = 43)
- 15.9 ± 9.3; p < 0.001
102.0 ± 16.4 (n = 30)
+ 6.5 ± 5.6; p < 0.001
95.5 ± 17.8 (n = 15)
- 13.2 ± 9.0; p < 0.001
+ 6.6 ± 5.5; p < 0.001
∆ BMI (kg/ m2)
∆ Screening
∆ Explantation
29.9 ± 4.1 (n = 43)
- 5.2 ± 3.0; p < 0.001
32.7 ± 4.3 (n = 30)
+ 2.1 ± 1.9; p < 0.001
31.6 ± 5.2 (n = 15)
- 4.3 ± 3.0; p < 0.001
+ 2.3 ± 3.0; p < 0.001
∆ TBWL (%)
∆ Screening
∆ Explantation
14.6 ± 7.8 (n = 43)
+ 14.6 ± 7.8; p < 0.001
6.9 ± 6.1 (n = 30)
- 6.0 ± 5.3; p < 0.001
12.0 ± 7.7 (n = n = 15)
12.0 ± 7.7; p < 0.001
- 6.1 ± 5.0; p < 0.001
∆ HbA1c (mmol/ mol)
∆ Screening
∆ Explantation
63.2 ± 17.3 (n = 39)
- 4.9 ± 16.7; p = 0.087
71.0 ± 18.2 (n = 25)
+ 6.9 ± 18.5; p = 0.085
74.8 ± 23.9 (n = 13)
+ 7.9 ± 19.2; p = 0.142
+ 15.3 ± 29.1; p = 0.059
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Supplementary table 5.1: Characteristics and mean changes at explantation and 12 and 24 
months after explantation (continued)
Explantation* 12 months post explantation*
24 months post 
explantation*†
Anti-diabetic drugs
Metformin
No. of users
∆ Screening
∆ Explantation
37
0; p = 1.000
26
-11; p = 0.250
14
- 23; p = 0.625
- 23; p = 0.625
Dosage (mg)
∆ Screening
∆ Explantation
1940 ± 870
- 65 ± 810; p=0.714; n=36
2230 ± 600
+ 100 ± 510; p=0.270; n=26
2340 ± 590
+ 250 ± 600; Analysis NP
+ 300 ± 510; Analysis NP
Glimepiride
No. of users
∆ Screening
∆ Explantation
20
+ 5; p = 0.441
13
-7; p = 0.625
4
- 11; p = 1.000
- 16; p = 0.125
Dosage (mg)
∆ Screening
∆ Explantation
3.5 ± 1.7
- 1.5 ± 2.5; p = 0.319; n = 4
3.7 ± 1.9
+ 0.3 ± 0.8; p = 0.166; n=12
6.5 ± 1.9
N/A; Analysis NP
+ 4.5 ± 2.1; Analysis NP
GLP-1 agonist
No. of users
∆ Screening
∆ Explantation
6
+ 1; p = 1.000
4
+ 2; p = 1.000
4
- 1; p = 0.688
- 2; p = 1.000
Dosage (mg)
∆ Screening
∆ Explantation
2.2 ± 0.9
0.0 ± 0.0; Analysis NP
3.0 ± 0.0
0.0 ± 0.0; Analysis NP
N/A; Analysis NP
0.0 ± 0.0; Analysis NP
Insulin
No. of users
∆ Screening
∆ Explantation
15
-11; p = 0.001
11
-4; p = 0.125
3
- 23; p = 0.000
- 12; p = 0.000
Dosage (IU)
∆ Screening
∆ Explantation
53 ± 31
- 62 ± 72; p = 0.007; n = 14
77 ± 41
+ 20 ± 25; p = 0.028; n=10
92 ± 49
- 50 ± 76; Analysis NP
+ 66 ± 37; Analysis NP
* Statistical analyses were performed with the Wilcoxon Signed Rank test and the McNemar 
test. A p value < 0.017 was considered statistically signifi cant. NP = not possible
† Follow-up complete (n = 15); lost to follow-up (n = 13); underwent Roux-en-Y gastric 
bypass (n = 4); follow-up visit scheduled in future (n = 12).
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 Adverse events of the duodenal-jejunal bypass liner: a 
systematic review
Bark Betzel, Joost P.H. Drenth, Peter D. Siersema
Obesity Surgery. 2018 Nov;28(11):3669-3677.
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Abstract
A systematic review was conducted on adverse events (AEs) associated with the use 
of the duodenal-jejunal bypass liner (DJBL). PubMed, EMBASE, and Cochrane library 
were searched up to January 2018. The quality of reporting AEs was determined by 
the McHarm questionnaire and the risk of bias by the Newcastle-Ottawa scale. Thirty-
eight studies were included. The comparability of the studies was low and the McHarm 
questionnaire showed incompleteness for most parameters in all studies. A total of 891 
AEs were reported in 1056 patients. Thirty-three AEs (3.7 %) were classified as severe, 
including hepatic abscess and esophageal perforation. The anchor of the DJBL caused or 
likely caused 85 % of the SAEs. To improve the safety margin of the DJBL, adjustments 
to the anchoring system are needed.
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Background
The duodenal-jejunal bypass liner (DJBL) is a 61-cm liner that is endoscopically 
placed aiming to prevent food uptake in the duodenum and fi rst part of the jejunum. 
This endoscopic bariatric therapy (EBT) creates food malabsorption and changes in 
gastrointestinal hormones similar to a Roux-en-Y gastric bypass, resulting in weight 
reduction and improved glucose control. The use of EBTs has signifi cantly increased 
over the last years and has been considered one of the strategies to combat obesity1. 
The current treatment pyramid for obesity and associated co-morbidities such as type 2 
diabetes mellitus usually starts with diet and lifestyle interventions, and ends with bariatric 
surgery2. Despite these interventions, the worldwide incidence of obesity, defi ned as a 
body mass index (BMI) ≥30 kg/m2, continues to increase3. Placement of a DJBL may 
serve as a potential therapy for patients that are not eligible or refuse bariatric surgery.
DJBL came into clinical practice as early as 2007, and early studies demonstrated 
metabolic improvements with a benefi cial safety profi le1,4. The expansion of its use 
beyond centers of expertise resulted in increasing numbers of implantations but also 
longer times the devices were in place compared to the initial series. The experience from 
these real world studies allows a better insight in the adverse events (AEs) profi le but has 
also suggested that the DJBL resulted in more and a wider range of complications than 
initially reported. If physicians and patients make informed decisions about EBTs such 
as the DJBL for treatment of obesity, a better understanding of the therapeutic effi cacy 
in terms of achieving weight reduction relative to the extent and type of complications 
of the procedure is needed. Hence, we conducted a systematic review to evaluate the 
current safety profi le of the DJBL. We also sought to identify the factors associated with 
unfavorable outcome of DJBL implantation and use. We anticipate that these data will 
increase knowledge on the effi cacy–safety profi le of the DJBL and that this information 
will aid in a balanced decision-making process with regard to patient selection.
Methods
This review was performed following the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) reporting guidelines. The review protocol was 
registered with PROSPERO (registration number CRD42018090644).
Search strategy
We conducted a systematic literature search of the electronic databases of PubMed, 
EMBASE, and the Cochrane Library searching from their earliest availability up to 
January 2018. We performed a wide free text search in all three databases in order to 
fi nd all relevant articles of the DJBL. We did not use any restrictions and performed the 
search with the key words: “duodenal-jejunal bypass liner,” “duodenal-jejunal bypass 
sleeve,” “djbl,” “djbs,” and “Endobarrier” (Supplementary fi le 6.1). To include all articles 
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related to the DJBL, we did not add any other terms like “adverse event”, since these 
would narrow the search and reduce the number of hits. Additional articles were obtained 
through citation snowballing to locate primary sources. Clinical trials, cohort studies, 
case reports, and case series were included. 
Study selection
After the search was performed and duplications were removed by B.B., two reviewers 
(B.B. and J.P.H.D) selected studies for potential eligibility by screening all titles and 
abstracts. If there was no consensus concerning inclusion of a study, a third reviewer 
(P.D.S.) was included for a final decision. For the systematic review, we selected articles 
that contained original data. Studies were included when they involved humans and were 
available in the English language and as full text. Animal studies, (systematic) reviews, 
letters, and conference abstracts were excluded.
Data extraction and quality assessment
From one study, we were not able to obtain full text despite repeated requests to the 
authors. Therefore, this case report was excluded5. Data was extracted from the 
studies using a predefined form. This included study characteristics, general patient 
characteristics, and all information regarding adverse events and early removals. In order 
to be able to generalize the data, AEs were categorized according to the severity grading 
system as defined by the American Society of Gastrointestinal Endoscopy (ASGE)6. This 
qualitative assessment grades AEs as mild, moderate, severe, or fatal. Severe AEs implied 
unplanned admission or prolongation beyond ten nights, ICU admission longer than one 
night, surgery for an AE, or permanent disability.
Data extraction revealed duplicate data from multiple studies (e.g., AEs reported in cohort 
studies were elaborated in case reports). Through deduction and personal communication 
we tried to minimalize that the same AEs that were reported in multiple studies were 
included more than once in this review. Duplicate reported AEs were removed from our 
data set and only included once in the analysis. Studies were included in this review when 
they contained original data in addition to duplicate data. Data from case reports and case 
series that included duplicate data were preferred over cohort studies if they contained 
additional information concerning AEs. 
Additionally, the quality of reporting AEs in each article was determined through scoring 
by the McMaster tool for assessing quality of harms assessment and reporting in study 
reports (McHarm)7. Additionally, the quality of included observational studies and 
thereby the risk of bias was determined using the Newcastle-Ottawa scale. Randomized 
controlled trials and case reports were excluded from the latter analysis.
Technical aspects of the DJBL
The DJBL consists of two parts; the anchor and the liner (Supplementary file 6.2). The 
self-expanding nitinol anchor is placed in the duodenal bulb and contains ten sharp barbs 
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in a proximal and distal direction to keep the DJBL in place and prevent migration. The 
anchor is aligned with a 61-cm fl uoropolymer liner that is located in the duodenum and 
the fi rst part of the jejunum. The liner prevents food from having contact with the small 
intestine and with bile and pancreatic fl uids.
Results
Our literature search covering three databases resulted in 408 abstracts, as shown in 
the PRISMA fl ow diagram in Figure 6.1. After removing duplicates, 325 studies were 
screened on title and abstract and 175 studies were included for full-text assessment. Four 
studies were excluded because of duplicate patient data. One descriptive, retrospective 
multicenter review reported data of DJBL treatment in seven hospitals8. This review 
reported DJBL related AEs that were also published in other studies. Four publications 
reported different aspects of the DJBL procedure in a set of 17 patients, and only one 
article presented data on AEs; hence we excluded the remaining three publications9-11.
Figure 6.1: Flow chart of systematic literature search
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Two studies were excluded because they reported on a target population outside the topic 
of this study. One study provided data on patients after removal of DJBL12. The other 
reported on implantation of a restrictive DJBL, an EBT with a distinct design from the 
regular DJBL that was used in all other studies13.
A total of 38 studies were included in this systematic review (Supplementary file 6.3)
Quality assessment of selected studies
The risk of bias of the selected cohort studies and case series is shown in Table 6.1. The 
Newcastle Ottawa Scale shows that only one study was considered as high quality (≥7). 
However, 64 % of the studies scored six out of nine stars. In the majority of studies the 
outcome parameters were sufficiently reported, although the comparability was low.
McHarm questionnaire
The results of the McHarm questionnaire (Figure 6.2) demonstrate that harms were well 
defined in 17% of the studies. Background information of the researchers involved in 
collecting the AEs was presented in only one of the 38 studies. Follow-up after an AE was 
reported in 68% of the studies.
Figure 6.2: McHarm questionnaire for determining the quality of registering adverse 
events. * Specification of questions. 1. Were the harms pre-defined using standardized 
or precise definitions? 2. Were serous events precisely defined? 3. Were severe events 
precisely defined? 4. Were the number of deaths in each study group specified or were the 
reason(s) for not specifying them given? 5. Was the mode of harms collection specified as 
active? 6. Was the mode of harms collection specified as passive? 7. Did the study specify 
who collected the harms? 8. Did the study specify the training or background of who 
ascertained the harms? 9. Did the study specify the timing and frequency of collection of 
the harms? 10. Did the author(s) use standard scale(s) or checklist(s) for harms? 11. Did 
the authors specify if the harms reported encompass all the events collected or a selected 
sample? 12. Was the number of participants that withdrew or were lost to follow-up 
specified for each study group? 13. Was the total number of participants affected by harms 
specified for each study arm? 14. Did the author(s) specify the number for each type of 
harmful event for each study group? 15. Did the author(s) specify the type of analyses 
undertaken for harms data?
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Safety data
Data extraction from the complete data set yielded a total of 891 AEs in 1056 patients 
(Table 6.2). In total 75.8 % AEs were classified as mild AEs, 20.5 % as moderate, and 3.7 
% as severe AEs. No mortality was reported. Eight patients required surgery as a result 
of an AE due to DJBL implantation. Early removal of the DJBL was performed in 255 
patients (24.1 %).
Severe AEs
In total 33 AEs were classified as severe according to the ASGE grading system6. Hepatic 
abscess (n = 11), gastrointestinal hemorrhage (n = 8), and esophageal perforation (n = 4) 
were among the most frequently reported SAEs. The majority (88 %) of SAEs occurred 
during implantation, the remaining were procedure-related. Figure 6.3 shows the location 
and frequency of all SAEs reported in the literature.
Moderate AEs
A wide range of moderate AEs were reported. During removal, mucosal laceration of 
the esophagus or oral cavity resulting from the sharp anchor barbs of the DJBL occurred 
in four patients. During implantation, several types of AEs occurred: general AEs (e.g., 
abdominal pain, vomiting) and gastrointestinal hemorrhages, anchor-related AEs (e.g., 
migration, ulceration, perforation), liner-related AEs (e.g., obstruction, eversion), and 
inflammation/ infectious AEs (e.g., pancreatitis, cholecystitis, cholangitis).
Figure 6.3: Location and frequency of reported serious adverse events related to the 
DJBL
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Table 6.2: Summary of reported AEs arranged by procedure related, wear & tear during implantation, and biochemistry
Number of events†
Mild†† Moderate Severe
Procedure related (implantation/ explantation)
Perforation esophagus 4
Mucosal laceration esophagus/ oral cavity 4
Procedural nausea/ vomiting 23
Anesthetic side reaction 1 1
Total 24 5 4
During implantation
General
Gastrointestinal events (e.g. abdominal pain, nausea, vomiting, diarrhea, 
constipation) 498 73 3
Gastrointestinal hemorrhage
GI hemorrhage 25 8
Melena 3
DJBL anchor related
Migration (>5 cm) of DJBL‡ 4
Partial migration (<5 cm) of DJBL 16 30
DJBL anchor ulceration/ infl ammation/ polyp formation 35 2
DJBL anchor tissue overgrowth 1
Stenosis duodenal bulb by ulceration and DJBL migration 1
Perforation duodenal bulb 1
DJBL anchor perforation 4
DJBL liner related
Obstruction liner 2 20
Eversion of liner 3
Inﬂ ammation/ infectious
Hepatic abscess 11
Acute pancreatitis 5 3
Acute cholecystitis 1 1
Cholangitis 2
Other
Portal vein thrombosis 1
Gallstones, symptomatic 1
Duodenitis 2 1
Esophagitis/ gastritis 2
Other 51* 2**
Total 610 173 29
Biochemistry
Hypoglycemia 19
Lipid disturbance 1
Electrolyte disturbances due to persistent diarrhea 1
Decreased iron/ ferritin 8
Anemia 13
Dehydration 4
Total 41 5 0
Total 675 183 33
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Table 6.2 notes: † Total patients, n = 1.056; surgery needed, n = 8; deaths, n = 0. ††  
Often unclear if the described complaints can be considered as mild (AEs) for which 
medical consultation is needed, or patients reported them at hospital visits and can 
be considered as incidents. ‡ Distance of migration in most cases is unclear. Therefore 
differentiation between migration and partial migration is difficult to assess. * Headache n 
= 1; adverse drug reaction n = 2; pyrexia n = 2; injury, poisoning, procedural complication 
n = 6; backpain n = 9; weakness n = 2; lower frontal chest pain n = 1; bezoar of poorly 
digested food n = 1; pill impaction that resolved conservatively at the ER n = 1; reflux n = 
7; unclassified n = 19. ** Elevated pancreatic enzymes n = 1; pylorospasm postprocedural 
leading to vomiting and thereby early removal n = 1
Mild AEs
The majority of the AEs were classified as mild and included procedural nausea and 
vomiting, general gastrointestinal events during implantation, ulceration surrounding the 
DJBL anchor, and several laboratory measure-related AEs such as hypoglycemia and 
anemia.
AEs attributed to the design of the DJBL
Anchor – in total 28 (85 %) SAEs were caused or likely caused by the anchor. Perforation 
of the esophagus, gastrointestinal hemorrhage, DJBL anchor tissue overgrowth, and 
perforation of the duodenal bulb had a causal relation with the anchor (n = 14, 42.5 
%). Hepatic abscess and acute pancreatitis were likely caused by the anchor (n = 14; 
42.5 %). Sixty-nine of the moderate AEs (38 %) were also likely caused by the anchor, 
including migration and anchor perforation. It was unclear which number of the general 
gastrointestinal events such as abdominal pain and nausea can be attributed to the anchor.
Liner – in total 25 (2.8 %) mild and moderate AEs were likely related to the liner of the 
DJBL, including obstruction and eversion of the liner. Several other AEs might have been 
related to the liner, but its association cannot be determined definitively. For example, a 
decreased iron or ferritin serum level could well have been caused by the prevention of 
uptake by the liner.
Discussion
Our systematic review shows that the use of the DJBL is associated with a wide range 
of AEs, with 20.5 % graded as moderate and 3.7 % graded as severe. No mortality was 
reported, but eight patients required surgery as a consequence of an AE. The analysis by 
the McHarm indicated inadequate reporting of the AEs in the majority of the studies, 
resulting in an underestimation of the true incidence of AEs. The mechanism of action of 
the reported AEs suggested that the anchor of the DJBL is likely responsible for 85 % of 
the SAEs.
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The introduction of new endoscopic devices that fi ll a gap of unmet needs, usually 
generates enthusiasm from the fi eld. For example, early studies after the introduction of 
the FerX-Ella stent, which was pioneered for the use of palliation of malignant dysphagia, 
reported a good effi cacy-safety margin14. Subsequent experience from centers other 
than expert centers reported a more disappointing effi cacy-safety margin and a higher 
frequency of AEs, such as hemorrhage15. As with many medical devices, initial studies 
focus on effi cacy but with the extension of its use and indications, an increasing number 
of AEs are often encountered and reported. This parallels the clinical development of the 
DJBL. An increase of AEs was reported in real world studies after the randomized clinical 
trials. Real world use is associated with patients that do not meet the stringent inclusion 
criteria of clinical trials, and implantation time took longer than in the initial trials where 
the majority of the studies considered a 3 to 6-month implantation period. We surmise 
that publication bias is a confounder, since authors prefer to report on effi cacy instead of 
safety. Therefore, determining the true safety profi le of a medical device requires close 
and prolonged monitoring after its introduction.
The use of the DJBL is associated with a wide range in severity of AEs, varying from 
incidents and mild AEs to SAEs requiring emergency surgery. The majority of the 
reported events consisted of mild general gastrointestinal complaints, such as abdominal 
pain, nausea, and vomiting. These occurred mainly during the fi rst 2 weeks after 
implantation, but in some cases persisted during the entire implantation time, leading to 
early removal in 73 patients. In total, nearly a quarter of implanted DJBLs were removed 
early due to AEs or intolerability of the device. Almost 4 % of the AEs were classifi ed 
as severe. These results are in line with the fi ndings presented in a systematic review of 
Zechmeister-Koss et al. that included 10 studies4. Our study captured a wider range of 
SAEs, while  Zechmeister-Koss et al. reported only gastrointestinal hemorrhages. Our 
data is in contrast with a review from the ASGE, published in 2015, suggesting a better 
safety profi le with only three SAEs in 271 implantations1.
The DJBL is positioned on the market as a minimal invasive device with a benefi cial 
safety profi le. We found 33 SAEs in a sample of 1056 patients. The majority of these 
SAEs were related or suspected to be related to the anchor of the DJBL. The anchor 
contains ten barbs that protrude into the mucosa and provide active fi xation to prevent 
migration (Supplementary fi le 6.2). These barbs, which are tiny needle-like pins, cause a 
penetrating trauma, resulting in local mucosal infl ammation. This may result in ulceration, 
tissue overgrowth, or hemorrhage. These barbs may also cause (micro) perforation of the 
duodenal bulb, which could be the cause of hepatic abscess formation. When the DJBL 
is endoscopically removed, a specially designed removal cap needs to be fi tted to the 
endoscope. When the barbs are not precisely in place and protrude out of the cap, damage 
to the esophagus or oral cavity might occur when they scrape the mucosa. This can result 
in perforation of the esophagus. Therefore, the anchor of the DJBL is the component that is 
a major contributor of AE development. Other medical devices that used self-expandable 
metallic stents (SEMS) in the gastrointestinal tract showed similar safety profi les. SAEs 
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such as bleeding, perforation, and pancreatitis were reported in 12 % in SEMS that were 
used for malignant gastroduodenal outlet obstruction16. A large pooled analysis of SEMS 
in malignant colorectal obstruction showed perforation in 3.7 %, migration in 11.8 %, 
re-obstruction in 7.3 %, and stent-related mortality of 0.6 %17. Therefore, a subgroup of 
AEs can likely be attributed to the location and working mechanism of these medical 
devices. The placement of a device in the gastrointestinal tract is associated with a risk 
on migration and obstruction, while the use of barbs adds an additional risk of bleeding 
and perforation.
As has been seen with other medical devices, the full range of AEs of the DJBL becomes 
more clear with extended use of the device in real world studies. Nonetheless, although an 
increasing number of AEs were reported, the use of the McHarm showed a disappointing 
registration of AEs. In order to recognize the occurrence of AEs in time, it is important that 
AEs are actively registered in a uniform way with the use of predefined forms. Therefore, 
adequate and complete registration of AEs is of utmost importance to fully determine the 
efficacy-safety margin in new introduced techniques and medical devices. Reporting the 
full range of potential AEs of a new device in relation to its potential beneficial effects 
may aid in balanced decision-making with regard to using the device.
Our systematic review has some strengths and limitations. One of the strengths is the 
extensive and systematic search with no limitations in order to find all DJBL studies. 
However, although our search was thorough, it is difficult to assess the real number of 
AEs related to the DJBL. It is possible that our strategy led to an overestimation of the 
reported AEs because some studies reported on the same patient population. Therefore, 
AEs from the same patients might have been reported across several publications. In this 
systematic review, we have tried to only include AEs once, and we left out the “double” 
publications. More likely however we believe that our results represent an underestimation 
of the true number of AEs. The results from the McHarm questionnaire clearly indicate 
incomplete reporting. This is particularly true for severe AEs, but also for mild AEs. It is 
reasonable to hypothesize that publication bias is an important confounder, since authors 
usually prefer to report on efficacy instead of safety. The introduction of an innovative 
device comes with a high need for efficacy data, and we saw that quite some articles in 
our analysis focus on efficacy rather than safety. Once efficacy has been established and 
use has expanded beyond expert centers, it seems likely that active scientific reporting of 
safety data is less likely to occur. Therefore the true incidence of AEs is still difficult to 
determine.
Conclusion
In conclusion, we showed that the use of the DJBL was associated with a wide range of 
AEs in the majority of patients. Some 4% of AEs is classified as severe. These SAEs, such 
as perforation of the esophagus, hemorrhages, and hepatic abscess, are likely to have a 
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great impact on patients’ quality of life. Focus on adjustments of the barbs that provide 
active fi xation is key to improve the effi cacy-safety margin of the DJBL. Moreover, 
we propose that the introduction of new devices should be performed in a standardized 
format, which not only reports on technical aspects of placing the device and its effi cacy, 
but also includes a predefi ned way of reporting (S)AEs during the placement procedure 
and during follow-up. By doing so, clinicians are able to determine the real effi cacy-
safety ratio of a new device and discuss this with patients in a balanced way, which allows 
comparing it with other modalities to treat the disorder.
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Supplementary File 6.1: Literature search 
 
[((((duodenal-jejunal bypass liner) OR duodenal-jejunal bypass sleeve) OR djbl) OR djbs) 
OR endobarrier]
Supplementary File 6.2: Duodenal-jejunal bypass liner, consisting of the anchor and liner
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Research with novel medical devices always invariably focus on performance of that 
device for new intended uses, new populations, new materials or design changes. The aim 
of most human device studies is to investigate the benefits of that device as an outcome 
of the supposed mechanism of action. Complications of that device is the unintended but 
inevitable secondary result of device use and rarely, if ever, the main focus of human 
studies. Device related complications or untoward medical occurrence, unintended disease 
or injury or any untoward clinical signs may be the result of a specific device subject 
interaction with effects on the subject (perforation of the gut), or to the device itself (stent 
fracture). In most studies these adverse events (AEs) are relegated to a paragraph in the 
result section of a paper. As a consequence AEs do not get the attention that is needed 
to make a correct judgment call on use of medical devices in a given clinical situation. 
The same is true for the duodenal-jejunal bypass liner (DJBL). Human studies early in 
the lifecycle of the novel medical device were clearly focused on the efficacy side of the 
medal. We started our studies with DJBL as a device to achieve weight loss in the obese 
population. During the course of our research, the dwelling time of the DJBL gradually 
increased as well as the number of patients treated. With the expanding exposure of 
patients to this device, we saw a growing number and a wider range of AEs. To determine 
a correct beneficial-safety ratio that supports in clinical decision making, we decided to 
focus on the safety issues. To this end we conducted a systematic review on the safety 
aspects of the DJBL as highlighted in the previous chapter. We think that it is relevant 
to share our own experiences with DJBL. The next chapters therefore focus on our own 
safety experience of the DJBL and we provide an overview of the broad spectrum of the 
observed AEs experienced in our own center. Additionally, we published a case series on 
the relationship and assumed etiology between acute pancreatitis and the DJBL. The last 
part of this chapter contains an illustrative casebook of the normal situation of the DJBL 
and endoscopic and radiological appearances of AEs related to use of the DJBL.
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Abstract
BACKGROUND: The duodenal-jejunal bypass liner (DJBL) is a new, device-based 
endoscopic treatment for type 2 diabetes mellitus (T2DM) and obesity. 
OBJECTIVE: To report serious safety events of subjects treated with the DJBL while 
offering a simple guideline to mitigate risk.
DESIGN: Single-center observational study.
SETTING: Tertiary referral center.
PATIENTS: For commercial use, patients were eligible for implantation of the DJBL 
when they met the following criteria: age 18 to 65 years, body mass index 28 to 45 kg/
m2, T2DM, and negative serum Helicobacter pylori test.
INTERVENTIONS: Endoscopic implantation of the DJBL.
MAIN OUTCOME MEASUREMENTS: Adverse events, serious adverse events, early 
explantation.
RESULTS: Between October 2007 and January 2014, 152 of 165 planned implantations 
(92%) and 94 explantations were performed in our center. Significant weight loss and 
improvement in T2DM and other cardiovascular parameters were achieved. Early 
removal of the device occurred because of persistent gastrointestinal symptoms in 16 
patients (11%). Serious adverse events were observed in a subset of patients: 7 GI bleeds, 
5 of which required early removal; 2 cases of pancreatitis; 1 case of hepatic abscess; and 
1 obstruction of the sleeve. Explantation resulted in an esophageal tear in 2 cases.
LIMITATIONS: Single-center study.
CONCLUSION: The DJBL improves glycemic control while causing weight loss. The 
safety profile of the DJBL demonstrates a reasonable tolerability profile. However, serious 
safety adverse events can occur. Patient selection, expert use of the device at placement 
and removal, and the supportive care of an experienced multidisciplinary team are key for 
safe and effective use of the DJBL. 
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Introduction
It is well recognized that obesity and type 2 diabetes mellitus (T2DM) are at worldwide 
epidemic proportions1,2. Unfortunately, behavioral modifi cation approaches and an array 
of pharmacologic agents, both orally administered and injectable, fail to demonstrate 
a sustained and impactful means to combat this metabolic epidemic3. The benefi cial 
effects of behavioral modifi cation and pharmacology are impeded by an innate diffi culty 
in patients to comply with a given regimen for sustained periods. Additionally, some 
antidiabetes pharmacologic agents incur further weight gain, worsening already 
established obesity. Bariatric surgery has emerged as an important intervention in the 
treatment for obesity and T2DM, manifesting with potent effects to normalize glycemia 
accompanied by robust weight loss4-6. According to international guidelines, bariatric 
surgery should only be considered for patients with a body mass index (BMI) ≥35 kg/
m2 combined with comorbidities7. This leads to a narrowing of its utility to a high-risk 
subpopulation and creates a reticence from some patients to undergo a permanent surgical 
procedure for a metabolic disorder. 
In recent years, a new therapeutic approach has emerged in the form of the duodenal-
jejunal bypass liner (DJBL; EndoBarrier; GI Dynamics, Lexington, Mass), a device 
placed temporarily in the gastrointestinal (GI) tract. It is placed endoscopically with 
minimal disruption to normal anatomy8,9, rendering it less invasive than bariatric surgery. 
After a recommended 12-month implant time, the device is endoscopically removed. 
Metabolic effects are seen in obese patients with T2DM with a lowering of glycemia 
to 6.5 % to 7.5 %, an excess weight loss of 39 % to 47 %, and positive effects on 
cardiometabolic parameters10-16. Its effects on glycemia are at least as competitive as 
optimized pharmacology approaches, and weight loss effects are beyond those seenwith 
pharmacology. Therefore, the DJBL is emerging as an intervention that may complement 
certain pharmacologic treatments in a setting where bariatric surgery is unattractive or 
unavailable13. 
The Rijnstate Hospital, Arnhem, the Netherlands, is a center pioneering the use of the 
DJBL as a treatment for obesity and T2DM, fi rst in earlier prototype forms, then in formal 
clinical trials17,18, and currently commercially. With increasing numbers, the experience 
and expertise in the use of the device continues to mature. 
The DJBL is considered to be a safe therapeutic option that is well tolerated by patients. 
However, early explantations have been reported8,10,11,13,16,17,19,20. Additionally, patients 
experienced GI bleeding because of the device21, and a laparoscopic intervention because 
of perforation has been reported22. 
The aim of this report is to leverage the expertise gathered at the Arnhem center by 
summarizing the overall safety experience using the DJBL thus far, while discussing 
methods to optimize safe use of the device for the future. In view of the study design, only 
limited effi cacy data are presented here. 
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Methods 
Between October 2007 and January 2014, 165 implantations and 94 removals of the DJBL 
were performed in the Rijnstate Hospital, Arnhem, the Netherlands. All patients who were 
approved for implantation in the Rijnstate Hospital were prospectively followed. These 
patients were selected from 3 studies: 2 clinical trials17,18 and 1 prospectively followed 
cohort study. All studies were approved by the institutional review board. 
Inclusion criteria 
Inclusion criteria were different between the studies. Patients had to meet the following 
inclusion criteria for the commercial device: age 18 to 70 years, BMI 28 to 45 kg/m2, 
fasting plasma C-peptide >0.27 nmol/L (normal range, 0.27-1.28 nmol/L), negative serum 
Helicobacter pylori test, and use of at least 2 different types of oral antidiabetic medication 
or use of insulin. With growing experience, inclusion criteria were adjusted, and patients 
who used anticoagulant medication (eg, acetylsalicylic acid and acenocoumarol) or 
nonsteroidal anti-inflammatory drugs were excluded to reduce the risk of GI bleeding. 
Additional exclusion criteria included abdominal surgery that disrupted GI anatomy, 
severe gastroesophageal reflux disease (GERD), active gastric or duodenal ulcer disease, 
coagulopathies, and severe systemic or end-organ disease. No gastric swallow tests or 
esophagogastroduodenoscopies (EGD) were performed before implantation. 
The main differences in inclusion criteria for the study by Schouten et al17 were age 
between 18 and 55 years and BMI between 40 and 60 kg/m2, or above 35 kg/m2 with 
obesity-related comorbidities. In the study by Koehestanie et al.18, patients were eligible 
with an age between 18 and 65 years, a BMI 30 to 50 kg/m2, and those who had T2DM for 
less than 10 years with glycosylated hemoglobin AIc levels between 7.5 % and 10.0 %. 
Follow-up 
Detailed information concerning DJBL procedure, delivery, and removal were captured 
prospectively with clinical follow-up of patients for up to 2 years after device removal. 
Patients receiving the commercial device were assessed by the clinician responsible for 
implantation before procedure and after placement. Patients were assessed clinically at 1 
week and at 1, 3, 6, 9, and 12 months thereafter. After removal, visits were scheduled at 1 
week and at 6, 12, and 24 months. Clinical assessment included symptom check, adverse 
event capture, physical examination, and blood draw for standard diabetes management 
purposes. Patients experiencing any unanticipated symptoms were instructed to contact 
our center. Additionally, if admitted to another hospital, patients were instructed to 
immediately inform their treating doctor about their DJBL. An adverse event was defined 
as any event that had negative consequences for the patient during device delivery, during 
the period the device was in place, or during removal. 
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DJBL placement (implantation) 
Placement of the device is performed endoscopically with fl uoroscopic guidance. 
In earlier use of the DJBL, the endoscopic procedure was performed with the patient 
under general anesthesia; however, with increasing experience and familiarity with the 
procedure, implantation is now performed with the patient under conscious sedation23. 
The anchor of the DJBL is placed in the duodenum, and, when the anchor is positioned, 
the proximal 61 cm of the small bowel is covered with an impermeable fl uoropolymer 
sleeve that is open at both ends9,24. During delivery, the liner and anchor are in a collapsed 
form contained in a protective capsule that is passed to the duodenum, just distal to the 
pylorus. The device folds out of the capsule, and the proximal part of the sleeve is fi xed 
to the wall of the duodenum with help from the pressure of the self-expanding nitinol 
anchor. This anchor contains 10 short barbs positioned in 2 directions that affi x the device 
to the duodenal wall to prevent the DJBL from migrating either distally or proximally. 
The fl uoropolymer liner is then passed distally from the anchor point. As food passes 
though the inner portion of the liner, bile and pancreatic fl uids pass outside, only mixing 
after passing 61 cm from the anchor position in the duodenum. 
DJBL removal (explantation) 
Removal of the device is also performed endoscopically with fl uoroscopic guidance and 
is now also performed with the patient under conscious sedation23. The DJBL is removed 
with the use of a customized retrieval device. One of the drawstrings located at the crown 
of the device is secured and pulled, thus collapsing the device crown. Subsequently, the 
device is retracted onto the endoscope, which is equipped with a hood to cover the anchor 
barbs. After the anchor is collapsed and the barbs are secured inside the hood, confi rmed 
by fl uoroscopy, the DJBL is removed by pulling it gently out of the duodenum, into the 
stomach, and then through the esophagus and mouth. 
Statistical analysis 
Data were analyzed using IBM SPSS for Windows, version 21.0 (IBM Corp, Armonk, 
NY). Results are presented as mean values with standard deviation, unless specifi ed 
otherwise. Differences between 2 time points within patients were analyzed with a paired 
t-test. A p <0.05 was considered statistically signifi cant. All tests were 2-tailed. 
Results 
Until January 2014, 165 patients met the inclusion criteria for implantation at our center: 
9 cases in a clinical study using an earlier device prototype17, 36 cases in a subsequent 
clinical study with the eventual commercial prototype18, and 120 commercial cases. Eight 
of the 36 cases in the second clinical trial were added to the 120 commercial cases in the 
analysis because their implantation period was prolonged from 6 to 12 months during the 
trial (Table 7b.1). 
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Of the 165 attempted implantations, 152 (92.1 %) were successfully conducted, and, at 
time of analysis, 94 devices had been removed. In total, 70 patients (46.1 %) completed 
their intended implantation period and a further 58 patients (38.2 %) had yet to complete 
their intended implant period with the device still in place (mean implantation duration of 
26 ± 1.7 weeks). The remaining 24 patients (15.8 %) had the device removed early (mean 
implantation duration of 22 ± 3.9 weeks) (Table 7b.1). 
Of the 152 patients who received the DJBL, 123 patients (80.9 %) reported no major 
adverse events. Sixteen patients experienced GI symptoms, leading to early removal 
of the device, but without evidence of other adverse events. However, more significant 
adverse events were noted in other patients, resulting in early removal of the device in 
some (Table 7b.2). 
Table 7b.3 shows patient characteristics and efficacy data for all 3 groups, divided by the 
length of the implantation period. Only descriptive statistics have been performed for the 
group of patients implanted for 12 weeks because of small patient numbers. 
Body weight and BMI decreased statistically significantly between baseline and 
explantation as well in the 6- and 12-month groups (p <0.001). Glycosylated hemoglobin 
AIc and fasting glucose decreased in all groups, but a significant decrease was only 
reached in the group implanted for 6 months. Total cholesterol and triglyceride decreased 
statistically significantly in both groups, and changes in low-density-lipoprotein 
cholesterol varied between the groups. Finally, the high-density-lipoprotein cholesterol 
decreased in all groups, significantly in the 6-month group. 
Table 7b.1: Overview of planned and actual implantations and explantations
Group
Intended 
duration of 
imlantation
Planned 
implantations
Succesful 
implantations
Unable to 
implant
Early 
explantation 
< 1 month
Early 
explantation 
> 1 month
I 12 weeks 9 8 1 0 1
II 6 months 28 26 2 2 1
III 12 months 128 118 10 4 16
Total 165 152 (92.1%) 13 (7.9%) 6 (3.9%) 18 (11.8%)
Unsuccessful implantations 
In 13 patients (7.9 %), implantation of the device was unsuccessful. This was mostly 
related to local anatomy of the small intestine. Three patients had a short duodenal bulb 
that offered too little space to position the anchor of the DJBL. Six patients had a sharp 
angle in the course of their proximal jejunum that led to folding of the DJBL. A tubular 
adenoma was seen in 2 patients, which made it unwise to implant the DJBL: 1 in the 
duodenal bulb and 1 in the horizontal part of the duodenum. Abnormal anatomy of the 
stomach because of previous surgery and severe gastritis were the cause of unsuccessful 
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implantation in 2 other patients. All other implantations were performed without any 
major diffi culties. 
Table 7b.2: Number of adverse events related to the DJBL
During 
implantation
When DJBL 
in situ
During 
explantation
Total
Procedural adverse events
Mucosal damage of oesophagus 1 (0.7%) 0 0 1 (0.7%)
Esophageal rupture 0 0 2 (1.3%) 2 (1.3%)
Intercurrent adverse events
Gastrointestinal bleeding, venous* 0 5 (3.3%) 0 5 (3.3%)
Gastrointestinal bleeding, arterial 0 1 (0.7%) 1 (0.7%) 2 (1.3%)
Pancreatitis 0 2 (1.3%) 0 2 (1.3%)
Liver abscesses 0 0 1 (0.7%) 1 (0.7%)
Perforation anchor next to pylorus 0 0 1 (0.7%) 1 (0.7%)
Obstruction 0 1 (0.7%) 0 1 (0.7%)
Total 1 (0.7%) 9 (5.9%) 5 (3.3%) 15 (9.9%)
*Two of 5 devices could remain in place because the venous bleeding resolved. DJBL, Duodenal-
jejunal bypass liner
Procedural adverse events 
Three patients experienced an adverse event because of the procedure. During the 
implantation procedure of 1 patient, after delivering the sleeve, the anchor unfolded 
incompletely. When manipulating the anchor, the capsule went back into the esophagus 
together with the endoscope. A superfi cial mucosal lesion was visible that was closed 
with 3 endoscopic clips. A swallow test showed no leakage of contrast, and the patient 
recovered well. 
During DJBL removal, damage to the esophagus occurred in 2 patients. This concerned 
our 21st and 49th explantation procedure. In the fi rst patient, at planned removal after 6 
months the endoscopic check after removal showed a longitudinal, partial full-thickness 
transmural tear of the last 6 cm of the esophagus, which was confi rmed by CT scan. 
This was likely caused by an exposed barb outside the hood at the time of retrieval. 
The lesion was treated with an esophageal stent for 3 weeks, resulting in uneventful 
healing. In the second patient, the DJBL was explanted because of pancreatitis 11 months 
postimplantation. The DJBL was collapsed and placed into the hood and then retracted 
into the stomach. After repositioning the collapsed barbs, the DJBL was explanted without 
any problems. Outside the body it appeared that because of torsion of the sleeve the barbs 
were intertwined. Endoscopic assessment showed 3 sites of superfi cial mucosal damage 
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that were treated with a stent and feeding tube. Both were removed after 7 and 10 days, 
respectively, followed by an uneventful recovery.
Adverse events during the implantation period 
Abdominal pain: After implantation, approximately 50 % of the patients complained of 
mild to moderate abdominal symptoms, including pain, nausea, and vomiting during 
the first 2 weeks. In all cases, a standard regimen of tramadol, butylscopolamine, and 
metoclopramide was prescribed to mitigate these symptoms. Persisting abdominal 
complaints during the complete implantation period, which could not be cured with 
lifestyle changes or medication, led to early explantation in 16 patients (10.5 %). 
Abdominal symptoms quickly improved after removal. 
GI bleeding: Seven patients had GI bleeding after implantation, of which 5 led to early 
explantation (Table 7b.2). Two patients complained of hematemesis and melena 3 and 6 
weeks after implantation of the DJBL, respectively. In both cases there was no evidence 
of a lowered hemoglobin or hematocrit and no signs of hypovolemia. Endoscopy showed 
slight erosions of the duodenal mucosa in 1 patient and 3 longitudinal ulcers with 2 blood 
clots below the anchor in the other patient. Because no active bleeding was apparent in 
these patients, the DJBL was not removed. The patients were treated with additional 
proton pump inhibitors (PPIs) and sucralfate. No further bleeding was noted during 
follow-up. 
One patient complained of fatigue and dizziness 40 weeks after implantation. Blood 
results showed a microcytic anemia. Endoscopy showed migration of the DJBL with 
superficial ulcerations without active blood loss. After removal of the DJBL, anemia 
resolved. 
A fourth patient presented with melena and a lowered hemoglobin 2 weeks after 
implantation. This patient had continued on acetylsalicylic acid therapy because of a 
previous cerebrovascular event. No active bleeding was seen, but the degree of blood 
loss resulted in device removal after which subsequent endoscopic coagulation of the 
bleeding ulcer was necessary. No further problems occurred. A fifth patient was treated 
with active anticoagulation (2 types of platelet aggregation inhibitors and heparin) 11 
months after device implantation because of a myocardial infarction requiring coronary 
artery bypass graft. A few days after initiating anticoagulation, the patient had melena 
and a fall in hemoglobin, requiring transfusion. The DJBL was removed without adverse 
event, bleeding ceased, and coronary artery bypass graft was carried out. 
There were 2 further cases of significant GI bleed. One patient presented with clear 
evidence of hypovolemia and hematemesis 6 weeks after implantation. CT angiography 
showed active blood loss from the gastroduodenal artery. After transfusion, and 
embolization of the artery, the patient stabilized and the DJBL was removed the next 
day without additional further adverse event. The other patient presented also with clear 
evidence of hypovolemia and melena 6 weeks after implantation, requiring transfusion. 
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No active bleeding in the surroundings of the anchor was visible on endoscopy. When 
removing the device, on separating the anchor from its position in the duodenal bulb, 
arterial bleeding ensued. This resulted in signifi cant blood loss that could not be managed 
endoscopically, and surgical removal of the DJBL was carried out through emergency 
laparotomy. Uneventful recovery followed, and the patient was discharged 8 days after 
surgery. 
Pancreatitis: Two patients developed mild pancreatitis 8.5 and 11 months after 
implantation, respectively. The fi rst patient presented with severe abdominal pain and 
vomiting. Blood tests showed serum amylase >1300 U/L (normal range, 1 to 220 U/L). 
Figure 7b.1: Migration of the DJBL. Migration of the DJBL through the duodenum was 
confi rmed with help of a CT scan (A), where it had passed the major duodenal papilla 
(B). The duodenum showed linear ulcerations of the duodenal mucosa as a result of the 
migrating DJBL (C) where food residues at the entrance of the DJBL had blocked the 
papilla (D)
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A CT scan showed migration of the DJBL, which passed the major duodenal papilla 
(Fig. 7b.1A). Additionally, an EGD confirmed migration of the DJBL past the swollen 
major duodenal papilla (Fig. 7b.1B) with linear ulcerations in the duodenal mucosa (Fig. 
7b.1C). Residual food at the entrance of the DJBL had blocked the papilla (Fig. 7b.1D). 
After retrieval of the DJBL, the patient recovered quickly with a serum amylase of 642 
U/L the next day. The second patient presented with 3 days of abdominal pain and an 
elevated serum amylase >14,000 U/L. EGD showed migration of the DJBL distally and 
hypertrophic tissue surrounding the major duodenal papilla. After removal of the DJBL, 
the patient quickly recovered. 
Hepatic abscess: One patient who had anemia because of GI bleeding checked in with 
the emergency department in another hospital. After transportation of the patient to our 
center, the DJBL could be removed normally. During admission, the patient presented 
with hepatic abscesses. The patient was treated with antibiotics for 8 weeks (4 weeks 
intravenous and 4 weeks oral) and made a full recovery. 
Perforation of the anchor of the DJBL: Twelve months after implantation, during 
explantation, EGD showed in 1 patient a perforation of 1 of the barbs of the anchor 
through the duodenal wall next to the pylorus into the stomach (Fig. 7b.2). The DJBL 
could be explanted endoscopically with help of the explantation set. The patient reported 
no pain and no complaints afterward. 
Discussion 
The DJBL is a promising, minimally invasive treatment for patients with T2DM and 
obesity. This study is the first in its kind that highlights the safety aspects of the DJBL. 
Therefore, the efficacy data presented in this article need to be carefully interpreted. 
Figure 7b.2: Perforation of the anchor of the DJBL into the stomach. EGD showed a 
perforation of a barb of the anchor of the DJBL. The barb perforated through the duodenal 
wall, next to the pylorus, into the stomach
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Although signifi cant improvements were seen in weight, diabetes, and other cardiovascular 
parameters in all 3 groups, this study is not designed to completely evaluate these effects. 
In particular, in the group of patients implanted with the DJBL for 12 months, half of 
the patients did not yet reach explantation. Therefore, additional research focusing on 
effi cacy of the DJBL is needed. 
The intended 12-month use occurs in most patients through a fairly straightforward 
placement and removal of the device and a manageable tolerability profi le, particularly 
in the early weeks after placement. There is the need for strong expertise and a 
multidisciplinary team to be in place to allow safe and effective use of this new device. 
However, unintended safety events can still arise. Additionally, there is a learning curve 
with regard to how the device is implemented: from the training of the endoscopist at the 
outset, the right selection of appropriate patients, the knowledge of the multidisciplinary 
team gathered over time, to the accumulation of experience as more device placements 
are conducted. 
The device platform in its earlier experimentation was studied with different prototypes 
and for shorter implant times to ensure some level of effi cacy and safety. This allowed 
optimization to its current form and a recommended implant time of 12 months. Although 
the pioneering work was conducted at a small number of centers initially, the device is 
now being used in an expanding number of sites, reaching over 2000 device placements 
worldwide currently. It is important at this stage to therefore take stock of the early results 
with the device and to review its safety profi le and how unintended safety matters may 
be mitigated. 
Procedural damage 
It is possible that with poor technique, faulty equipment, or very abnormal anatomy, 
damage may occur to the local anatomy, most typically the esophagus. Initial training 
is of utmost importance, and having experienced proctors and trainers on-site in the 
early stages of use is critical. An important step at removal is to ensure the barbs of the 
anchor are fully covered by the removal hood because they can damage the esophagus. 
Fluoroscopic assistance is of utmost importance. After the anchor is collapsed, it is fi rst 
pulled into the stomach where more space is available to reposition the anchor in the hood. 
Once secured, it is then removed from the stomach and esophagus. Recently, the hood has 
been modifi ed and is now slightly larger, further facilitating safe removal. It is important 
to realize that although removal can be a quicker procedure than placement, it can also 
be more challenging. The 2 esophageal ruptures caused while explanting the DJBL with 
the short protection hood occurred within our fi rst 50 cases. Although familiarity with the 
procedure facilitates safer removal, it remains of utmost importance to carefully remove 
the DJBL by an experienced endoscopist. 
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Abdominal symptoms 
With the intended use of the DJBL, GI symptoms are likely after placement. Adhering 
to a low residue, semiliquid diet in the 2 weeks after implantation seems to mitigate 
these symptoms, and a consultation with a dietician before and after placement is highly 
impactful. Complaints such as acid reflux can be mitigated and are the rationale for 
treating with high-dosage PPIs (40 mg twice a day) during the time of implantation. 
When this is insufficient, a switch to a different PPI can be made and sucralfate can be 
added. Mild to severe constipation is also observed. Therefore, maintaining a minimum 
of 2 liters of fluid a day is necessary. Occasional use of laxatives and enemas might be 
useful. However, in some cases GI symptoms are persistent and excessive, leading to 
early removal of the device.
Bleeding 
We observed GI bleeding in 7 cases. The foreign presence of the device, the anchor crown 
and barbs, and the possible alteration of local acid production might all be contributing 
factors for inflammation of the mucosa and potential bleeding. Two of the 7 cases we 
reported may have been avoided because anticoagulations complicated those cases. When 
a medical condition requiring anticoagulation during the implantation period supersedes, 
the device should be removed as soon as possible. Additionally, we advise excluding 
patients known to have a past or current history of gastric or duodenal complaints such as 
severe acid reflux disease not responding to PPI treatment and peptic or duodenal ulcers. 
When GI blood loss is suspected, an endoscopy should be performed. When blood loss 
has been significant or there is evidence of active bleeding, we advise removal of the 
DJBL. The uncommon, but very important, adverse event of an apparent arterial bleed, 
likely caused by the barbs of the anchor, needs to be managed promptly. The ability 
to treat this adverse event endoscopically is low, and angiographic detection and 
embolization, or even surgical intervention, may be needed. Therefore, implantation and 
explantation should always be performed in a hospital with sufficiently trained personnel 
and equipment that can manage such serious adverse events. 
Pancreatitis and hepatic abscess 
Two patients had pancreatitis without a complicated course. Although it is understood 
that this target population, obese subjects with T2DM, are predisposed to pancreatitis, 
the foreign presence of the device may independently put patients at risk of episodes of 
pancreatitis. For example, it is feasible that migration of the DJBL distally may cover the 
major duodenal papilla or cause local irritation and edema of the papilla. One method to 
reduce migration to the papilla is to implant the DJBL proximal into the duodenal bulb so 
the distance to the papilla is increased. However, the anatomy of the patient, especially 
a short duodenal bulb, might make it necessary to advance the anchor distally during 
implantation. 
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We observed 1 case of hepatic abscess. The exact pathology is still unclear, but the foreign 
presence of the device might cause local seeding of infection that may pass to the liver 
bed. Further experience is necessary to better understand the potential causal relationship 
and pathology. 
In conclusion, the DJBL is a new treatment platform for patients with T2DM with 
obesity. The device is relatively easy to deliver and remove in most patients, and it is 
therefore able to manifest its benefi cial effects in most patients without major tolerability 
or safety issues. However, more serious adverse events can occur, especially on removal 
of the DJBL. Therefore, an expert multidisciplinary team should be on hand for both 
implants and, more importantly, explants. There is a low rate of adverse events during 
the implantation period, most importantly, GI bleeding. Clinicians should be mindful 
of symptoms and signs of blood loss from the GI tract so appropriate measures may 
be taken. A surgical team and interventional radiologist should be available on demand 
for managing severe adverse events. One signifi cant asset the device offers is that it is 
temporary in its design, such that if more severe adverse events manifest, they quickly 
resolve after device removal. Gaining experience with this new treatment approach will 
continue to allow safe and effective use of the DJBL.
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Abstract
Placement of the duodenal-jejunal bypass liner (DJBL) is a minimally invasive technique 
for the management of patients with type 2 diabetes mellitus and obesity. Acute 
pancreatitis was seen in 5 of 167 patients (3 %) in our series. It is suggested that acute 
pancreatitis in patients with the DJBL results from either direct blockage or edema of the 
major duodenal papilla, which may be caused by the following: migration of the anchor 
of the DJBL, accumulation of food debris between the liner and the duodenal wall, or 
reflux of duodenal contents into the pancreatic duct due to intraluminal hypertension 
caused by the liner. Early removal of the DJBL resulted in fast and complete recovery, 
whereas delayed diagnosis and removal led to severe, necrotizing acute pancreatitis. 
Boek.indb   152 21-03-2019   10:23
153
7c
Acute pancreatitis as an adverse event in patients with the DJBL
Introduction
Placement of the duodenal-jejunal bypass liner (EndoBarrier; GI Dynamics, Lexington, 
Massachusetts, USA) is a new, minimally invasive technique for the treatment of the 
combination of type 2 diabetes mellitus and obesity1. The duodenal-jejunal bypass liner 
(DJBL) consists of two parts: a nitinol self-expanding anchor, which is placed under 
endoscopic guidance in the duodenal bulb, and a 61-cm fl uoropolymer liner, which is 
deployed within the proximal small bowel (Fig.7c.1). Until now, only small randomized 
controlled studies have been published that demonstrate benefi cial effects of the DJBL in 
patients with type 2 diabetes and obesity1-4. Gastrointestinal bleeding is the main reported 
adverse event5. However, the number of treated patients in these studies is too small to 
defi ne the ultimate safety profi le of the device. We report a series of patients in whom 
acute pancreatitis developed while the device was in place.
Patients and methods
In this retrospective cohort study, we included all patients who received a DJBL in our 
tertiary obesity referral center between December 2011 and October 2014. The two main 
inclusion criteria for implanting the DJBL were type 2 diabetes and a body mass index 
(BMI) between 28 and 45kg/m2. Exclusion criteria were the use of anticoagulants, the use 
of nonsteroidal anti-infl ammatory drugs (NSAIDs), and symptomatic cholecystolithiasis 
at the time of screening. A diagnosis of acute pancreatitis was established based on 
clinical, biochemical, and/or radiologic fi ndings. According to the revised Atlanta 
classifi cation, patients had to meet two or more of the following criteria: abdominal pain 
consistent with acute pancreatitis, serum lipase or amylase activity at least 3 times the 
Figure 7c.1: The duodenal-jejunal bypass liner, used for the management of patients with 
type 2 diabetes mellitus and obesity, consists of two parts: a nitinol self-expanding anchor, 
which is placed in the duodenal bulb, and a 61-cm fl uoropolymer liner, which is deployed 
within the proximal small bowel
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upper limit of normal (ULN), and findings characteristic of acute pancreatitis on contrast-
enhanced computed tomography and less commonly on magnetic resonance imaging 
(MRI) or transabdominal ultrasonography. These parameters can be used to classify acute 
pancreatitis as mild, moderately severe, or severe6. To rule out other possible causes of 
acute pancreatitis, each patient’s hospital chart was thoroughly reviewed for reported 
alcohol consumption and drug use7, results of laboratory tests (e. g., liver function tests, 
triglyceride levels, calcium levels), and results of imaging procedures.
Procedure description
The DJBL consists of a self-expanding anchor that is positioned in the duodenal bulb 
during upper gastrointestinal endoscopy. The anchor is fixed by pressure in the duodenal 
wall, and 10 barbs oriented in two directions help to keep the DJBL in place. A 61-
cm fluoropolymer liner that is attached to the anchor is deployed within the proximal 
small bowel. This liner covers the wall of the proximal small bowel, including the papilla 
of Vater, but bile and pancreatic fluids can pass and mix with bowel contents further 
downstream. Food is transported from the stomach into the liner and bypasses the first 
part of the small bowel. The changes in incretin levels caused by bypassing the proximal 
intestine lead to quick increases in insulin sensitivity and satiety8. After 12 months, or 
if a patient experiences persistent abdominal symptoms associated with the DJBL, or 
if another adverse event occurs, the DJBL is endoscopically removed with a retrieval 
system that encloses the anchor within a protective hood.
Statistical analysis
In this retrospective study, descriptive statistics were used. Data were reported as median 
and range.
Results
Acute pancreatitis was diagnosed in 5 of the 167 patients (3 %) in our series while the 
DJBL was in place. The median age of the patients at diagnosis was 53 years (range 
44–57). All patients presented with acute epigastric pain, 4 of the 5 had an elevated 
lipase or amylase level, and pancreatitis was confirmed by contrast-enhanced computed 
tomography in 3 of the 5 patients. In 1 patient, abdominal ultrasonography showed 
cholecystolithiasis but not choledocholithiasis. None of the patients had a dilated common 
bile duct, and only 2 patients had an alanine aminotransferase (ALT) level more than 2 
times the ULN, which decreased immediately after removal of the DJBL (Table 7c.1). 
None of the patients reported alcohol abuse (>3 units per day), and none used a drug 
that could induce pancreatitis. Acute pancreatitis was diagnosed at a median of 33 weeks 
(range 2–49) after implantation of the DJBL (Table 7c.2). 
In 4 of the 5 patients, distal migration of the DJBL was seen during endoscopy ( Fig. 
7c.2). In 4 of the 5 patients, the DJBL was removed within 2 days after the onset of 
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the symptoms. They all had a mild course of acute pancreatitis, recovered quickly, 
and were discharged after a median of 10 days (range 3–13) (Table 7c.2). During their 
hospitalization, these 4 patients received supportive care (analgesics, fluid resuscitation, 
and nutritional management). One of them also received antibiotic treatment because of 
blood cultures that were positive for Streptococcus anginosus. 
A fifth patient was admitted to another hospital, where it was suspected that he had 
gastroenteritis and acute pancreatitis of biliary origin, with cholecystolithiasis and an 
ALT level more than 2 times the ULN. An infection caused by Campylobacter jejuni was 
diagnosed, and after receiving supportive care, the patient was discharged at 1.5 weeks 
after admission. However, after 2 days, the patient was admitted to another hospital with 
similar problems. He was transferred to our center after 3 days, where cholecystolithiasis 
without choledocholithiasis was reconfirmed, along with signs of acute pancreatitis. The 
liver function test values had normalized, and the DJBL was uneventfully removed the 
following day. However, severe acute pancreatitis with infected necrosis and persistent 
organ failure developed within days afterward. After 18 weeks of hospitalization, the 
patient was discharged to a physical rehabilitation center for further recovery. 
Discussion
For the first time in the literature, we report 5 of 167 patients (3 %) in whom acute 
pancreatitis developed while the DJBL was in place. Worldwide, the majority of the 
patients in whom the DJBL is implanted have diabetes and obesity. These patients are 
at increased risk for the development of cholelithiasis because of their obesity and 
rapid weight loss, which is caused by the DJBL and is also seen after bariatric surgery9. 
Additionally, obesity increases the risk for a severe course of acute pancreatitis. In our 
Figure 7c.2: Migration of the duodenal-jejunal bypass liner (DJBL) distal to the region 
of the major duodenal papilla. Ulcerations are seen in the intestinal mucosa at the former 
location of the DJBL
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group of patients, acute pancreatitis was not related to medication toxicity or the use of 
alcohol. Although a biliary cause could not be ruled out in 1 patient, this was excluded in 
the other patients. Therefore, implantation of the DJBL seems to be an independent risk 
factor for acute pancreatitis. Because acute pancreatitis can be associated with severe 
morbidity, as in necrotizing pancreatitis, which has an overall mortality rate of 15 %10, 
physicians must be made aware of this adverse event.
Early recognition
In 4 of the 5 patients, acute pancreatitis was recognized in an early phase, the device was 
removed immediately, and the course of the acute pancreatitis proved to be mild. In the 
patient in whom acute pancreatitis was not recognized until severe, necrotizing disease 
had developed, the course of the disease was far worse. Therefore, early recognition 
of the symptoms related to acute pancreatitis in patients with a DJBL in place and 
removal of the device in these cases are of the utmost importance. Unspecifi c abdominal 
complaints are often observed, especially in the early period after implantation of the 
device. Therefore, the early symptoms of acute pancreatitis can easily be mistaken for 
such relatively harmless abdominal discomfort. However, acute pancreatitis must be 
considered in patients with a DJBL in place and acute epigastric pain. Diagnostic tests, 
such as measurement of the serum lipase or serum amylase level, and ultrasonography 
must be easily accessible.
Possible mechanisms of action causing acute pancreatitis
The self-expanding anchor of the DJBL, which contains 10 barbs oriented in two directions, 
should keep the DJBL in place during the entire implantation period, preventing the DJBL 
from migrating proximally or distally in the small intestine. Despite this mechanism, 
migration of the DJBL has been reported after implantation for 1 year11. Migration is 
probably caused by the continuous peristalsis of the small intestine, combined with the 
development of hypertrophic tissue surrounding the anchor, which may weaken fi xation 
of the anchor. 
Migration itself does not necessarily cause problems. If the DJBL migrates only a 
few centimeters and the mucosa or region of the major duodenal papilla has not been 
damaged, there will be no negative outcome. However, we hypothesize that four possible 
mechanisms can cause acute pancreatitis, all involving obstruction of the pancreatic duct. 
First, direct blockage of the pancreatic duct may occur when the DJBL migrates distally 
and the anchor reaches the area where the major duodenal papilla is located. Second, 
blockage of the papilla may occur after hypertrophic tissue has caused the anchor to tilt, 
leading to the accumulation of food debris between the liner and the duodenal wall. The 
third mechanism may be an increase in duodenal intraluminal pressure surrounding the 
major duodenal papilla, as is also described after double-balloon enteroscopy12,13. The 
liner may occlude the region surrounding the papilla, leading to increased pressure and 
thereby inducing the refl ux of duodenal contents into the pancreatic duct. The fourth 
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mechanism is thought to be edema of the papilla due to irritation caused by the migrated 
anchor distal to the papilla.
In conclusion, the DJBL is a promising device in the treatment of type 2 diabetes and 
obesity. We report 5 patients with acute pancreatitis following placement of the DJBL. 
Although these patients a priori had an increased risk for acute pancreatitis, we believe 
that, at least in part, the DJBL may be an independent risk factor for the development 
of acute pancreatitis as an adverse event. Acute pancreatitis appears to be caused by 
direct blockage or edema of the major duodenal papilla due to migration of the DJBL 
or blockage by food debris between the papilla and the liner. Additionally, intraluminal 
hypertension surrounding the papilla, caused by the liner, may lead to acute pancreatitis. 
Our experience shows that with the quick recognition of acute pancreatitis and removal 
of the DJBL, the course will be mild, whereas delayed recognition and late removal of 
the DJBL will lead to severe acute pancreatitis. However, a biliary cause cannot be ruled 
out in our patient with severe acute pancreatitis. Nevertheless, we stress the importance 
of the early recognition of acute pancreatitis in patients with a DJBL in place and urge 
physicians to take advantage of the guidance and quick removal available in specialized 
centers.
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Figure 7d.1: Implantation - Fluoroscopy guided implantation is shown in figure A and B 
were the DJBL subsequently is located inside and outside the protective capsule. A plain 
radiograph of the abdomen with a fully expanded DJBL is shown in figure C; with barium 
enema in figure D. A normal position of the DJBL in the duodenal bulb is shown in figure 
E and F on abdominal CT scan
Figure 7d.2: Anatomy after placement - The DJBL is located post pyloric in the duodenal 
bulb in figure A. Just after placement, the anchor of the DJBL expands in the duodenal bulb 
(B and C). Figure D, E, and F show an open sleeve, accessible for food passage
Figure 7d.3: Explantation - The DJBL is explanted with the endoscope that is equipped 
with a protective hood to cover the barbs and an extra capuchon to protect passage through 
the esophagus (A). By pulling a wire with help of an explantation device, the anchor 
collapses (B and C), all guided by fluoroscopy (D and E). After removal of the DJBL mild 
blood loss is seen were the anchor was located (F)
Figure 7d.4: Explantation complicated - When normal explantation was not possible, 
alternative strategies were used, such as inversion of the liner (A and B), use of an overtube 
(C and D), and as last resort surgical removal (E and F)
Figure 7d.5: Migration and ulceration - Migration of the DJBL distal into the duodenum 
is shown with endoscopy images (A and B) and in a coronal reconstruction of a CT scan of 
the abdomen to the horizontal part of the duodenum (C and D). Pressure of the anchor of 
the DJBL in the mucosa can result in linear ulcerations (E and F)
Figure 7d.6: Polyp formation - Pressure of the anchor of the DJBL combined with irritation 
of the mucosa due to the barbs of the DJBL result in polyp formation, ranging from only 
minor polyps to severe inflammation (A – F)
Figure 7d.7: Gastrointestinal hemorrhage - The barbs of the anchor can result in mucosal 
hemorrhage. Figure A, B and C show a blood clot from a recent hemorrhage located below 
the sleeve, and free in the duodenum (D). Figure E and F show active mucosal bleeding 
during the explantation procedure in a patient with tissue overgrowth of the anchor
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Figure 7d.8: Perforation - The barbs of the anchor resulted in an esophageal perforation 
requiring an esophageal stent. Fluoroscopy of the distal esophagus after a swallow of 
iodinated contrast material shows persisting extravasation of contrast (A). Figure B shows 
an endoscopic view after esophageal stent removal with a remaining longitudinal mucosal 
laceration. Figure C, D, and E show perforation of one of the barbs from the duodenal bulb 
into the antrum next to the pylorus. After removal of the DJBL a fi stel to the duodenal bulb 
next to the pylorus was still present (F)
Figure 7d.9: Hepatic abscess - Figure A – F show CT scans of multiple patients who 
developed hepatic complications due to the DJBL: a subcapsular fl uid collection near the 
duodenum (A), hepatic abscess in segment II en V (B), hepatic abscess in segment VIII (C), 
hepatic abscess in segment VI (D), hepatic abscess parahepatic in segment V (E), hepatic 
abscess in the caudal lobe of the liver (F)
Figure 7d.10: Miscellaneous - The DJBL was likely to be associated with severe acute 
pancreatitis, as is shown on a coronal reconstruction of a CT scan of the abdomen after 
administration of IV and oral contrast. The scan shows free fl uid around the liver, in the 
paracolic gutter on the left side, and in het lower abdomen. Additionally there is indurated 
fat around the pancreas with air bubbles in the pancreas parenchyma due to infected 
necrosis (A). Figure B shows the remains of a broken liner. A food bolus was not able 
to pass the pylorus due to obstruction by the DJBL (C). A superfi cial mucosal laceration 
was created by one of the barbs of the anchor when removing the DJBL (D). One patient 
showed during the DJBL explantation procedure multiple small fi brin covered ulcerations 
without known cause in the antrum of the stomach (E); another patient showed longitudinal 
mucosal lesions without ulceration and without known cause (F)
Boek.indb   165 21-03-2019   10:23
Figure 7d.1: Implantation
Boek.indb   166 21-03-2019   10:23
Figure 7d.2: Anatomy after placement
Boek.indb   167 21-03-2019   10:23
Figure 7d.3: Explantation
Boek.indb   168 21-03-2019   10:23
Figure 7d.4: Explantation complicated
Boek.indb   169 21-03-2019   10:23
Figure 7d.5: Migration and ulceration
Boek.indb   170 21-03-2019   10:23
Figure 7d.6: Polyp formation
Boek.indb   171 21-03-2019   10:23
Figure 7d.7: Gastrointestinal hemorrhage
Boek.indb   172 21-03-2019   10:23
Figure 7d.8: Perforation
Boek.indb   173 21-03-2019   10:23
Figure 7d.9: Hepatic abscess
Boek.indb   174 21-03-2019   10:24
Figure 7d.10: Miscellaneous
Boek.indb   175 21-03-2019   10:24
Boek.indb   176 21-03-2019   10:24
Discussion and appendices
Boek.indb   177 21-03-2019   10:24
Boek.indb   178 21-03-2019   10:24
Chapter 8
8
 Summarizing discussion and future perspectives: 
new opportunities in the fi ght against obesity and diabetes
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Scope of the thesis
The studies in this thesis focused on treatment of obese patients with type 2 diabetes 
(T2DM). There is a wide range in severity of obesity and T2DM for which several 
strategies can be employed, starting with lifestyle changes, followed by use of diabetic 
medication, and finally as the ultimate option: bariatric surgery. There is a need to tailor 
these strategies to specific patients’ needs, taking into account that many of the noninvasive 
options are insufficient in reducing weight and improving glucose intolerance. In view 
of the rising incidence of obesity and related diseases such as T2DM and its associated 
morbidity and mortality, there is a strong demand for new and effective therapies1-4. 
One of the new mechanical treatment options is the duodenal-jejunal bypass liner (DJBL). 
This endoscopic device is placed in the gastrointestinal tract. It is developed to mimic the 
effects of the Roux-en-Y gastric bypass (RYGB) in a minimal invasive manner. Previous 
work on the DJBL focused on its mechanism of action5,6.
The work presented in this thesis has several goals, of which the main goal was to study 
the effect of the DJBL on body weight and T2DM. The second objective was to assess 
the safety profile of the DJBL. In these studies we used the (morbid) obese patient with 
T2DM in need of treatment as a human model.
This final chapter summarizes and integrates the main findings of this thesis. Furthermore, 
methodological and ethical issues, strengths and limitations within the studies performed, 
and suggestions for future research and daily clinical practice are discussed.
Mechanism of action
Although this thesis does not focus on the mechanism of action of the DJBL, this is an 
important element of the device that needs elucidation. The mechanism of the DJBL 
mimics that of the RYGB that has shown good results in morbidly obese patients with 
or without T2DM. Previous studies showed that after RYGB, patients show a significant 
percentage of total body weight loss (TBWL) in the range of 25-32 % three years after 
surgery. Additionally, improvement of diabetes and amelioration of other cardiovascular 
diseases are seen7-9. A long term follow-up study found continuous improvements on 
weight and metabolic parameters 12 years after RYGB10. This results in an increased life-
expectancy compared to patients who forego bariatric surgery11,12. 
Since in patients with a RYGB food passes only a small gastric pouch with a volume 
of approximately 30 mL and subsequently bypasses the duodenum and the proximal 
jejunum, previously many physicians attributed the beneficial effects to food restriction 
and malabsorption. However, the current believe is that several metabolic mechanisms 
jointly lead to reduction in weight and accompanying metabolic improvement. 
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RYGB results in a reduced macronutrient absorption in the proximal part of the small 
bowel and increased delivery of less digested macronutrients to the distal part of the 
jejunum and ileum. This leads to an upregulation of the so-called L-cells that line the 
intestinal wall. These cells are deemed responsible for the metabolic changes that result 
in weight loss and improved glycemic control. In bariatric surgery literature this has been 
termed as the hindgut theory13. This mechanism (chyme bypassing the duodenum and 
proximal jejunum) is also thought to be responsible for the benefi cial effects of the DJBL. 
The small intestine produces numerous gastrointestinal peptides14. These are hormones 
that are produced by endocrine cells throughout the whole gastrointestinal tract. 
Presumably only a small proportion of these peptides and their functions have been 
discovered. Studies have focused on the main players such as CCK, DDP-4, Ghrelin, GIP, 
GLP-1, Leptin, and PYY. Especially, GLP-1 is of great interest to patients with T2DM 
and patients undergoing bariatric surgery15,16. This peptide is mainly produced in the distal 
part of the small intestine by L-cells and adjusts serum glucose levels by stimulating 
insulin secretion from pancreatic beta-cells17. Other gastrointestinal peptides are also 
related to insulin sensitivity and satiety. DJBL is thought to alter plasma concentrations of 
these gastrointestinal peptides and thereby increases insulin sensitivity and reduces body 
weight18,19. However, the exact mechanism for the DJBL as well as the RYGB require 
further study.
Main fi ndings
Effectiveness of the duodenal-jejunal bypass liner
The patients studied in our cohort had an excess weight loss (EWL) of 46 % (weight 
reduction of 13kg; TBWL 12%) after a mean DJBL placement of 46 weeks (Chapter 
2). This is in line with other studies, that showed an EWL ranging from 33 to 47 % after 
52 weeks of DJBL implantation20-23. A meta-analysis of 10 studies showed weight loss of 
11.3kg at time of explantation (9.2 months after implantation), with an EWL of 36.9 % 
(4 studies included)24.
Our patients showed a mean decrease in HbA1c of 6 mmol/mol. Moreover, 50 % of the 
patients stopped the use of insulin and the patients still on insulin decreased their mean 
daily dose with 40 IU (44 % decrease compared to baseline). The magnitude of HbA1c 
decrease in our studies is less impressive compared to other DJBL studies20-22. The meta-
analysis of Jirapinyo et al. showed a mean HbA1c decrease in 14 studies of 13.3 mmol/ 
mol, comparable with 1.3 %24. Studies published following the publication of this meta-
analysis reported decreases in HbA1c ranging from 0.8 to 1.4 %23,25,26. However, most 
studies reported diabetic parameters of only a limited number of patients. Additionally, 
the majority of studies lack clear descriptions of changes in the use of diabetes medication. 
Therefore, it is unclear to what extent medication changes may be compared and whether 
our patient group is comparable to those from other studies. Since the goal of DJBL 
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treatment was to be superior to life style treatment, direct comparison between DJBL and 
RYGB was not intended and is therefore lacking. As can be expected by the difference in 
invasive nature, improvements in diabetic parameters accomplished with DJBL seem to 
be inferior to those seen after bariatric surgery27. 
Cardiovascular parameters such as total cholesterol, LDL-cholesterol, triglycerides and 
blood pressure showed a significant decrease at time of removal of DJBL compared to 
the period before implantation (Chapter 2). However, these improvements are inferior 
compared to reported improvements by RYGB28.
The cross-over study described in Chapter 3 shows that after an initial improvement of 
weight and diabetic and cardiovascular parameters by dietary restrictions, implantation 
with the DJBL could improve these parameters even further. Six months after removal 
of the DJBL, an increase in weight and fasting insulin levels was observed, while all 
other parameters remained stable. Unfortunately, Chapter 4 shows that the beneficial 
effects obtained during the implantation period with the DJBL in our cohort largely 
disappeared in the year after explantation. While a significant reduction in weight of 8.0 
kg (TBWL 7.4 %) was still maintained, HbA1c, FPG, total cholesterol, and triglycerides 
had increased significantly compared to the period prior to placement. Only a few studies 
published results after removal of the DJBL. A recent study showed stabilization of BMI 
and HbA1c until 6 months after explantation26. Another study, in which Riedel et al. 
created a statistical model, BMI and HbA1c increased after explantation29. It is unclear if 
the observed relapse will stabilize or increase even further over time.
When implantation time is extended to 24 months, stabilization of body weight and 
HbA1c occurs after 12 months, rather than further improvement of these parameters 
(Chapter 5). The largest effect size is observed during the first 3 months, which gradually 
increases till 12 months, after which stabilization occurs. In contrast 45% required early 
explantation between month 12 and 24, and over two thirds of the patients experienced 
at least 1 AE. These results are comparable with the study of Quezada et al. were DJBL 
was implanted up to 36 months30. Therefore, an implantation time exceeding 12 months 
is not recommended.
In order to select patients who benefit most from DJBL treatment we identified two 
independent factors at the time of screening: C-peptide >1.0 nmol/L and body weight 
≥107 kg (Chapter 2). A C-peptide level of <1.0 nmol/L in patients undergoing bariatric 
surgery was suggested to have a reduced chance of complete reduction of T2DM in an 
earlier study, probably by partial β-cell failure31. In our cohort a body weight of 107 kg was 
comparable with a BMI of 35 kg/m2, suggesting that more obese patients benefit better 
from DJBL therapy. Therefore it can be speculated that the impact of weight reduction 
caused by the DJBL is a larger contributor in treatment success than improvement in 
glycemic control.
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Safety profi le of the duodenal-jejunal bypass liner
In addition to effectiveness, we also studied the safety profi le of the DJBL. With increasing 
numbers of implantations worldwide and a longer dwelling time, it was hypothesized that 
more AEs could come to light. Therefore we conducted a systematic review, described 
in Chapter 6, to explore the AEs associated with the use of DJBL. Although the 
comparability of the 38 selected studies was low and incompleteness for registering AEs 
was large in most studies, 3.7 % of the AEs were classifi ed as severe, including hepatic 
abscesses and esophageal perforations. In 85 % the anchor of the DJBL caused or likely 
caused the SAEs. Therefore, we think focus on adjustments of the barbs of the anchor is 
key to improve the effi cacy-safety margin of the DJBL. Moreover, a predefi ned way of 
reporting AEs should be introduced and adhered to for all medical devices.
One of the major issues with use of the DJBL is the necessity to remove the device 
early (before the intended implantation period of 52 weeks) in almost one third of the 
patients. This is mainly due to persisting abdominal complaints such as abdominal pain 
and nausea, leading to intolerability. In addition to these mild adverse events, 9-17 % 
of the patients developed SAEs related to the DJBL. Chapter 7b reports about the (S)
AEs we encountered in our center and how to recognize and manage them. These AEs 
included esophageal perforation, necrotizing pancreatitis, gastrointestinal hemorrhages, 
and liver abscesses. The majority required intensive and prolonged treatment and were 
suggested to have a signifi cant impact on the quality of life. Our observation of DJBL 
related AEs is corroborated by an increasing number of case reports and our own 
systematic review in the previous chapter32-34. Bariatric surgery mortality rate within and 
after 30 days postoperative is reported to be 0.08% and 0.31 %, respectively35. Since no 
mortalities related to DJBL treatment have been reported, DJBL is considered to be safer 
than bariatric surgery.
We hypothesized in Chapter 7c that the occurrence of acute pancreatitis might be related 
to the specifi c design of DJBL. We formulated four theories that could explain why DJBL 
may cause acute pancreatitis. Since the consequences of this AEs can be severe, we stress 
physicians who detect AEs possibly related to DJBL to contact and refer to specialized 
centers and urge quick removal. Finally, Chapter 7d provides an overview of endoscopic 
and radiologic appearances of the (S)AEs related to the DJBL.
Table 8.1 provides an overview of the main fi ndings, implications, and limitations for 
each chapter of this thesis.
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Table 8.1: Main findings, implications, and limitations of this thesis (part A)
Part A. Efficacy of the duodenal-jejunal bypass liner
# Main findings Implications Limitations
2  ◦ 12 Months treatment with DJBL 
results in significant decrease in 
body weight and HbA1c
 ◦ Decrease in number of users and 
dosage of insulin
 ◦ 31% Of DJBL required early 
explantation and 17% of patients 
experienced an AE resulting in 
hospitalization of prolonged hospital 
stay
 ◦ C-peptide ≥1.0 nmol/L and body 
weight ≥107 kg are independent 
predictive factors for success
 ◦ Largest beneficial effects of DJBL 
on weight and HbA1c during first 
3-6 months after implantation
 ◦ Significant percentage of patients 
requires early explantation or 
experiences AEs
 ◦ Careful selection of patients is 
required for an optimized safety-
efficacy ratio
 ◦ Observational cohort study. 
Therefore no correction for 
confounders (e.g. lifestyle, diet)
 ◦ 31% Early explantations
 ◦ Variable changes in diabetic 
medication, making true changes in 
HbA1c unclear 
3  ◦ Preceded by 6 months treatment 
with dietary restrictions, 6-12 
months treatment with DJBL results 
in significant decrease in body 
weight, HbA1c and lipid levels
 ◦ 6 Months after explantation weight 
and fasting insulin levels increased 
significantly. Other parameters 
remained stable
 ◦ 78.6% Of patients experienced 
mild gastrointestinal complaints; 6 
AEs required hospitalization; 36% 
required early removal
 ◦ Improvements in weight and 
HbA1c by 6 months of dietary 
restrictions are further improved 
when treatment with 6-12 months 
DJBL is followed 
 ◦ Crossover cohort; thereby no 
randomization
 ◦ Limited patient numbers
4  ◦ 12 Months after explantation 
significant increase in body weight. 
However, body weight was still 
significant lower compared to 
baseline
 ◦ Significant increase in Hba1c 12 
months after explantation compared 
to baseline and explantation
 ◦ 12 Months after explantation a 
significant lower number of insulin 
users compared to baseline. Insulin 
dosage is comparable
 ◦ Explantation of DJBL results in 
weight gain and increase of HbA1c
 ◦ New strategies are required to 
preserve the beneficial effects of 
DJBL treatment after explantation
 ◦ Observational cohort study. 
Therefore no correction for 
confounders (e.g. lifestyle, diet)
 ◦ High lost-to-follow-up rate
 ◦ Unclear relation between 
explantation and HbA1c changes 
due to variable adjustments in 
diabetic medication
5  ◦ 24 Months of DJBL implantation 
resulted in significant weight loss 
and a decreasing trend of HbA1c. 
Number of insulin users and daily 
dose decreased significantly
 ◦ Largest beneficial effects of DJBL 
are observed in first 9-12 months 
after implantation, after which 
stabilization occurs
 ◦ 45% Of patients required early 
explantation; 68% experienced at 
least one AE
 ◦ 24 Months of DJBL results in 
prolonged stabilization of beneficial 
effects, but no further improvement 
is accomplished compared to 12 
months of implantation
 ◦ Cumulative risk of developing AEs 
increases with potential high severity
 ◦ Advice to not extent dwelling 
time over 12 months until a better 
efficacy-safety margin is achieved
 ◦ Observational cohort study. 
Therefore no correction for 
confounders (e.g. lifestyle, diet)
 ◦ Patient selection; only patients 
who responded well and had no 
complaints during first 9 months 
of implantation were selected for 
extended dwelling time
 ◦ High lost-to-follow-up rate
Boek.indb   184 21-03-2019   10:24
185
Summarizing discussion and future perspectives
8
Table 8.1: Main fi ndings, implications, and limitations of this thesis (part B)
Part B. Safety of the duodenal-jejunal bypass liner
# Main fi ndings Implications Limitations
6  ◦ Comparability between 38 studies 
was low; quality of reporting AEs 
was low
 ◦ DJBL is associated with a wide 
range of AEs
 ◦ 3.7% of the 891 reported AEs 
were classifi ed as severe, including 
hepatic abscess, gastrointestinal 
hemorrhage, and esophageal 
perforation
 ◦ The anchor of the DJBL is likely 
responsible for 85% of the SAEs
 ◦ A standardized format is needed for 
registering AEs for medical devices
 ◦ To improve the safety profi le of 
DJBL, adjustments to the anchor 
are needed
 ◦ True number of AEs is diffi cult to 
assess due to duplicate reporting of 
AEs, as well as under reporting
7a  ◦   ◦   ◦  
7b  ◦ 7.9% Of the 165 attempted 
implantations were unsuccessful, 
mostly related to local anatomy
 ◦ 15.7% Early explantations
 ◦ 9.9% Of the patients experienced 
signifi cant AEs, e.g. esophageal 
rupture, gastrointestinal hemorrhage, 
acute pancreatitis, and liver abscess
 ◦ 12 Months of implantation resulted 
in a statistically signifi cant decrease 
in body weight. A decreasing trend 
for HbA1c was observed
 ◦ Expert multidisciplinary team 
should be on hand for implantations 
and explantation since SAEs can 
arise
 ◦ A surgical team and interventional 
radiologist should be available on 
demand for managing AEs
 ◦ Observational cohort study. 
Therefore no correction for 
confounders
 ◦
 ◦ AEs not reported in a standardized 
manner
 ◦
 ◦ Expert opinion
7c  ◦ 5 (3%) Patients implanted 
with DJBL suffered from acute 
pancreatitis, ranging from mild to 
severe
 ◦ Hypothesis 4 mechanisms causing 
acute pancreatitis: 1. direct blockage 
of major duodenal papilla (MDP) by 
anchor; 2. edema of MDP caused by 
migrating anchor; 3. accumulation 
of food debris between liner and 
duodenal wall; 4. refl ux of duodenal 
contents into pancreatic duct due 
increased duodenal intraluminal 
pressure
 ◦ Early removal results in fast and 
complete recovery, as delayed 
diagnosis led to severe, necrotizing 
acute pancreatitis
 ◦ Patients with DJBL are at increased 
risk for acute pancreatitis, although a 
biliary cause cannot be ruled out
 ◦ When acute pancreatitis is 
suspected, quick removal is 
recommended for a mild course
 ◦ Advice to physicians to take 
advantage of guidance and quick 
removal in specialized centers when 
encountered with AEs
 ◦ Case series
 ◦ Expert opinion
7d  ◦   ◦   ◦  
AEs: adverse events; DJBL: duodenal-jejunal bypass liner; MDP: major duodenal papilla
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Ethics of new medical devices
In the field of bariatric surgery a substantial part of treatments are performed in a 
commercial setting. There is an ongoing race to develop less invasive techniques to treat 
obesity and related diseases, resulting in an impressive increase in new medical devices 
and techniques36.
While conducting our studies and writing this thesis, questions arose concerning the 
implementation of these new medical devices. Novel medical devices can be introduced 
and implemented in routine clinical practice relatively easy. However, these devices are 
often introduced to the market after limited testing in a small number of clinical studies in 
targeted patient categories with often limited patient numbers. Moreover, devices might 
not be tested at all after adjustments have been made. Therefore the true effects of a new 
medical device are discovered during real world clinical use. However, it is difficult to 
justify this strategy when both efficacy and safety are ill explored and the balance between 
efficacy and safety is not known. Only with robust and carefully designed scientific 
studies a complete picture of the safety and efficacy of a novel treatment method may be 
obtained. The difficulty remains that overall large patients groups are required to present 
a complete picture on beneficial effects and AEs of a new technique.
In Europe, products that are provided with a CE-marking can be sold and transported 
through the European Economic Area. However, a CE-marking is often wrongly 
interpreted as a quality mark. Thus, it is entirely possible that devices are already sold 
to market parties and used in clinical settings when there is a clear lack of well executed 
clinical studies. This places individual patients at risk, certainly when a complete risk 
assessment is absent.
Since there are several regulatory bodies spread around the world instead of one global 
regulatory body, it can be difficult to obtain a complete overview of the benefits and 
risks of new techniques. The American Society for Gastrointestinal Endoscopy (ASGE) 
pleads for the introduction of registries for endoscopic bariatric therapies (EBTs). With 
help of these registries, the benefit and safety of different EBTs can be established more 
precisely37.
As our data shows, we identified several (S)AEs of the DJBL that were not possible 
to discern from studies with smaller patient numbers. We did not perform a RCT and 
as a consequence not all registered AEs could without doubt be related to the DJBL. 
Therefore, there is need of large RCTs for new medical devices to determine their safety 
profile. On the other hand, post marketing studies are crucial in obtaining a complete 
safety profile, as the incidence of SAEs can be very low.
Strengths and limitations
This thesis contains both strengths and limitations with reflection of the methodological 
aspects of the conducted studies and suggestions for future research that should lead to an 
increased level of evidence.
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A major strength of the studies presented in this thesis is the design and data collection 
of a large cohort of patients with DJBL implantations. Our cohort with 185 patients with 
implanted DJBL, is the largest cohort published in literature. This is in contrast to the 
majority of studies with limited patients and consisting largely of patients without T2DM. 
Patients followed from the beginning a strict protocol that required regular hospital visits 
with collection of pre-specifi ed clinical parameters. This made it possible to determine the 
metabolic and cardiovascular effects of DJBL implantation in combination with lifestyle 
adjustments in a diverse cohort of obese patients with T2DM.
Another strength is that with help of our design the cohort represented a varied patient 
population as in real life. This is in contrast to most RCTs in which often only relatively 
healthy patients without multi morbidity are included. Such a randomized, sham 
controlled trial was started in the United States several years ago, but unfortunately had 
to be terminated early because of a higher incidence of SAEs than expected (hepatic 
abscesses)38. Observational studies such as ours may be criticized because they are 
thought to overestimate treatment effects, yet a formal study comparing outcomes of 
randomized and observational studies concluded that the observational studies neither 
over- nor underestimated treatment effects to any signifi cant degree39. The choice 
of our design allowed us to prospectively evaluate the safety of DJBL in this specifi c 
patient population. With this design we were able to include a larger number of patients 
receiving the DJBL. The size and duration of our cohort allowed us to study the safety 
profi le in more depth by sampling a larger range of also rare AEs that were not shown in 
previous studies. These studies included small patient groups with often a relatively short 
implantation time of six months and no follow-up after removal40. 
Finally, we continued where most studies stopped: collection of data on clinical parameters 
after removal of the DJBL. This demonstrated the durability of effects, which was unclear 
until now. These data are often lacking in novelty device research. However, this aids in 
estimating the effectiveness and cost-benefi t ratio of a new device more accurately.
Besides the outlined strengths, there are some general limitations that need to be 
mentioned. The fi rst limitation is related to the design of our studies. The model we used 
considers observations in human subjects through observational cohort studies, case-
series, and a cross-over trial. Except for the cross-over trial where patients served as their 
own controls, none of our studies included a control group. Since the patients who were 
implanted with a DJBL received counseling of a dietician and were stimulated to change 
their health behavior to a healthier lifestyle, it is not possible to determine to what extent 
these interventions clouded the true effects of the DJBL. Additionally, other unknown 
confounders and effect modifi ers might affected the results of our study. Furthermore, 
our design precludes direct comparison with untreated patients, lifestyle or other EBTs. 
Another limitation of our study is the wide variety in included patients, the complete 
range from overweight to morbid obesity, and from patients using one oral anti-diabetic 
drug to those using a high dosage of insulin. This makes it diffi cult to determine the 
Boek.indb   187 21-03-2019   10:24
188
Chapter 8
8
effect of DJBL in specific patient populations. In contrast, our cohort represented a varied 
patient population representing a real life practice.
During follow-up after explantation a significant proportion of patients did not appear at 
outpatient visits resulting in missing data. This introduces bias, since it is unclear what 
type of patients were absent during follow-up; patients who obtained good results and 
did not require any further consultation, or patients with disappointing results who lacked 
motivation for further follow-up visits. Since our study design lacked a control group, 
definite conclusions concerning efficacy are difficult to formulate.
Finally, we advise in our systematic review to adhere to a predefined way of reporting 
(S)AEs during introduction of medical devices to be able to determine the real efficacy-
safety ratio. This also applies to our own studies in which AEs were not registered in a 
uniform way. To compare the safety profile between different treatment modalities, this 
is of utmost importance.
Future perspectives
DJBL has superior beneficial effects on weight loss and glycemic control compared to 
diet41. It remains unclear whether DJBL is superior to other EBTs, such as the intragastric 
balloon. When we compare the benefits of one year of DJBL implantation to bariatric 
surgery, combined with almost one third of early removals and a significant percentage 
of SAEs related to the DJBL, we believe that the DJBL in its current state is inferior to 
bariatric surgery. Additionally, the costs of DJBL implantation combined with its intensive 
follow-up program approaches the costs of bariatric surgery (own data not presented in 
this thesis). However, because of the difference in therapeutic area between the DJBL and 
bariatric surgery, a true comparison is not needed.
To genuinely compare the true effects of DJBL with other therapies, a triple arm RCT is 
required with a diet group, a DJBL group, and another EBT. DJBL dwelling time needs to 
be one year, with a minimum of two years of follow-up after removal (3 years in total for 
each group) and an advised 5 year follow-up. Precise documentation in a predefined way 
for AEs is essential. Ideally we advise to compare definite endpoints, such as resolution of 
diabetes or cardiovascular death. However, it is fairly impossible to carry out such a study 
when developing a new technique, considering the costs and duration of such a study. 
Therefore, exact defined surrogate parameters need to be used such as changes in FPG, 
HbA1c, cholesterol values, and blood pressure. Additionally, questionnaires concerning 
quality of life, patient satisfaction, experiencing satiety, and the composition of their diet 
should be included. Recently, two promising study protocols have been published. One is 
a multicenter RCT were DJBL is compared with standard medical therapy in 160 obese 
patients with T2DM42. The other protocol considers a multicenter RCT comparing DJBL, 
intragastric balloon, and a sham procedure in 150 obese patients, with or without T2DM43.
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When treatment with DJBL therapy is continued the following years, the biggest gain can 
probably be achieved by adjusting the anchoring mechanism. This is the most important 
part of the device by which it distinguishes itself from other intraluminal techniques. 
However, this anchoring mechanism is also the perilous part of the DJBL and needs 
further improvement in order to decrease the numbers of AEs. Yet longer barbs create a 
greater risk of perforation and gastrointestinal hemorrhage, and a technique that results 
in higher pressure in the wall of the duodenal bulb creates a greater risk of ulceration. 
We doubt if there is any technical solution possible to create a medical device that can be 
inserted in the gastrointestinal tract for a prolonged period of time without damaging the 
mucosa. The continuous peristaltic movements of the intestine with its vulnerable mucosa 
have to make you wonder whether this is the right place for a prolonged dwelling time of 
a medical device.
Since there is a great variability in effectiveness of patients undergoing DJBL treatment 
and the occurrence of AEs, patients should be carefully selected. Body weight and 
C-peptide may be of use in patient selection. Future research should focus on other 
clinical parameters that can be helpful to optimize benefi cial effects and minimize the 
risk on AEs.
The global incidence of obesity and diabetes keeps increasing which results in an 
increased morbidity and mortality44-47. Although bariatric surgery is a solution for some, 
we believe the largest success can be accomplished by investing more in prevention of 
these diseases. This can be realized by good education, an active lifestyle, stimulation of 
consumption of healthy food, decreasing their prices, and maybe even increase taxes of 
unhealthy food.
Apart from adjusting eating behaviors through education, a therapeutic mechanism of 
action might be infl uencing gastrointestinal peptides by medication. Two large RCTs 
showed that 1 and 3 years of use with Liraglutide, a GLP-1 agonist, was associated with 
reduced body weight, improved metabolic control, and improvements in health-related 
quality of life compared to placebo48,49. Therefore, research should focus on elaborating the 
working mechanism of gastrointestinal peptides and how to infl uence them. Additionally, 
discovering new gastrointestinal peptides could lead to new therapeutic strategies.
Conclusion
With the increasing worldwide problem of obesity and related diseases such as T2DM, 
new therapies need to be developed to treat these diseases. Current preventive strategies 
fail to stop the increase in obese patients. Obese patients often cling on to new therapies 
in the hope they will turn the tide. Therefore, this patient group is extremely vulnerable. 
Whether in the future endoscopic bariatric techniques will be successful over a prolonged 
period of time is questionable. For now, although the DJBL shows benefi cial effects on 
body weight, T2DM, and cardiovascular parameters, these effects only last for a limited 
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period of time after explantation. Furthermore, the DJBL is accompanied by adverse 
events resulting in early removal. To become successful, the anchoring mechanism needs 
to be refined. In the meanwhile bariatric surgery seems to be a solution for many patients 
when conservative treatment is insufficient. Since not all patients are eligible for bariatric 
surgery or willing to undergo surgery, the search in optimizing current techniques and 
development of new techniques continues. More important, the main approach should 
focus on prevention, instead of developing new temporary minimal invasive bariatric 
techniques to treat these man-made diseases.
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nieuwe behandelmogelijkheden in de strijd tegen obesitas 
en diabetes
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Doel van het proefschrift
De studies in dit proefschrift richten zich op de behandeling van obese patiënten met 
diabetes mellitus type 2 (DM2). De ernst van obesitas en DM2 varieert sterk, waarbij 
voor de behandeling diverse strategieën gebruikt kunnen worden. De behandeling start 
met leefstijlveranderingen voor zowel obesitas als DM2, wordt gevolgd door medicatie 
voor DM2 en als laatste optie is er bariatrische chirurgie voor beide aandoeningen. Het is 
belangrijk om deze verschillende strategieën aan te passen aan de specifieke behoefte van 
iedere patiënt, hierbij rekening houdende met het feit dat veel niet-invasieve methoden 
resulteren in onvoldoende gewichtsverlies of verbetering van de glucose-intolerantie. In 
het kader van de toenemende incidentie van obesitas en gerelateerde ziekten zoals DM2 
en de hiermee geassocieerde morbiditeit en mortaliteit, is er een sterke vraag naar nieuwe 
en effectievere therapieën.
Eén van deze nieuwe behandelmethoden is de duodenal-jejunal bypass liner (DJBL). Dit 
endoscopisch medisch hulpmiddel wordt in het duodenum geplaatst en reikt tot in het 
jejunum. De DJBL is ontwikkeld om op een minimaal-invasieve manier de effecten na te 
bootsen die ontstaan na een Roux-en-Y gastric bypass (RYGB). Eerdere studies hebben 
zich gericht op dit veronderstelde werkingsmechanisme.
De studies die worden besproken in dit proefschrift hebben meerdere doelen, waarvan 
het primaire doel is om het effect van de DJBL op het lichaamsgewicht en DM2 te 
bestuderen. Het tweede doel is het vaststellen van het veiligheidsprofiel van de DJBL. In 
deze studies bestaat onze onderzoekspopulatie uit de (morbide) obese patiënt met DM2 
met een noodzaak tot behandeling.
In dit hoofdstuk worden de belangrijkste resultaten van dit proefschrift samengevat en 
geïntegreerd met elkaar en de literatuur. Tevens komen methodologische en ethische 
vragen aan bod, wordt gereflecteerd op sterke punten en beperkingen van de studies en 
worden er suggesties voor toekomstig onderzoek en de huidige praktijk bediscussieerd.
Werkingsmechanisme
Hoewel dit proefschrift zich niet richt op het werkingsmechanisme van de DJBL, is dit 
een belangrijk element van het hulpmiddel dat toelichting behoeft. De DJBL bootst het 
mechanisme van de RYGB na, een operatie die goede resultaten laat zien in morbide obese 
patiënten, zowel met als zonder DM2. Eerdere studies toonden aan dat patiënten drie jaar 
na een RYGB een significante gewichtsreductie lieten zien, met een total body weight 
loss (TBWL) variërend van 25-32 % en verbetering van DM2 en andere cardiovasculaire 
ziekten. Een lange termijn studie toonde blijvende verbeteringen in gewicht en metabole 
parameters 12 jaar na RYGB aan. Dit resulteert in een verbeterde levensverwachting ten 
opzichte van patiënten die geen bariatrische chirurgie hebben ondergaan.
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In patiënten met een RYGB passeert het voedsel een kleine maagpouch met een volume 
van circa 30 milliliter en door een verandering van de anatomie worden het duodenum en 
proximale jejunum gebypassed. Daarom werd vroeger gedacht dat de positieve effecten 
van de RYGB veroorzaakt werden door voedselrestrictie en -malobsorptie. Tegenwoordig 
wordt verondersteld dat verscheidene metabole mechanismen tezamen leiden tot de 
gewichtsreductie en metabole verbeteringen.
De RYGB resulteert in een verminderde opname van macronutriënten in het duodenum 
en het proximale deel van het jejunum en een verhoogd aanbod van minder verteerde 
macronutriënten in het distale deel van het jejunum en het ileum. Dit leidt tot een 
toenemende activiteit van de L-cellen in de darmwand. Deze cellen worden geacht 
verantwoordelijk te zijn voor de metabole verandering die resulteren in gewichtsverlies 
en verbeterde glycemische controle. In de bariatrische literatuur wordt hier ook wel naar 
gerefereerd als de “hindgut” theory. Dit mechanisme (chymus welke het duodenum en 
proximale jejunal bypassed) is mogelijk ook verantwoordelijk voor de positieve effecten 
van de DJBL.
De dunne darm produceert verscheidene gastro-intestinale peptiden. Dit zijn hormonen die 
worden geproduceerd door endocriene cellen verspreid door het gehele gastro-intestinale 
stelsel. Waarschijnlijk is er tot op heden slechts een klein deel van deze peptiden en hun 
functies ontdekt. Studies hebben zich met name gericht op de belangrijkste peptiden, zoals 
CCK, DDP-4, Ghreline, GIP, GLP-1, Leptine en PYY. Met name GLP-1 is van groot belang 
in patiënten met DM2 die bariatrische chirurgie ondergaan. Dit peptide wordt voornamelijk 
geproduceerd in het distale deel van het gastro-intestinale stelsel door de L-cellen en zorgt 
voor aanpassing van de serum glucoseconcentratie door stimulatie van insulinesecretie 
door de pancreatische bètacellen. Andere gastro-intestinale peptiden zijn ook gerelateerd 
aan de insulinegevoeligheid en het verzadigingsgevoel. Er wordt verondersteld dat de 
DJBL invloed heeft op de serumconcentraties van deze gastro-intestinale peptiden en 
hiermee de insulinegevoeligheid verhoogt, het verzadigingsgevoel vergroot en hiermee 
het lichaamsgewicht verlaagt. Echter, voor het precieze werkingsmechanisme van zowel 
de DJBL als de RYGB is vervolgonderzoek noodzakelijk.
Belangrijkste bevindingen
Effectiviteit van de duodenal-jejunal bypass liner
Om het effect van de DJBL op gewicht en DM2 te onderzoeken verzamelden we prospectief 
een cohort van 198 patiënten waarbij de DJBL in 185 patiënten succesvol geplaatst kon 
worden voor een beoogde implantatieduur van 12 maanden. De onderzochte patiënten in 
ons cohort bereikte een excess weight loss (EWL) van 46 % (absoluut gewichtsverlies 
van 13 kg; TBWL 12 %) na een gemiddelde DJBL implantatieduur van 46 weken 
(Hoofdstuk 2). Deze gewichtsafname is vergelijkbaar met andere studies, waarbij na 
52 weken implantatie een EWL werd gezien van 33 tot 47 %. Een recent gepubliceerde 
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meta-analyse van 10 studies liet een gewichtsverlies van 11.3 kg zien op het moment van 
verwijdering van de DJBL (gemiddeld 9.2 maanden na implantatie), vergelijkbaar met 
een EWL van 36.9 % (4 geïncludeerde studies). De patiënten uit ons cohort toonden een 
gemiddelde HbA1c afname van 6 mmol/mol. Bovendien stopten 50 % van de patiënten 
met het gebruik van insuline. Patiënten die insuline bleven gebruiken verminderde hun 
gemiddelde dagelijkse dosering met 40 eenheden (44 % afname ten opzichte van voor de 
start van behandeling). De grootte van de daling van het HbA1c is in onze studies minder 
indrukwekkend in vergelijking met andere studies. Een meta-analyse van Jirapinyo et al. 
toonde een gemiddelde HbA1c afname in 14 studies van 13.3 mmol/mol, vergelijkbaar 
met 1.3 %. Studies welke werden gepubliceerd na deze meta-analyse rapporteerden 
afnames in HbA1c van 0.8 tot 1.4 %. De meeste studies rapporteerden slechts diabetische 
parameters van een beperkt aantal patiënten. Bovendien ontbrak in de meerderheid van 
de studies een heldere beschrijving van veranderingen in diabetes medicatie. Daarom is 
het onduidelijk in welke mate medicatieveranderingen tussen studies vergeleken kunnen 
worden en of onze patiënten vergelijkbaar zijn met patiënten uit andere studies. Omdat 
het doel van behandeling met de DJBL is om superieur te zijn aan leefstijlveranderingen 
en niet aan de RYGB, ontbreekt een directe vergelijking tussen de DJBL en de RYGB. 
Hoewel de behandelingen niet direct zijn vergeleken in studies, lijken de verbeteringen 
in diabetische parameters door behandeling met de DJBL inferieur vergeleken met de 
veranderingen na bariatrische chirurgie. Het verschil in effect zou ten gevolge van het 
verschil in invasiviteit kunnen zijn.
Cardiovasculaire parameters zoals totaal cholesterol, LDL cholesterol, triglyceriden en 
bloeddruk  zijn significant gedaald ten tijde van explantatie vergeleken met de periode 
voor implantatie (Hoofdstuk 2). Echter, deze verbeteringen zijn inferieur vergeleken met 
in de literatuur gerapporteerde verbeteringen na RYGB.
In Hoofdstuk 3 hebben we een multicenter cross-over studie verricht waarbij patiënten 
na 6 maanden dieet-aanpassingen gedurende 6 tot 12 maanden werden behandeld 
met de DJBL. Hierin zien we dat na initiële verbetering in gewicht, diabetische en 
cardiovasculaire parameters door dieetrestricties, implantatie met de DJBL tot verdere 
verbetering van deze parameters leidt. Zes maanden na verwijdering van de DJBL zijn 
alle parameters stabiel gebleven ten opzichte van explantatie, behoudens het gewicht en 
de nuchtere insuline waarden, welke waren toegenomen.
Er zijn tot nu toe slechts enkele studies die data na verwijdering van de DJBL hebben 
gepubliceerd. In Hoofdstuk 4 beschrijven we 59 patiënten die gedurende minimaal 
6 maanden behandeld zijn met de DJBL en 12 maanden follow-up na explantatie van 
de DJBL hebben ondergaan. Dit cohort toont dat de bereikte positieve effecten tijdens 
de implantatieperiode grotendeels verdwijnen in het jaar na explantatie. Hoewel een 
significante gewichtsafname van 8.0kg (TBWL 7.4 %) behouden blijft, zijn HbA1C, 
nuchter glucose, totaal cholesterol en triglyceriden significant gestegen ten opzicht van de 
periode voor DJBL plaatsing. Een recente studie toonde stabilisatie van BMI en HbA1c 
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tot 6 maanden na verwijdering van de DJBL. Een andere studie, gepubliceerd door Riedel 
et al., toonde een statistisch model met hierin enige toename van BMI en HbA1c 12 
maanden na explantatie. Het is onbekend of de beschreven terugval zal stabiliseren of 
verder zal verslechteren in de loop der tijd.
Om te onderzoeken wat de effecten zijn van een verlenging van de implantatieduur tot 
24 maanden zijn 44 patiënten geïncludeerd in een prospectieve cohort studie (Hoofdstuk 
5). Na een implantatieduur van 12 maanden treedt stabilisatie van het gewicht en HbA1c 
op. Het grootste positieve effect wordt geobserveerd gedurende de eerste 3 maanden na 
implantatie, waarna de positieve effecten geleidelijk verder toenemen tot 12 maanden en 
hierna stabiliseren. Tussen de 12e en 24e implantatiemaand is in 45 % van de patiënten 
vroegtijdige explantatie noodzakelijk en krijgt meer dan twee derde van de patiënten 
minimaal één complicatie. Deze effectiviteit- en veiligheidsaspecten zijn vergelijkbaar 
met een studie van Quezada et al., waar de DJBL werd geïmplanteerd tot maximaal 
36 maanden. Derhalve adviseren wij op basis van deze resultaten een maximale 
implantatieduur van 12 maanden.
Om patiënten te selecteren die het meeste van de behandeling met de DJBL zullen 
profi teren, hebben we twee onafhankelijke factoren op het screeningstijdstip 
geïdentifi ceerd: een C-peptide >1.0 nmol/L en een gewicht >107 kg (Hoofdstuk 2). 
Een eerdere studie suggereerde dat patiënten die bariatrische chirurgie ondergingen met 
pre-operatief een C-peptide <1.0 nmol/L, een verminderde kans hadden op volledige 
genezing van DM2, waarschijnlijk ten gevolge van gedeeltelijk β-cel falen. Mogelijk dat 
patiënten met een C-peptide >1.0 nmol/L een grotere kans hebben op een verbetering van 
de insulinegevoeligheid en daarom goed reageren op de DJBL behandeling. Het gewicht 
van 107 kg is in ons cohort vergelijkbaar met een BMI van 35 kg/m2. Dit zou kunnen 
veronderstellen dat meer obese patiënten meer profi teren van de DJBL behandeling. 
Daarom kunnen we speculeren dat de impact van gewichtsreductie door de DJBL een 
grotere rol speelt in het behandelsucces van de DJBL dan de impact van glycemische 
controle.
Veiligheidsprofi el van de duodenal-jejunal bypass liner
Naast de effectiviteit van de DJBL hebben we ook het veiligheidsprofi el bestudeerd. 
Met wereldwijd toenemende aantallen implantaties en een langere implantatieduur, is 
de hypothese dat er meer complicaties aan het licht zouden komen. Daarom hebben we 
in Hoofdstuk 6 een systematic review verricht om de complicaties die geassocieerd zijn 
met het gebruik van de DJBL in kaart te brengen. Hoewel de vergelijkbaarheid van de 
38 geselecteerde studies slecht was en er een grote mate van onvolledigheid was in de 
registratie van de complicaties in de meeste studies, werd 3.7 % van de complicaties 
als ernstig geclassifi ceerd, waaronder onder andere het ontstaan van leverabcessen en 
oesofagusperforaties. In 85 % van de ernstige complicaties heeft het anker van de DJBL 
de complicatie veroorzaakt of waarschijnlijk veroorzaakt. Daarom zijn wij van mening 
dat het essentieel is dat er veranderingen worden aangebracht aan de weerhaakjes van 
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het anker van de DJBL om de veiligheid-effectiviteit ratio te verbeteren. Bovendien zijn 
wij van mening dat een vooraf gedefinieerde uniforme manier van complicatieregistratie 
geïntroduceerd en toegepast zou moeten worden voor alle medische hulpmiddelen.
Eén van de belangrijkste nadelen van het gebruik van de DJBL is de noodzaak tot 
vroegtijdige verwijdering (voor het einde van de beoogde implantatieduur) in bijna 
een derde van de patiënten door intolerantie of complicaties. Intolerantie wordt 
voornamelijk veroorzaakt door persisterende abdominale klachten zoals buikpijn en 
misselijkheid. Hoofdstuk 7b beschrijft in een cohort van 152 geïmplanteerde DJBL’s 
de (ernstige) complicaties waarmee we in ons centrum werden geconfronteerd, hoe deze 
te herkennen en hoe hiermee om te gaan. Deze complicaties omvatten onder andere 
oesofagusperforaties, necrotiserende pancreatitis, gastro-intestinale bloedingen en 
leverabcessen. Voor de meerderheid van deze complicaties was intensieve en langdurige 
behandeling noodzakelijk. Ondanks dat dit niet onderzocht is, wordt verondersteld dat 
deze complicaties een grote impact op de kwaliteit van leven hebben. Onze observaties 
van de DJBL-gerelateerde complicaties werden bevestigd door een toenemend aantal 
gepubliceerde case reports en onze eigen systematic review in het voorgaande hoofdstuk. 
De binnen 30 dagen en na 30 dagen mortaliteit gerelateerd aan bariatrische chirurgie is 
gerapporteerd als 0.08% en 0.31 % respectievelijk. Aangezien er geen DJBL-gerelateerde 
sterfte is gerapporteerd, wordt de DJBL beschouwd als een veiligere ingreep dan 
bariatrische chirurgie.
In Hoofdstuk 7c beschrijven we een case serie van vijf patiënten waarin we hypothetiseren 
dat het optreden van acute pancreatitis in patiënten met een DJBL mogelijk gerelateerd 
is aan het specifieke ontwerp van de DJBL. We hebben vier theorieën geformuleerd 
welke de mogelijk causale relatie tussen acute pancreatitis en de DJBL kunnen verklaren. 
Aangezien de consequenties van deze complicaties ernstig kunnen zijn, benadrukken we 
dat behandelaars die patiënten treffen met mogelijk DJBL-gerelateerde complicaties, 
direct contact op dienen te nemen met gespecialiseerde centra voor verwijzing en spoedige 
verwijdering van de DJBL. Tenslotte geeft Hoofdstuk 7d een overzicht van normale 
endoscopische en radiologische beeldvorming en van (ernstige) DJBL-gerelateerde 
complicaties.
Ethiek van medische hulpmiddelen
In het veld van de bariatrische chirurgie wordt een substantieel deel van de behandelingen 
uitgevoerd in commerciële setting. Er is een aanhoudende race om de minst invasieve 
techniek te ontwikkelen tegen obesitas en gerelateerde ziekten. Dit heeft geresulteerd in 
een indrukwekkende stijging van nieuwe medische hulpmiddelen en technieken. 
Tijdens het verrichten van onze studies en het schrijven van dit proefschrift ontstonden 
er vragen met betrekking tot de implementatie van deze nieuwe medische hulpmiddelen. 
Nieuwe medische hulpmiddelen kunnen relatief makkelijk in de klinische praktijk worden 
geïntroduceerd en geïmplanteerd. Deze hulpmiddelen worden vaak al geïntroduceerd 
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nadat er slechts onderzoek beschikbaar is van een klein aantal klinische studies in specifi ek 
geselecteerde patiëntencategorieën met vaak beperkte patiëntaantalen. Bovendien is 
het mogelijk dat medische hulpmiddelen überhaupt niet meer worden getest nadat er 
aanpassingen aan het hulpmiddel zijn geweest. Hierdoor komen de ware effecten van het 
nieuwe medisch hulpmiddel pas aan het licht tijdens het gebruik in de klinische praktijk. 
Het is moeilijk om deze strategie te rechtvaardigen wanneer zowel de effectiviteit en 
veiligheid slechts beperkt zijn onderzocht en de balans hiertussen nog onbekend is. 
Slechts met robuuste en nauwkeurig opgezette wetenschappelijke studies verkrijgen we 
een compleet beeld van de effectiviteit en veiligheid van een nieuwe behandelmethode. 
De moeilijkheid blijft dat in het algemeen grote patiëntgroepen noodzakelijk zijn om een 
compleet beeld van de voor- en nadelen van een nieuwe techniek te schetsen.
In Europa kunnen producten die zijn voorzien van een CE-markering worden verkocht en 
getransporteerd door de Europese Economische Ruimte. Hierbij wordt de CE-markering 
vaak foutief geïnterpreteerd als een kwaliteitskeurmerk. Hierdoor is het mogelijk dat 
hulpmiddelen al worden verkocht aan commerciële partijen en worden gebruikt in de 
klinische praktijk terwijl er een gebrek is aan gedegen uitgevoerde klinische studies. 
Dit leidt er toe dat individuele patiënten een risico lopen, zeker wanneer een adequate 
risicoschatting ontbreekt.
Aangezien er verspreid over de wereld verscheidene toezichtshouders zijn in plaats 
van één wereldwijd, kan het moeilijk zijn om een compleet overzicht te krijgen van de 
voordelen en risico’s van nieuwe technieken. De American Society for Gastrointestinal 
Endoscopy (ASGE) pleit voor de introductie van registraties voor endoscopische 
bariatrische therapieën (EBT’s). Met behulp van deze registraties kan de effectiviteit en 
veiligheid van verschillende EBT’s accurater bepaald worden.
Onze studies hebben verschillende ernstige complicaties van de DJBL geïdentifi ceerd 
die niet naar voren kwamen in studies met kleinere patiëntaantallen. Aangezien we geen 
gerandomiseerde klinische studie (RCT) hebben verricht, kunnen hierdoor niet alle 
geregistreerde complicaties zonder twijfel worden gerelateerd aan de DJBL. Daarom is 
er voor nieuwe medische hulpmiddelen noodzaak tot het verrichten van grote RCT’s om 
hun veiligheidsprofi el te bepalen. Daarentegen zijn post-marketing studies cruciaal voor 
het verkrijgen van een compleet veiligheidsprofi el aangezien de incidentie van ernstige 
complicaties erg laag kan zijn.
Refl ectie
Dit proefschrift refl ecteert op de methodologische aspecten van de verrichte studies en 
geeft suggesties voor toekomstig onderzoek dat moet leiden tot een hoger niveau van 
bewijslast.
Een sterk punt van de studies in dit proefschrift is de opzet en datacollectie van een 
groot patiëntcohort met DJBL implantaties. Ons cohort van 185 patiënten met een 
geïmplanteerde DJBL is het grootste cohort beschreven in de literatuur. De meerderheid 
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van de studies hebben maar een beperkt aantal patiënten en bevatten vaak patiënten 
zonder DM2. In onze studies werd de data systematisch verzameld waarbij patiënten 
vanaf het begin van de studie een strikt protocol volgden met polibezoeken op vaste 
tijdstippen na implantatie. Hierin werden gestructureerd vooraf gedefinieerde klinische 
parameters verzameld. Hierdoor waren we in staat om de metabole en cardiovasculaire 
effecten van de DJBL implantatie in combinatie met leefstijlaanpassingen te bepalen in 
een divers cohort obese patiënten met DM2.
Een ander sterk punt is dat met behulp van onze studieopzet het cohort representatief 
was voor de klinische praktijk. Dit is in tegenstelling tot de meeste RCT’s waarin vaak 
uitsluitend relatief gezonde patiënten worden geïncludeerd zonder multi-morbiditeit. 
Een dergelijke gerandomiseerde, sham gecontroleerde studie is enkele jaren geleden 
in de Verenigde Staten van start gegaan, maar moest helaas vroegtijdig beëindigd 
worden vanwege een hogere incidentie van ernstige complicaties (leverabcessen) dan 
verwacht. Observationele studies zoals onze kunnen worden bekritiseerd omdat ze 
mogelijk het behandeleffect overschatten. Echter een studie waarin de uitkomsten van 
gerandomiseerde en observationele studies werden vergeleken concludeerde dat er in de 
observationele studies geen sprake was van een significante over- of onderschatting van 
de behandeleffecten. Met de keuze van onze studieopzet waren we in staat om prospectief 
het veiligheidsprofiel van de DJBL te evalueren. Bovendien konden we doordat de 
DJBL niet vergeleken werd met een andere therapie, meer patiënten includeren voor 
behandeling met een DJBL. De grootte en duur van ons cohort stelde ons in staat om 
het veiligheidsprofiel van de DJBL uitgebreider te bestuderen doordat er een grote range 
van zeldzame complicaties aan het licht kwam welke in eerdere studies niet naar voren 
was gekomen. Dit waren studies met kleine patiëntaantallen met vaak een relatief korte 
implantatieduur van 6 maanden zonder follow-up na verwijdering van de DJBL.
Tenslotte zijn we verder gegaan waar de meeste studies waren gestopt: dataverzameling 
van klinische parameters na het verwijderen van de DJBL. Hiermee werd de duurzaamheid 
van de  bereikte effecten getoond, welke tot nu toe onduidelijk was. Deze data ontbreken 
vaak in onderzoek van nieuwe medische hulpmiddelen. Echter, deze data helpen om een 
accuratere schatting te maken van de effectiviteit en kosten-baten analyse van een nieuw 
medisch hulpmiddel.
Naast de benoemde sterke punten zijn er ook enkele algemene beperkingen die 
geadresseerd dienen te worden. De eerste limitatie is gerelateerd aan de opzet van onze 
studies. Het model dat we hebben gebruikt betreft observaties van klinische parameters 
in mensen met behulp van observationele cohort studies, case-series en een cross-over 
studie. Behoudens de cross-over studie waar patiënten dienden als hun eigen controles, 
bevatte geen enkele andere studie een controlegroep. Aangezien de patiënten die werden 
geïmplanteerd met een DJBL ook begeleiding van een diëtiste ontvingen en werden 
gestimuleerd hun gedrag te veranderen naar een gezondere leefstijl, is het niet mogelijk 
om het ware effect van de DJBL te bepalen. Het is namelijk onduidelijk in welke mate 
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deze overige interventies het effect van de DJBL hebben beïnvloedt. Bovendien hebben 
mogelijk ook andere onbekende confounders en effectmodifi catoren de resultaten van 
onze studies beïnvloedt. Tevens belet onze studieopzet een directe vergelijking met 
onbehandelde patiënten, leefstijlaanpassingen of andere EBT’s.
Een andere limitatie van onze studie is de grote variatie van geïncludeerde patiënten: 
van overgewicht tot morbide obesitas en patiënten met uitsluitend één oraal anti-
diabeticum tot hoge doseringen insuline. Dit maakt het moeilijk om de effecten van de 
DJBL in specifi eke patiëntpopulaties te bepalen. Echter, ons cohort geeft hiermee wel een 
representatieve weergave van de klinische praktijk met een gevarieerde patiëntpopulatie.
Tijdens de follow-up na explantatie verscheen een signifi cante proportie van de patiënten 
niet op hun poliklinische afspraken wat resulteerde in onvolledige data. Dit zorgt voor 
mogelijk bias aangezien het onduidelijk is welk type patiënten afwezig was tijdens follow-
up; patiënten die goede resultaten hadden bereikt en geen verdere consultatie meer nodig 
hadden, patiënten met teleurstellende resultaten die hierdoor geen motivatie meer hadden 
voor follow-up bezoeken of was het willekeurig verdeeld. Aangezien in onze studieopzet 
een controlegroep ontbrak is het moeilijk om harde conclusies over de effectiviteit te 
formuleren.
Tenslotte adviseren we in onze systematic review om een vooraf opgestelde wijze van 
rapporteren van complicaties te gebruiken gedurende de introductie van medische 
hulpmiddelen om de ware effectiviteit-veiligheidratio te bepalen. Dit heeft ook 
betrekking op onze eigen studies waarin de complicaties niet op een uniforme manier 
zijn geregistreerd. Om het veiligheidsprofi el tussen verschillende behandelmodaliteiten 
te bepalen is dit van zeer groot belang.
Toekomst perspectieven
De DJBL is superieur aan dieetveranderingen met betrekking tot positieve effecten op 
gewichtsverlies en glucoseregulatie. Echter, het blijft onduidelijk of de DJBL superieur 
is aan andere EBT’s, zoals de maagballon. Wanneer we de voordelen van één jaar DJBL 
implantatie vergelijken met bariatrische chirurgie, in ogenschouw nemende dat bijna 
een derde van de DJBL’s vroegtijdig wordt geëxplanteerd en dat er sprake is van een 
signifi cant percentage ernstige DJBL-gerelateerde complicaties, zijn we van mening dat 
de DJBL in zijn huidige staat inferieur is aan bariatrische chirurgie. Bovendien benaderen 
de kosten van een DJBL implantatie met het intensieve follow-up programma de kosten 
van bariatrische chirurgie (eigen data, niet gepubliceerd). Echter, gezien het verschil in 
therapeutisch gebied van de DJBL en bariatrische chirurgie, is een ware vergelijking 
tussen deze twee therapieën niet noodzakelijk.
Om een echte vergelijking te maken tussen de ware effecten van de DJBL met andere 
therapieën, is een RCT noodzakelijk met een dieet-groep, DJBL-groep en een groep met 
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een andere EBT. De implantatietijd van de DJBL dient 1 jaar te zijn, met een minimale 
follow-up van 2 jaar na verwijdering (3 jaar in totaal voor alle groepen) en een advies 
tot 5 jaar totale follow-up. Precieze documentatie op een vooraf gedefinieerde uniforme 
manier van complicaties is essentieel. Idealiter adviseren we om harde eindpunten te 
vergelijken, zoals genezing van DM2 en cardiovasculair overlijden. Echter het is vrijwel 
onmogelijk om een dergelijke studie uit te voeren bij de ontwikkeling van een nieuwe 
techniek met het ogenschouw op de kosten en de duur van een dergelijke studie. Daarom 
dienen goed gedefinieerde surrogaat parameters gebruikt te worden, zoals veranderingen 
in nuchter serum glucose, HbA1c, cholesterolwaarden en bloeddruk. Bovendien dienen 
er vragenlijsten te worden afgenomen die betrekking hebben op de kwaliteit van leven, 
patiënttevredenheid, verzadigingsgevoel en de samenstelling van het dieet. Recent zijn 
er twee veelbelovende studieprotocollen gepubliceerd. Eén betreft een multicenter RCT 
waar de DJBL wordt vergeleken met standaard medische therapie in 160 obese patiënten 
met DM2. Het andere protocol beschrijft een multicenter RCT waarin de DJBL wordt 
vergeleken met de maagballon en een sham procedure in 150 obese patiënten, met of 
zonder DM2.
Als de behandeling met de DJBL wordt voortgezet de komende jaren, dan kan de grootste 
winst naar ons inzicht worden behaald door het ankermechanisme aan te passen. Dit 
ankermechanisme is het meest heikele punt van de DJBL en zal verder verbeterd dienen te 
worden om het aantal complicaties te verminderen. Aan de andere kant is dit mechanisme 
het belangrijkste onderdeel waarmee de DJBL zich onderscheidt van andere intraluminale 
technieken. Een eenvoudige oplossing is er niet: langere weerhaakjes zullen zorgen voor 
een groter risico op perforaties en gastro-intestinale bloedingen en een techniek waarbij 
een grotere druk in de bulbus duodeni wordt uitgeoefend zorgt voor een groter risico 
op ulceraties. We betwijfelen of er een technische oplossing zal komen voor langdurige 
implantatie van een medisch hulpmiddel in het gastro-intestinale stelsel zonder dat het 
de mucosa beschadigd. De continue peristaltiek van de darm met zijn kwetsbare mucosa 
doen je afvragen of dit de juiste plaatst is voor langdurige implantatie van een medisch 
hulpmiddel.
Omdat er een grote variabiliteit is in effectiviteit en het optreden van complicaties bij 
patiënten die worden behandeld met een DJBL, zullen patiënten zorgvuldig geselecteerd 
dienen te worden. Zoals wij hebben aangetoond kunnen lichaamsgewicht en C-peptide 
mogelijk van toegevoegde waarde zijn in de patiëntselectie. Toekomstig onderzoek zal 
zich moeten richten op andere klinische parameters die van toegevoegde waarde zijn bij 
het optimaliseren van de positieve effecten en het minimaliseren van de risico’s.
De wereldwijde incidentie van obesitas en diabetes blijft toenemen, wat resulteert in een 
toenemende morbiditeit en mortaliteit. Hoewel bariatrische chirurgie een oplossing is 
voor een groep patiënten, zijn wij van mening dat het grootste succes kan worden bereikt 
door meer te investeren in de preventie van deze ziekten. Dit kan worden gerealiseerd 
door goed onderwijs en voorlichting, een actieve levensstijl en het stimuleren van gezonde 
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voeding. Hierbij zou gezonde voeding goedkoper dienen te worden en zou zelfs eventueel 
de belasting op ongezonde voeding verhoogd moeten worden.
Naast het aanpassen van het eetpatroon door onderwijs en voorlichting, zou een 
therapeutische mogelijkheid het medicamenteus beïnvloeden van gastro-intestinale 
peptiden kunnen zijn. Twee grote RCT’s lieten zien dat één en drie jaar gebruik van 
liraglutide – een GLP-1-analoog – ten opzichte van placebo was geassocieerd met afname 
van het lichaamsgewicht, verbeterde metabole parameters en verbetering in gezondheid 
gerelateerde kwaliteit van leven. Daarom zou toekomstig onderzoek zich moeten richten 
op het verder ontrafelen van het werkingsmechanisme van gastro-intestinale peptiden 
en hoe deze te beïnvloeden. Bovendien zou de ontdekking van nieuwe gastro-intestinale 
peptiden kunnen leiden tot nieuwe therapeutische strategieën.
Conclusie
Met het toenemende probleem van obesitas en gerelateerde ziekten zoals DM2, zullen 
er nieuwe therapieën ontwikkeld dienen te worden voor de behandeling hiervan. De 
huidige preventieve strategieën falen om de toename in obese patiënten te stoppen. Obese 
patiënten klampen zich vaak vast aan nieuwe therapieën in de hoop dat deze het tij kunnen 
keren. Daarom is deze groep patiënten zeer kwetsbaar. Het is de vraag of in de toekomst 
endoscopische bariatrische technieken gedurende een langere periode succesvol zullen 
zijn. Ondanks dat de DJBL voordelige effecten laat zien op lichaamsgewicht, DM2 en 
cardiovasculaire parameters, houden deze momenteel slechts voor beperkte duur stand 
na explantatie. Daarnaast gaat behandeling met de DJBL gepaard met intolerantie en 
complicaties wat leidt tot vroegtijdige verwijdering. Om de DJBL succesvol te laten 
zijn dient het ankermechanisme verbeterd te worden. In de tussentijd lijkt bariatrische 
chirurgie de oplossing voor de vele patiënten waarin conservatieve therapie onvoldoende 
blijkt. Verder zal preventie de belangrijkste focus voor deze door de mens veroorzaakte 
ziektebeelden moeten zijn in plaats van de ontwikkeling van nieuwe tijdelijke minimaal 
invasieve bariatrische therapieën. Maar voor de vele patiënten waarvoor preventie te 
laat is en die niet geschikt of bereid zijn om bariatrische chirurgie te ondergaan, blijft 
de zoektocht naar het optimaliseren van de huidige technieken en het ontwikkelen van 
nieuwe technieken gaande.
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Dankwoord
Het is af! Ruim 6,5 jaar dataverzameling, analyseren, schrijven, herschrijven en 
samenvoegen heeft geresulteerd in dit proefschrift. Het heeft een grote investering van 
tijd en energie gekost, van mijzelf, maar zeker ook van anderen. Veel mensen hebben 
in meer of mindere mate, direct of indirect, bijgedragen aan het complementeren van 
dit proefschrift. Daarnaast is er een grote groep die misschien geen woord bijgedragen 
hebben aan al deze pagina’s tekst, maar voor mij wel van onschatbare waarde zijn geweest 
om dit project tot een goed einde te volbrengen.
Allereerst wil ik beginnen met de belangrijkste groep: ik wil alle patiënten die hebben 
bijgedragen aan ons onderzoek hartelijk bedanken. Ik heb een grote waardering voor de 
mensen die meewerken aan wetenschappelijk onderzoek waarin altijd in meer of mindere 
mate een tijdsinvestering en openheid in jezelf en medisch dossier noodzakelijk is met 
alle onzekerheden die er zijn. Zonder zulke mensen is progressie op vele vlakken in de 
medische wetenschap onmogelijk. Mijn dank gaat tevens uit naar GI Dynamics, welke 
verantwoordelijk is geweest voor de lancering van dit innovatieve product en patiënten 
met twee moeilijk te behandelen ziektebeelden getracht hebben handvatten te bieden om 
de controle terug te winnen. Alexander, fijn dat je altijd bereikbaar was voor overleg en 
ondanks je bizar drukke vliegschema altijd overal op tijd wist te zijn. Karl, thank you for 
the pleasant contact.
Prof. dr. Drenth, beste Joost, hartelijk bedankt voor je begeleiding. Je manier van sturing 
heeft me in de richting gebracht die zorgde voor de afronding van het proefschrift. De 
wekelijkse directe begeleiding en snelle reacties heeft voor mij zijn vruchten afgeworpen. 
En ik denk dat er na mij nog vele promovendi zullen volgen die mogen profiteren van 
deze strategie.
Beste dr. Berends en drs. Janssen, beste Frits en Ignace, dank voor de kansen die jullie me 
hebben geboden om dit onderzoek uit te voeren en de vrijheid die ik hierin kreeg. Ook wil 
ik jullie bedanken voor het kijkje in de keuken bij tal van andere projecten in de wondere 
wereld van de bariatrie. Ik vind het knap hoe jullie op eigen kracht zo’n onderzoeksgroep 
op hebben weten te zetten met behulp van Vitalys. Ik wil jullie veel succes wensen met de 
andere weg die jullie inmiddels zijn ingeslagen.
Beste dr. Groenen en dr. Wahab, beste Marcel en Peter, ik wil jullie hartelijk danken voor 
de prettige begeleiding. Terwijl we zij aan zij stonden bij de implantaties en explantaties 
werd mijn enthousiasme voor de MDL groter en groter. Ik vond het mooi om te zien hoe 
jullie binnen de advanced endoscopy aan de slag gingen. Inmiddels ben ik over de helft 
van mijn MDL-opleiding en besef ik me heel goed dat jullie daar een grote rol in hebben 
gespeeld, bedankt!
Beste prof. Rosman, prof. Fütterer en prof. Fockens, hartelijk dank voor de beoordeling 
van mijn proefschrift en jullie bereidheid om met mij tijdens mijn verdediging van 
gedachte te wisselen over dit proefschrift.
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Prof. Bouvy, dr. Greve en dr. de Boer, hartelijk bedankt voor het bestuderen van mijn 
proefschrift en het plaatsnemen in mijn corona. Fijn om met personen die allemaal nauw 
betrokken zijn geweest bij het onderzoek naar de DJBL tijdens mijn verdediging te 
kunnen discussiëren. Hans, bedankt voor de mooie samenwerking in het Rijnstate tussen 
de interne geneeskunde en de bariatrische chirurgie.
Beste Edo, vanaf het begin tot het einde van het traject was je altijd beschikbaar om mee 
te sparren, te overleggen of een manuscript te corrigeren. Bedankt voor je altijd snelle en 
vriendelijke reactie en veel succes met je carrière!
Zonder de bijdrage van alle co-auteurs waren de artikelen niet zo mooi tot stand gekomen 
zoals ze nu zijn. In het bijzonder wil ik Selwyn bedanken voor de samenwerking bij de 
cross-over studie.
Parweez! Je ging me voor bij het onderzoek en je ging me voor bij de MDL-opleiding. 
Heel fi jn dat je me hebt laten zien hoe ik dit pad kon bewandelen en leuk dat we zo’n tijd 
samen hebben kunnen werken! Ik waardeer het erg dat je in mijn corona plaatsneemt en 
het zou leuk zijn als in de toekomst onze paden elkaar blijven kruisen.
Kemal, lange tijd zaten we tegenover elkaar hard te werken aan het onderzoek. Afgelopen 
jaar heb je ook je proefschrift afgerond waarin je mooie stukken hebt geschreven. 
Heel veel succes met het afronden van je opleiding en ik denk dat je een uitstekende 
laparoscopische chirurg wordt, oude Simendo-koning!
Jens, ook wij hebben een lange tijd samen de onderzoeksbureau’s van de bariatrie bemand. 
Het was een mooie tijd met het samen wegwerken van de poli’s, elkaars stukken reviseren 
en onze kennis verspreiden op de congressen. Succes met je verdere opleiding tot chirurg.
Davey, Thijs, Martijn en Leo. Ik denk dat ik wel kan zeggen dat de assistentenkamer 
samen met de andere bariatriejongens ons domein was. Het waren mooie tijden en we 
hebben veel gelachen en geborreld. En dan zijn we nu allemaal bezig met een mooie 
vervolgopleiding, dat had niet iedereen gedacht! Ik wens jullie allemaal veel succes in 
de toekomst.
Kristy en Nadine, wat hebben we leuk samengewerkt! Kristy, ik vind het 
bewonderenswaardig hoe je gegroeid bent en die plek als manager van Vitalys met beide 
handen hebt vastgegrepen en fantastisch uitvoert! Nadine, ik denk dat iedereen van je kan 
leren hoe in het leven te staan: open, eerlijk en vriendelijk naar iedereen!
Wendy, Laura, Mellody en alle nieuwe aanwas van de bariatrische onderzoeksgroep, 
veel succes met het afronden van jullie onderzoek! Willemien, jij natuurlijk ook hartelijk 
bedankt voor je hulp met de dataverzameling en -verwerking.
Ik wil alle dames van Vitalys (Ada, Frieda, Gül, Ellen, Annemiek, Peggy, Caroline, Erna, 
Linda) van harte bedanken voor de samenwerking. Het was altijd erg gezellig op de 
donderdagochtend en na het broodje bal kon ik er weer tegenaan. Maar in het bijzonder 
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wil ik uiteraard Anja bedanken! Anja, zonder jou was ik nog steeds brieven aan het 
versturen. Vanaf dat je ons mee bent gaan helpen, namen de aantallen een enorme vlucht. 
Dank voor alles!
Martin, ik heb het enorm gewaardeerd hoe je in je volle agenda altijd spontaan weer wat 
tijd wist vrij te maken om met me over het onderzoek aan tafel te zitten. Ik heb veel van 
je geleerd hoe je alles vanuit management perspectief bekeek, maar nog meer over hoe 
oprecht en vriendelijk je met iedereen om gaat. Dankjewel daarvoor!
Na mijn onderzoeksperiode heb ik als arts-assistent bij de intensive care en interne 
geneeskunde met veel verschillende collega’s samen mogen werken. Geneviève, Sam en 
Stijn, we hebben veel mooie gesprekken gehad (applaus!) waar ik met een brede glimlach 
aan terug denk. Onze paden kruisen elkaar in de toekomst vast weer.
Mijn MDL-carrière startte in het Jeroen Bosch Ziekenhuis. Lauranne, Marten, Kirill, 
Govert, Tanja, Rosel, Angela, Floor en Veerle dank voor de samenwerking en ik hoop 
jullie nog regelmatig te zien de komende jaren tijdens het werk of op congressen. De staf 
van de MDL uit het JBZ wil ik van harte bedanken voor hun begeleiding tijdens mijn 
eerste jaar van de MDL-opleiding.
Thomas, Chris, Nienke, vd Klift en Loes; de co-schappen hebben ons bij elkaar gebracht 
en we hebben zowel binnen als buiten de universiteit samen mooie dingen meegemaakt. 
Fijn dat we elkaar nog zo nu en dan spreken en dank voor jullie altijd bemoedigende (…) 
woorden op de momenten dat m’n onderzoek net iets minder soepel liep dan ik wilde.
RJ en Hein, samen gingen we het versnelde traject van geneeskunde door. Om te beginnen 
met vier blokken MPV achter elkaar, wat een feest. Maar we hebben het alle drie gered. 
RJ, jammer dat je liefde voor de MDL net niet sterk genoeg was, maar als huisarts kom je 
denk ik helemaal tot je recht. Hein, nu heb je wel weer genoeg gereisd ;)
Thijs en Ellen, 2002 ging het allemaal van start! Als echte BMW’ers hebben we 
de opleiding afgemaakt. Jullie zijn toen aan een glansrijke carrière begonnen in het 
onderzoek terwijl ik voor een 2e opleiding ging. Ik ben erg blij dat we elkaar nog steeds 
zo vaak spreken en wil jullie heel erg bedanken voor alle tips en mentale ondersteuning 
(met uiteraard wat kracht bij gezet door een biertje) de afgelopen jaren!
Anton, onze wederzijdse interesse in de medische wereld was maar van korte duur, maar 
inmiddels kennen we elkaar al 16,5 jaar. Jij vertoeft in Schijndel, ik in Ewijk, wie had 
dat ooit gedacht! Ik hoop dat er nog vele avonden met goede gesprekken en vooral goede 
muziek volgen!
Mark en Frans, inmiddels wonen we verspreid door het land, maar al die geniale avonturen 
met de Mustangs nemen ze ons niet meer af. Die periode en het team waren uniek en heeft 
voor ons alle drie voor een mooie basis gezorgd!
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Nora en Wim, jullie enthousiasme voor de promotie van Myrella en mij is aanstekelijk! 
Ik heb veel bewondering voor hoe jullie thuis alles regelen en hoe jullie mij bewust (of 
onbewust…) wisten te motiveren om m’n proefschrift af te maken. Jullie waren een waar 
feestnummer op het feestje van Myrella, hopelijk zijn jullie dat op mijn feest weer!
Herders en herderinnen, indirect hebben jullie enorm bijgedragen aan dit proefschrift 
en hoe kan ik jullie daar ooit voor bedanken? Bart, Jeroen, Nick, Lars en Stan, in al die 
jaren hebben we veel samen meegemaakt. Onze dagen en avonden samen zijn voor ons 
allemaal belangrijke momenten die ons allemaal goed doen. Bart en Lars, ik vind het 
fantastisch dat jullie mijn paranimfen zijn. Met jullie aan m’n zijde moet het helemaal 
goedkomen tijdens de verdediging!
Ron en Jeanette, dank voor de onvoorwaardelijke steun die jullie kinderen, familie en 
“schoonfamilies” krijgen. Jullie staan altijd voor ons klaar en zijn altijd motiverend 
geweest in het werk aan ons proefschrift! Richelle en Bas, Wilco en Ellis, het is altijd 
erg gezellig als we met z’n allen bij elkaar zijn en dat is heel wat waard! Wilco, heel erg 
bedankt dat je de lay-out van mijn proefschrift hebt gemaakt, wat een werk! Richelle, 
hopelijk is jouw proefschrift ook snel af, je hebt het dubbel en dwars verdient!
Lieve Milou, ik ben heel blij met je als kleine zusje. De afgelopen periode is niet altijd 
even makkelijk geweest, maar met elkaar hebben we ons er doorheen geknokt. Jij hebt 
veel steun aan Giuseppe gehad en daar ben ik hem erg dankbaar voor. En dan Giulio, wat 
een geweldige jongen is dat! Ik vind het fantastisch dat er een kleine op komst is en ik zal 
m’n uiterste best doen om een goede oom te zijn!
Lieve mam, waar zou ik zijn geweest zonder de opvoeding van pap en jou? Ik zou 
het in ieder geval niet zo ver geschopt hebben als nu. Ik ken niemand met zoveel 
doorzettingsvermogen als jij. Dat we afscheid hebben moeten nemen van pap heeft er 
fl ink ingehakt, maar met vastberadenheid gaan we door, al blijft dat af en toe moeilijk. 
Pap en mam, bedankt voor alles, jullie hebben me gemaakt tot wie ik ben.
Lieve Myrel, dank je wel dat je aan m’n zijde staat en voor al je steun de afgelopen jaren. 
Dank je wel dat je me er doorheen hebt gepraat als het wat minder ging tijdens het werk of 
met het proefschrift. Dank je wel dat we al zoveel leuke dingen samen hebben gedaan. Nu 
zijn beide proefschriften af en kunnen we die tijd gaan gebruiken om samen te genieten 
van alle dingen die komen gaan!
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